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Abstract
The thesis describes the epidemiology of selected somatic and psychiatric conditions in 
epilepsy and the health care demands of people with epilepsy, and presents broad 
estimates of life expectancy in people with epilepsy in the community in comparison to 
people without epilepsy.
A cross-sectional study was conducted extracting data from the General Practice 
Research Database for the period 1995-1998. Psychiatric disorders occurred twice as 
often and the risk of groups of most somatic disorders across categories was increased 
in people with epilepsy. The risk of neoplasia excluding intracranial tumours was not 
increased in epilepsy. The risk of brain tumours, meningiomas and neurodegenerative 
disorders was particularly increased. Other conditions occurring more frequently in 
epilepsy include upper gastrointestinal bleed, cardio- and cerebrovascular disorders, 
fractures, pneumonia and chronic lung diseases, and diabetes.
Analysis of data from the fourth national survey of morbidity in general practice 
(1991-92) revealed that patients with epilepsy used health services (consultations with 
a general practitioner, home visits, referrals to secondary care) more often than people 
without epilepsy, irrespective of age, sex and social class. A higher proportion of 
patients with epilepsy consulted for neoplasms, haematological and mental health 
disorders, dementia, stroke and gastrointestinal bleeding.
Previous studies have shown that epilepsy carries a risk of premature death. Life 
expectancy was estimated using data from a cohort of 564 patients with definite 
epilepsy followed for nearly 15 years (177 deaths) (registered through the National 
General Practice Study of Epilepsy) by employing a parametric survival model based 
on the Weibull distribution. Reduction in life expectancy can be up to 2 years for 
people with a diagnosis of idiopathic/cryptogenic epilepsy and the reduction can be up 
to 10 years in people with symptomatic epilepsy. Reductions in life expectancy are 
highest at the time of diagnosis but diminish with time.
People with epilepsy can be affected by a number of psychiatric and somatic 
conditions more frequently than people without the condition. They make a higher 
use of health services at all levels of care, which may be partly related to the 
presence of coexisting disorders. It appears that higher mortality rates in epilepsy 
translate into reductions in life expectancy.
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Epilepsy
Epilepsy is a multifactorial and multifaceted condition, with particular management 
considerations for different groups of patients, and has a significant impact on the 
lives of affected people and on society. Epilepsy is defined as the tendency in an 
individual to the occurrence of unprovoked seizures1 and, in practice, is said to be 
present when two or more seizures have occurred. It can occur as a consequence of 
a wide range of genetic disorders, structural and functional abnormalities, as well as 
metabolic and other insults; however, no clear cause is found in about 60% of cases.3 
The collective term epilepsies refers to those neurological conditions involving 
chronic recurrent epileptic seizures (Box l).4 According to the current aetiological 
classification of the International League Against Epilepsy (ILAE), epilepsies are 
divided into idiopathic (presumed to be genetic with no structural brain lesion and 
usually age-dependent), symptomatic (seizures are the consequence of a known CNS 
disorder), and cryptogenic (presumed to be symptomatic but with no identifiable 
aetiology).5 Seizures are classified into partial or focal (where there is initial 
activation of only part of one cerebral hemisphere) and generalised (where there is 
initial activation of both cerebral hemispheres), according to their origin and 
manifestations as assessed clinically and by EEG.6
Epilepsy is one of the most common chronic neurological conditions, affecting an 
estimated 50 million people worldwide.7 The incidence (40-70 cases per 
100,000/year), point prevalence (6-10 cases per 1,000) and lifetime prevalence (2- 
5%) in industrialised countries1 emphasise its numerical importance. Both the 
incidence and prevalence of epilepsy are dramatically higher among elderly people
I ' 8than among those who are younger.
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BOX 1. 
Definitions according to the Glossary of Descriptive Terminology for Ictal 
Semiology, ILAE Commission Report4
EPILEPTIC SEIZURE
Manifestation(s) of epileptic (excessive and/or hypersynchronous), usually self­
limited activity of neurons in the brain.
EPILEPSY
a) Epileptic Disorder: A chronic neurological condition characterised by recurrent 
epileptic seizures.
b) Epilepsies: Those conditions involving chronic recurrent epileptic seizures that 
can be considered epileptic disorders.
Epilepsy is associated with significant morbidity and mortality: Depending on its 
severity and response to treatment, epilepsy can have deleterious effects on a 
person’s life, as it may affect cognitive, psychological and social development;9’10
11  *7pose lifestyle restrictions; be complicated by treatment side effects; and be 
associated with increased mortality and risk of sudden death.1 12 Although the 
prognosis is favourable for the majority of patients, 20-30% develop refractory 
epilepsy, meaning that they continue to experience seizures and/or unacceptable side 
effects, despite optimal antiepileptic drug (AED) treatment, that limit their ability to 
live life fully.10'13 An important determinant of morbidity in epilepsy is comorbidity.
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The concept of comorbidity -the co-existence of two or more disorders in the same 
person- has not received adequate attention in epilepsy, although in clinical practice 
only a fraction of seizures occur in otherwise healthy individuals. Although the 
presentation, management and prognosis of numerous systemic disorders that cause 
seizures has been discussed,1415 information on the frequency of disorders co­
existing with epilepsy in people with the condition is limited. This is particularly the 
case for somatic disorders. The great majority of studies on the frequency or risk of 
co-existing disorders in epilepsy has been conducted in small and/or special 
populations that do not provide estimates for these conditions in the general 
population. The medical care for the majority of people with epilepsy in UK is 
provided by general practitioners and neurologists in the community16 and, therefore, 
it is important to know the risk of these disorders in an epilepsy population in this 
setting.
Mortality is known to be increased in epilepsy, especially in people with
i  ^
symptomatic epilepsy. Standardised mortality ratios (SMRs) have been calculated 
for the major ILAE aetiological groups and for a number of specific conditions in 
epilepsy. However, the effect of the increased mortality rates on the life expectancy 
of people with epilepsy is not known.
This thesis addresses the issues of comorbidity and life expectancy in people with 
epilepsy. It attempts to estimate the prevalence ratio of a number of common 
disorders in people with epilepsy compared to people without epilepsy in the primary 
care setting, and to estimate the number of years of life lost in people with epilepsy 
compared to the general population using data from large health databases.
18
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THE COMORBIDITY OF THE EPILEPSIES
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Chapter 1
INTRODUCTION TO COMORBIDITY
People with epilepsy may develop any other condition during their lives that may 
precede, co-occur with, or follow the diagnosis of epilepsy. Comorbidity refers to the 
coexistence of more than one condition in the same person. The term was originally 
used by Feinstein with reference to coexistent conditions in clinical trials.17 These 
conditions are then referred to as comorbid,17 and the coexistence may also indicate
I 7an association between them that is more than coincidental. This means that a 
statistically significant association may exist between two disorders. In a slightly 
different version, comorbidity has also been defined along the lines of concomitant
1 Xbut unrelated pathological or disease processes.
As a general term, the comorbidity of epilepsy refers to the coexistence or co­
occurrence of other conditions in a person with epilepsy. These conditions can be 
related or unrelated to the underlying cause of epilepsy. Lipton and Silberstein19 have 
suggested a scheme of possible causal explanations for statistically significant 
comorbid conditions that may provide clues towards the pathogenesis of the studied 
condition.
First, the disorders may be unrelated and their apparent association may have arisen 
by coincidence or selection bias. For example, if patients with both epilepsy and 
depression are more difficult to treat and therefore more likely to be referred to an 
epilepsy specialist, then the association between the two disorders will be
overestimated in studies conducted in epilepsy speciality clinics. This bias, also
20known as Berkson’s bias, is a problem in clinic-based studies and can be avoided 
by undertaking population-based studies.
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A second explanation may be that one condition causes the other. An example is the 
relationship between epilepsy and migraine. Headaches have been associated with 
seizures as ictal or post-ictal phenomena, particularly in occipital lobe seizures, and 
migraine aura may trigger seizures.21
Third, the conditions may be related due to shared environmental or genetic risk 
factors. An example of a shared environmental factor is head injury, a risk factor for 
both epilepsy and migraine that may account for part of the relationship between the 
disorders. Shared genetic factors, such as mutations affecting genes encoding ion 
channels expressed in tissues outside the CNS as well, may account for associations
yybetween comorbid disorders. For example, mutations in potassium channels may 
predispose to seizures, sensorineural hearing loss and long QT interval on ECG.
A proposed fourth mechanism would involve independent genetic or environmental 
risk factors, producing a brain state that favours the association of two conditions. 
Migraine and epilepsy have been attributed to a condition of neuronal 
hyperexcitability that results from genetic as well as environmental risk factors such 
as head trauma.24 In this context, a number of generalised epilepsies are associated 
with channelopathies that lead to neuronal hyperexcitability.25 For example, 
abnormalities in calcium channels have been implicated in episodic ataxia, 
spinocerebellar ataxia, familial hemiplegic migraine and idiopathic generalised 
epilepsy.26*29 The development of a particular brain state increases the probability of 
the two disorders developing in the same person.
The above scheme does not include conditions that can be the cause or the effect of 
the epilepsy. Duchowny and Bourgeois described the conditions that contribute to 
the development of epilepsy as “causal” comorbidity and the conditions presenting as
21
a consequence of repeated seizure activity or its treatment as “resultant” 
comorbidity.30 People with epilepsy are at risk of dysfunction in a number of 
physiological systems. This can manifest clinically as disturbances in the sleep-wake 
cycles,31 in autonomic nervous system32 33 and endocrine function,34’35 and in general 
medical and reproductive health.36 Disorders in these physiological systems may be a
^ 7 . 1 0  O Q
consequence of the epileptic syndrome, ’ the interictal epileptiform activity, the 
seizures,40 or the antiepileptic drugs.41-44 In addition, epilepsy and its treatment can 
have adverse cognitive and behavioural consequences.45
The study of the comorbidity of epilepsy is important for diagnosis and treatment, as 
well as for epidemiology and health services. For the clinician, a high degree of 
symptom overlap among co-occurring conditions may pose diagnostic difficulties. 
Both epilepsy and vertebrobasilar migraine can cause transient alterations of 
consciousness, as well as headache.46 The challenge for the clinician is to recognise 
any other disease(s) that might be present in a patient with epilepsy. For the 
statistically significant comorbidity of epilepsy, the principle of diagnostic 
parsimony does not apply. In this case, the presence of epilepsy should increase, not 
reduce, the suspicion that other disorders might be present. For example, patients 
with epilepsy often have medically undiagnosed migraine or depression 47,48
It has been stated that “comorbidity refers to the effect of other diseases and 
conditions on the management of epilepsy and to the special problems posed by the 
underlying condition of epilepsy on the management of other diseases”.15 Coexisting 
disorders can provoke seizures in patients with epilepsy through lowering the seizure
22
threshold; systemic illness is known to cause severe psychological and physical
49stress.
In the treatment of epilepsy, a comorbid disorder can provide therapeutic 
opportunities but also impose certain limitations. In some instances, a single drug 
may treat two conditions. For a patient with epilepsy and migraine or epilepsy and 
bipolar psychosis, sodium valproate may ameliorate the comorbid disorders. 
Tricyclic antidepressants and neuroleptics may lower the seizure threshold and 
exacerbate seizures in patients with epilepsy and depression or psychosis and 
therefore must be used cautiously. Patients with hepatic or renal insufficiency require 
careful adjustment of their antiepileptic medication. Interaction of AEDs with other 
medication needs to be taken into account when prescribing. Seizures can be a 
particular problem in patients with severe osteoporosis and high fracture risk, and in 
those with bleeding tendency. Long-term use of phenytoin has been associated with 
cerebellar atrophy and folate deficiency. The management of epileptic seizures in 
the presence of comorbidity in children and adults, as well as the medical causes of 
seizures have been extensively reviewed elsewhere.14,15’49
As a condition, epilepsy encompasses a plethora of types and syndromes that differ 
from each other in terms of aetiopathogenesis, localisation, age of onset, severity and 
prognosis. Its treatment, either medical or surgical, can have different (side-) effects 
on patients. The interaction of biological, clinical and therapeutic factors with the 
environment generates the phenocopy of epilepsy and possibly affects the 
presentation of (co)morbidity in each affected patient.
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DEFINITION For the purposes of this thesis comorbidity refers to the disorders that 
co-occur more frequently in people with a given condition than would be expected in 
the general population without the condition, irrespective of causal association. 
Comorbidity in epilepsy is divided in two major categories: the somatic, including all 
disorders arising from the body, and the psychiatric, including disorders arising from 
the mind.
In case-control studies, epilepsy has been associated with a number of somatic 
disorders, such as learning disability and cerebral palsy,50 51 migraine21 and 
cardiovascular conditions. Information, however, on the risk of somatic 
comorbidity in epilepsy is limited.
Psychiatric disorders appear to occur more frequently in epilepsy, although most 
studies have been conducted in highly selected groups of patients, mainly with 
temporal lobe or refractory epilepsy. The psychiatric comorbidity in epilepsy has 
been studied much more rigorously than the somatic comorbidity, particularly the 
presentation of various psychiatric conditions in epilepsy, in association with specific 
types of seizures, antiepileptic drug treatment and surgical treatment. The subject of 
psychiatric comorbidity in epilepsy is extensively reviewed in the following chapter, 
in terms of epidemiology, clinical presentation, risk factors, aetiology, diagnosis and 
treatment.
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Chapter 2
THE PSYCHIATRIC COMORBIDITY OF EPILEPSY
2.1 Introduction
Epilepsy can be accompanied by changes in cognition and behaviour and can also be 
associated with psychiatric illness.45,53
Psychiatric disorders accompanying epilepsy are comorbid with epilepsy and may 
precede, co-occur or follow a diagnosis of epilepsy. The increased risk for 
psychiatric disorders in epilepsy can be related to a number of clinical, psychosocial 
and biological factors (table 1 ).53
Psychiatric diagnoses in patients with epilepsy in published studies follow either the 
International Classification of Diseases (ICD) or the Diagnostic and Statistic Manual 
(DSM) classifications. The most commonly reported comorbid psychiatric conditions 
fall into the category of psychoses, neuroses and mood disorders (DSM-III-R axis I 
disorders), or of personality disorders (DSM-III-R axis II disorders) and behavioural 
problems. The psychiatric conditions can present either periictally (in prodromal, 
ictal or postictal periods), or interictally. Higher rates of psychopathology are 
observed in people with epilepsy compared with the general population, other
c *2
neurological control groups, and people with chronic non-neurological disorders.
A key question regarding psychiatric disorders occurring in patients with epilepsy is 
whether they are phenomenologically comparable to disorders in patients without 
epilepsy. Opposing views have been proposed, but the subject remains unclear.54 The 
answer is important because the presence of recognisable psychiatric syndromes in 
patients with known brain pathology may lead to an understanding of the 
pathophysiology of these disorders in patients without epilepsy, and because specific
25
Clinical factors
Age at onset of epilepsy
Duration of disorder
Type and frequency of seizures
Hemisphere of cerebral dysfunction (if present)
Interictal and ictal EEG abnormalities
Family history of epilepsy or psychiatric disorder
Psychosocial factors
Chronic nature of disease
Low socio-economic status
Low educational level
Negative cultural approach to epilepsy
Difficulties in adjustment to the consequences of the illness
Fear of seizures
Social stigma
Overprotection by families
Legal limitations (i.e., driving regulations)
Low self-esteem 
Biological factors
Neuropathologic damage to areas connected with psychic functioning 
(i.e., amygdala, limbic system , frontal cortex, basal ganglia) 
Emotional and cognitive side effects of antiepileptic drugs 
Forced normalisation
Table 1. Factors related to the risk for psychiatric disorders.
(Adapted from Torta & Keller, 199953)
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psychiatric syndromes seen in patients with epilepsy may respond to specific 
psychiatric treatments.
The risk and characteristics of psychiatric disorders in patients with epilepsy have 
been assessed in a number of studies, which were conducted in different populations 
and employed different methodologies. The current epidemiology of psychiatric 
disorders in epilepsy is surveyed here taking into account these differences. A 
descriptive approach is adopted, where the risk of all psychiatric disorders, as well as 
individual disorders, in adults and children with epilepsy is described according to 
type of epilepsy and study population. The relationships between individual disorders 
and seizure occurrence are discussed, as well as the aetiology, recognition and 
treatment of these disorders in association with epilepsy.
2.2 Risk of any psychiatric disorder
2.2.i Studies of unselected populations 
ADULTS
Few population-based studies have assessed the prevalence of psychiatric 
comorbidity in epilepsy. In a survey of 713 adults with active epilepsy in northern 
Sweden, 5.9% of patients were reported to have had psychoses, alcohol dependence 
syndrome, or other psychiatric disorders.55 Lifetime mental abnormalities were 
reported in 6.7% of 225 patients with childhood-onset epilepsy.56 In a population- 
based case controlled study with 35-year follow-up, concurrent illnesses were
S7reported in 245 adults with childhood-onset epilepsy. A 4-fold increased risk for 
psychiatric disorders was found, regardless of whether or not patients were still 
receiving AEDs. In a study of all individuals with epilepsy in Iceland (N=987), 52% 
had some non-psychotic mental abnormality, and 7% had psychosis at some time in
27
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their life. In a nation-wide survey in the UK, an annual rate of 0.1% was calculated 
for new cases of acute psychological disorders (N=64) among patients with active 
epilepsy attending neurology clinics (estimated N»60,000).59
Psychiatric disorders may pose a considerable burden in people with epilepsy. In a 
community-based survey in Rochester, Minnesota, 19% of an adult population with a 
recent history of active epilepsy (within five to six years) and without learning 
difficulties (N=125) were considered to have major psychosocial problems.60 A 
community-based survey in North East England found that epilepsy patients with an 
associated neurological or psychiatric handicap had higher unemployment rates 
(79%) compared with all patients with epilepsy and with age/sex matched controls 
(59% and 16% respectively).61
CHILDREN
A population-based English study showed that the rate of psychiatric disorders was 
higher for children of school age with epilepsy (27%, N=63) than for children with 
other chronic physical conditions (12%, N=138) or children in the general population 
(7%, N=2,189).62 In a population-based study in South India, 23% of 26 children 
with epilepsy aged 8-12 years were diagnosed with psychiatric disorders in 
comparison to 8.1% of controls from the general population (N=1166).63 In another 
study, behaviour problems requiring mental health consultation affected 22% of 
patients of normal intelligence with childhood-onset epilepsy (N=337).64
2.2.ii Selected population studies 
ADULTS
Case-controlled65'67 and cross-sectional studies68’69 have used a variety of methods to
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detect psychiatric disorders in adult patients. Two studies found no significant 
difference in the prevalence of psychiatric disorders between people with epilepsy 
and a healthy control group.67,69 In other studies, patients with epilepsy were at 
higher risk of developing psychopathological disorders than the general population,65 
but the risk was not greater than among patients with other chronic diseases66 
including neurological.65 The percentage of patients identified with psychiatric 
disorders ranged between 19 and 48<>/066’68’69 jn a number of studies reflecting 
differences in methodology. The majority of patients with epilepsy included in these 
studies were adults of normal intelligence with no other neurological disorder. A 
review of the literature published in 1986 reported that patients with epilepsy 
demonstrated more emotional and psychiatric problems than healthy individuals and 
more difficulties than other patient groups with non-neurological disorders. They had 
about the same incidence of these problems as people with other neurological 
disorders.70
CHILDREN
A few studies have reported prevalence rates of behavioural problems in children 
with new-onset epilepsy. In one study, children with chronic and newly diagnosed 
epilepsy were significantly more disturbed (48% and 45% respectively) than those 
with newly diagnosed diabetes (17%) or children in the general population (10%).71 
In another study, the percentage of behavioural problems in children with previously 
unrecognised seizures was found to be 34%, compared with an expected 10% in the 
general population. Presumed causes for the behavioural problems in childhood 
included the effects of seizures, effects of antiepileptic drugs (AEDs), poor child and
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family adaptation to seizures, and neurological dysfunction that could be responsible
71 71for both seizures and behaviour problems.
2.3 Risk of any psychiatric disorder in patients with temporal lobe or refractory 
epilepsy
Selected population studies 
ADULTS
Acute psychological disorders appear to be more common in patients with complex 
partial seizures.59 In 88 patients with epilepsy from a general practice cohort, the risk 
of developing psychiatric illness was higher among patients with temporal lobe 
epilepsy (TLE) (60%) and other focal epilepsy (54%) than among patients with
z  o
primary generalised epilepsy (37%). In one study, patients with TLE (N=20) had 
higher rates of psychiatric disorders (80%) than patients with juvenile myoclonic 
epilepsy (22%) and patients with diabetes (10%).74 In a study of 21 patients from an 
epilepsy centre in the US who had auras -most of whom (72%) had complex partial 
seizures (CPS) - 71% met criteria for a psychiatric diagnosis.75 In comparison, a 
retrospective study of patients with adult-onset idiopathic generalised epilepsy (N=42) 
reported that 33% were diagnosed and treated for mental disorders.76
Cross-sectional studies have assessed the prevalence of psychiatric disorders in 
cohorts of patients with refractory epilepsy, the great majority of whom had temporal 
lobe epilepsy. Lifetime prevalence ranged between 44 and 88% in candidates for
epilepsy surgery or patients undergoing neurodiagnostic evaluation54'77'80 and was
• 81 75% in a study of patients awaiting temporal lobectomy. The lifetime prevalence
for DSM axis I disorders ranged between 44 and 71% in several studies,54’75’77'80 with
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an estimated mean of 60%. This compares to rates of 22% for patients followed for 
medical illnesses83 and 26% for primary care patients.84 Current prevalence in 
surgical candidates was reported at 36%,79 and 35-87% in patients prior to surgery
91 67 • •for epilepsy. ’ ‘ Patients with chronic, intractable, localisation-related epilepsies, 
who are on polytherapy and experience a range of psychosomatic symptoms appear
SQ’6 0 '78 '81  96to be particularly prone to developing psychiatric comorbidity.
CHILDREN
A significantly greater number of children with temporal lobe epilepsy (N=62) 
experienced emotional disturbance (18% vs. 6%) and psychiatric abnormalities (79% 
vs. 47%) than children with generalised epilepsy (N=70).89 Neuroses (37% vs. 16%), 
psychoses (19% vs. 10%), and personality disorders (23% vs. 21%) occurred more 
commonly in the TLE group (all statistically significant differences, p<0.001). In 
another study, 85% of children with TLE (N=100) followed into adult life suffered 
psychiatric problems.90 However, the occurrence of overt psychiatric disorder in 
adult life was low: among people who were not gravely mentally retarded 70% were 
regarded as psychiatrically healthy.
2.4 Risk and characteristics of individual psychiatric disorders
2.4.i Affective/Mood disorders 
Risk & Predominant types
In a cohort of 100 patients with cryptogenic epilepsy and normal intelligence, 3% 
were diagnosed with dysthymia and 3% with depression.69 In a UK nation-wide 
survey, 30% of patients with epilepsy presenting with acute psychological disorders 
suffered acute affective disorders (depressive, manic and dysthymic episodes).59 The
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lifetime prevalence of mood disorders in patients with TLE or refractory epilepsy 
ranged between 24 and 72% in a number of studies,54'75 79,81 while the respective 
current prevalence was between 24 and 30%.79,81 Mania or bipolar psychosis are not 
considered more common in patients with epilepsy.91 Rates of 5% have been 
reported in some studies of patients with partial and/or intractable epilepsy.75,92
Depression represents the most common interictal psychiatric condition in patients 
with epilepsy 47,93 Depression appears to occur more frequently in patients with 
epilepsy than in patients with other neurological disorders,94,95 chronic medical 
conditions, or normal controls.74,96 Lifetime prevalence for major depression ranges 
between 8 and 48% in patients with TLE or refractory epilepsy,54,75,77,79,80,86 with an 
estimated mean of -30%  across studies. The corresponding rate in the general 
population has been reported as 6% and 17% in two major epidemiologic studies.82 
Reported rates for dysthymia in epilepsy range from 3-21% depending on the 
population studied.54,68,69 75,79 Depression can develop de novo in 4-8% of patients
70’ OC-QQfollowing temporal lobectomy for refractory epilepsy ’ but rates as high as 38%
o z
have been reported. Symptoms of depression appear to be also common in children 
with epilepsy.97
Clinical features o f  depression 
PREICTAL
One third of patients with partial seizures report premonitory symptoms, usually 
before secondarily generalised tonic clonic seizures (SGTCS). Prodromal moods of 
depression or irritability may occur hours to days before a seizure and are often 
relieved by the convulsion. These prodromal symptoms may be related to subclinical
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seizure activity, or to physiologic or biologic processes involved in the initiation of 
both the lowered mood and the seizure. In some patients, the presence of negative, 
depressed, or dysphoric mood in combination with negative life events may increase
no
the likelihood of seizures.
ICTAL
Depressed mood can occur as part of an aura in about 1% of patients and is more 
common in TLE. It is of sudden onset and occurs out of context (i.e., not related to 
environmental stimuli). Its severity ranges from mild feelings of sadness to profound
Q O
hopelessness and despair. In children, affective symptoms have been reported as 
part of benign partial epilepsy."
POSTICTAL
Flattened or depressed affect has been observed, particularly in patients with TLE, 
lasting hours to days after seizures. It is postulated that this is a consequence of the
Q O
inhibitory mechanisms involved in the termination of seizures. Clinically, severity 
is variable and some people may even become suicidal.
INTERICTAL
Interictal depression is believed to affect up to two thirds of patients, especially those 
with severe and/or frequent seizures. Diagnosis of major depression and dysthymia 
in epilepsy follows established criteria as in the rest of the population. Many patients 
with TLE, however, develop depressive symptoms characterised by a fluctuating
78course and a pleomorphic presentation. Blumer coined the term “interictal 
dysphoric disorder” to describe a syndrome comprising eight symptoms, of which
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patients must experience at least three: depressive moods, anergia, pain, irritability,
70.00
insomnia, anxiety, fear, and euphoric mood. ’ In severe form, this disorder may 
become associated with sudden suicide attempts during episodes of intense 
depressive mood in some patients, and with psychotic features (hallucinations, 
paranoia, delusions or bizarre behaviour) in others. Affective and somatoform 
symptoms tend to be intermittent, lasting hours to a few days, while the interictal 
psychoses may last a few days to a few weeks. In one series of patients (N=75) with 
epilepsy undergoing neurodiagnostic monitoring, 44% were found to suffer from an 
interictal dysphoric disorder. Similar symptomatology was also reported by 
others.81
Clinical /  Risk factors
It appears that men with epilepsy are most at risk of developing depression, while the 
prevalence of depression in the general population is higher in women. Factors such 
as seizure type, laterality of epileptic focus, seizure frequency, and age of onset and 
duration of epilepsy have been implicated, but findings are inconsistent.9198
Aetiology /  Biological factors
Depression may be associated with a neurological condition that is also responsible 
for epilepsy (e.g. CVA, dementia, head injury) and may be commoner in patients 
with a structural lesion or patients with learning difficulties.98 The development of 
depression may be a reaction to stresses in life (reactive depression), including the 
effect of any underlying conditions. Alternatively and more usually, depression may 
be related to biological factors, such as folate deficiency (due to AEDs),47 frontal
qq fic os inn
lobe dysfunction, anterior temporal lobectomy, ’ and AEDs (particularly with
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polytherapy, phenobarbital, vigabatrin, topiramate, and tiagabine) (endogenous 
depression). It has been suggested that a history of depressive episodes is a risk 
factor for the occurrence of unprovoked seizures in adults and children.93,101 In 
addition, a family history of depression has been observed in over 50% of patients 
with both epilepsy and depression suggesting a genetic predisposition.93 These 
findings, together with evidence of decreased serotonergic, noradrenergic, 
dopaminergic and GABAergic activity in both disorders, suggest that epilepsy and 
depression may share common pathogenic mechanisms.93
Recognition & Diagnosis o f  depression
In over 50% of paediatric and adult patients with epilepsy, depression may remain 
undiagnosed. It is important to recognise depression in people with epilepsy, not only
O '}  .Q -)
to enable appropriate treatment but also to identify patients at risk for suicide. 
Additional burden imposed on patients with epilepsy
Major depression in epilepsy has been associated with significantly decreased self- 
reported quality of life, increased disability and missed work, increased medical
• • • 0 } . Q ^utilisation and medical costs. Mental illness, drug addiction, early onset of 
epilepsy (particularly onset during adolescence), and personality disorder have been 
associated with increased risk, with some evidence that risk of suicide may decline 
with duration of epilepsy.102,103 Anticonvulsants, particularly barbiturates, were used 
in most cases of self-poisoning in the past.104
Suicide is an important and potentially avoidable cause of death in epilepsy, but the 
extent of its risk varies considerably across studies. It has been reported that people
35
with epilepsy are at higher risk of committing suicide than the general 
population103,105' 111 but other investigators have been unable to demonstrate such an 
increase.112'115 In these studies the proportion of deaths from suicide ranged between 
0 and 20% and the SMRs between 1 and 5.8. Incidence cohorts114,116 are known to 
have lower mortality rates than prevalence cohorts because the former include small 
numbers of cases with symptomatic or severe epilepsy, which are over-represented in 
prevalence cohorts and which are associated with higher mortality. In addition, 
people who attend hospitals have higher morbidity and mortality than community 
cohorts. In the large prevalence study of 9,061 adult patients who were once
10Rhospitalised for epilepsy in Sweden the SMR for suicide was 3.5 (95% Cl 2.6-4.6).
A literature review based on studies published up to 1983 concluded that patients 
with severe epilepsy had a suicide rate 5 times higher, and patients with TLE 25 
times higher, than the general population.103 A later meta-analysis by the same group 
concluded that the overall SMR for death due to suicide in epilepsy was 5.1 (95% Cl 
3.9-6.6). This was based on studies mostly published in the 1970s and 1980s, and 
mainly including patients with TLE, institutionalised patients, patients from surgical 
series, and out-patients.117 In this analysis, the highest suicide rates were observed in 
patients with surgically treated TLE whose risk was increased by a factor of 80 
[SMR 87.5 (95% Cl 35-180)].117 However, this was estimated on the basis of earlier
£7 t 1 £surgical series published in 1968 and 1969 that do not reflect current standards of 
treatment and/or patient selection criteria. Rates from these early studies may be 
higher than we would expect today with modem management and less use of 
barbiturates. The recently published follow-up results of the UK NGPSE study with a 
total of 11,400 patient-years did not show any excess of suicides.116 Another recent 
study reported five suicides in a 12-year period in a total of 10,739 patients with
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epilepsy seen at a single US centre from 1987 to 1999.119 This number is comparable 
with the average number of suicides in the general US population of about one per 
10,000 people per year. All suicide cases had a history of early onset (mean age 9.5 
years), long-standing CPS (mean duration 29 years) and very high seizure frequency 
(often daily). Suicide occurred in all patients after a short interval (3 months to 3 
years) of having obtained full seizure control for the first time after temporal 
lobectomy (3 patients), vagal nerve stimulation, or medication. These patients had 
been diagnosed with interictal dysphoric disorder (IDD), a syndrome described
78previously by the authors. IDD comprises intermittent affective and somatoform 
symptoms, presenting with intense depressive moods with suicidal intensity in some, 
and with psychotic features and dysphoric symptoms (i.e., irritability, fear, anxiety)
Q O
in others. According to the authors, suicide in epilepsy results from specific 
neuropsychiatric disorders (including IDD and post-ictal depression) associated with 
epilepsy rather than as the result of unfortunate psychosocial difficulties imposed by 
the chronicity and severity of epilepsy.119
Treatments strategies for depression
Antidepressants remain the mainstay of pharmacological treatment for depressed 
patients, despite concerns about the potential lowering of seizure threshold by 
tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). 
Although pre-ictal and ictal depression does not usually require treatment,
improvement in seizure frequency is expected to reduce its occurrence. Post-ictal
08depression may additionally require small doses of antidepressants. Support groups 
and/or psychotherapy are sufficient to treat depressive reactions. SSRIs are 
considered first-line treatment of interictal depression. Non-fluoxetine SSRIs such as
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sertraline, citalopram, and paroxetine are particularly recommended.47 Nefazodone, 
moclobemide, and TCAs can be used as second-line drugs, but special caution is 
required for potential interactions with enzyme-inducing AEDs. In addition, TCAs 
have not been shown to ameliorate depressive symptoms in children 47 Symptoms of
oo
interictal dysphoric disorder usually respond well to low doses of imipramine. 
Electroconvulsive treatment (ECT) is not contraindicated in people with epilepsy and 
may be life-saving.47 People with epilepsy and previous psychiatric history, 
including a history of suicide moods or attempts, should be referred to a 
neuropsychiatrist with experience in epilepsy.
2.4.ii Neuroses
Risk & Predominant types
Anxiety disorders appear to affect 10-25% of patients with epilepsy in the
1 70 Aft1191community and in general practice populations. Rates vary between 7 and 
27% in hospital89 and between 11 and 44% in patients with intractable 
epilepsy.54,75’79'81’86'87’120,122 In one study, symptoms of anxiety were reported in 16% 
of an outpatient paediatric epilepsy population (N=44).97 In the general population, 
one-year prevalence rates for generalised anxiety disorders range between 2.5 and
19^6%. Phobia has been reported in up to 20% of patients with intractable 
epilepsy54’79 but has been as low as 1% and 5% in less selected series.69 75 Similarly, 
the rates for obsessive compulsive disorder ranged between 4 and 10% across 
studies.75 79 87
A probably small proportion of patients with epilepsy suffer from non-epileptic 
attack disorder (NEAD), a condition categorised with the dissociative disorders.124 It
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has to be noted that about 30% of people with NEAD do also have epilepsy.
Patients with NEAD are usually female and have high rates of psychopathology,
1especially dissociative disorders and post-traumatic stress disorder.
Clinical features o f  anxiety 
ICTAL
Nervousness, fear, anger, and irritability may occur as part of an aura. Fear is 
reported as an aura by 10-15% patients with partial seizures. Ictal affective 
symptoms tend to be stereotyped, paroxysmal, of brief duration (30-120 min), 
unprovoked by environmental stimuli, and may be accompanied by autonomic signs. 
These symptoms can be mistaken for a panic disorder and not recognised as epileptic 
in nature.
POSTICTAL
Post-ictal anxiety, like post-ictal depression, is not uncommon. It may be a feature of 
temporal lobe epilepsy but most usually is associated with the stresses related to 
seizure occurrence.127
INTERICTAL
Symptoms of anxiety may develop as a result of stressful events. Some people with 
epilepsy develop anticipatory anxiety of the attacks in public and may become
1 9ftagoraphobic. Many people find that periods of anxiety and stress increase the 
frequency of seizures.
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Clinical /  Risk factors
People with seizures originating in the left temporal lobe may be more prone to 
develop anxiety than people with seizures originating in the right. According to one 
study, patients with left-sided TLE systematically showed higher levels of anxiety 
and lower estimates of quality of life on self-assessment compared with patients with 
right-sided TLE.129
Aetiology /  Biological factors
Anxiety symptoms can be attributed to the unpredictable nature of epilepsy, with 
lack of control, sudden onset of seizures, and the possibility of injury or 
embarrassment.130 Such symptoms, however, may be biologically driven127 and have
on
been found to be more common in patients with TLE.
Recognition & Diagnosis o f  anxiety
Anxiety symptoms (i.e., panic attacks) can be mistaken for epilepsy and vice versa,
• 1 97' 1 98especially fear and anxiety as part of a simple partial seizure. The diagnosis of 
these symptoms is more difficult in children who may present with disruptive 
behaviour and irritability and have their symptoms overlooked as a result.97
Additional burden imposed on patients with epilepsy
This is difficult to quantify. People with a history of suicide attempt had higher rates 
of anxiety than people without such history.131 Older people with epilepsy diagnosed 
in later life were more anxious and depressed than those diagnosed earlier, and their 
overall perception of quality of life was more likely to be negative.132
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Treatments strategies for anxiety disorders
Treatment options include counselling, cognitive behavioural therapy and anxiety- 
reducing measures. Benzodiazepines should not be used as anxiolytics in people with 
epilepsy because of the danger of dependence and the potential for withdrawal 
seizures.
2.4.iii Personality disorders 
Risk & Predominant types
Personality disorders in people with epilepsy have been diagnosed in between 0.7%
CC.SO
and 2% of general practice populations, ’ and in 4% of people with cryptogenic 
epilepsy.69 Rates of personality disorders range from 13% to 35% in patients with 
partial epilepsy (mainly TLE),74’80,89 133 and from 18% to 42% in surgical candidates
54*79 ‘81 85 122or patients who have undergone surgery. ’ In comparison, the prevalence of
personality disorders in the general population ranges between 6 and 13%.134'136 
Reported types in epilepsy include antisocial,79,89 avoidant,54,133 obsessive- 
compulsive,54,85 schizoid,85 schizotypal,54 dependent,85,133 and dissociated
O f
personality. In a recent study assessing these disorders in patients with intractable 
epilepsy (N=52), dependent and avoidant personality disorders were by far the most 
common diagnoses.133 In a study assessing the long-term psychiatric outcome in 
children with TLE (N=100), 12% were diagnosed with antisocial personality during 
adulthood 90 A diagnosis of organic personality disorder -signifying a profound and 
enduring change in personality attributed to an organic cause- has also been 
described.74,81,85 An “epileptic” personality has been reported in 3-5 % of patients 
with TLE in some studies.87,89
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Clinical features /  Personality changes
It appears that some patients with epilepsy (particularly those with TLE) develop 
certain personality traits or an interictal behaviour syndrome. Estimated rates 
obtained from cluster analysis studies using the Minnesota Multiphasic Personality 
Inventory vary from 7% to 21%.91 The most commonly described traits are a 
preoccupation with philosophical and religious concerns, anger, excessive
7 0 '  1 77 -1  7ftemotionality, viscosity, circumstantiality, altered sexuality, and hypergraphia. ’
This profile has been suggested as more specific for patients with TLE and is 
sometimes referred to as the Gastaut-Geschwind syndrome. The same traits are also 
seen in patients with other chronic illnesses, either medical or psychiatric.65,70’139
Clinical /  Risk factors
Factors such as type and frequency of seizure, age at onset and duration of epilepsy 
were found to be associated with personality disorders in some studies65,140’142 but 
not in others.133 The lateralisation of the epileptogenic region may contribute to 
certain personality traits in patients with TLE,137,143 but this has not been consistent
. .  133 144across studies.
Aetiology /  Biological factors
The presence of personality disorders in patients with epilepsy could be an 
adaptation or reaction to psychosocial factors (such as stigmatisation, low self­
esteem, social isolation, etc.) and/or biological factors (such as long-term effects of 
seizures or interictal spike activity, head injury after recurrent seizures, brain lesions, 
and medication effects).91
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Recognition & Diagnosis
There is considerable controversy about the existence of an “epileptic” personality as 
has been suggested in previous studies.145'148
Additional burden imposed on patients with epilepsy
Personality disorders may affect AED compliance in patients with epilepsy and can 
represent a problem of interpersonal behaviour, which in turn can affect 
management.91
Treatments strategies
There is some evidence that risperidone in low doses is useful for the treatment of 
severe personality disorders, such as the borderline personality disorder.149
2.4.iv Psychoses
Risk & Predominant types
The prevalence of psychoses in epilepsy in population-based studies varies from 2% 
to 7%.55’58’150151 in a study on the population with epilepsy in Iceland the prevalence
r  o
of psychoses was 6% and 9% for males and females respectively. In a general 
practice study in epilepsy the prevalence of psychoses was 4%, while no such 
diagnosis was made in a population of people with cryptogenic epilepsy (N=100).69 
A national Danish study reported rates, and estimated standardised incidence ratios 
(SIRs), of non-organic non-affective psychoses developing after a diagnosis of 
epilepsy in a cohort of all people admitted to a general hospital with a diagnosis of
1 S9epilepsy within a 15-year period (N=67,116). The prevalence of psychiatric 
disorder (ICD-8, 290-309) in the epilepsy cohort was 16.8% and the incidence 6.0%.
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The SIR of non-organic non-affective psychoses (according to ICD-8) was 3.00 and 
remained significant even after patients with learning disabilities or substance misuse 
were excluded [SIR 2.30 (95% Cl 2.02-2.59)]. The SIRs for non-affective psychosis 
and schizophrenia were 2.74 and 2.15 respectively. The risk of psychoses may be 6- 
12 times higher in patients with epilepsy than in the general population.53 A study 
conducted at an epilepsy centre in Japan found an incidence rate of newly developed 
psychosis of 0.3%.153
The prevalence of psychoses in patients with TLE and/or refractory epilepsy varies 
from 10% to 19% in most studies80,87,89'90’92’154 and was reported to be nearly double
o n
(19% vs. 10%) compared to respective rates in generalised epilepsy. It has to be 
noted that patients with interictal psychoses were excluded in most recent epilepsy
7Q . o  i . o / :
surgery series, as it was believed that these do not improve with surgery. ’ In 
older studies, the incidence of psychoses in patients with TLE was 11-12%155,156 
compared to 1% in patients with generalised epilepsy.155 Frontal lobe epilepsy (FLE)
1 c*j
can be also associated with inter- or post-ictal psychoses. Patients undergoing 
epilepsy surgery (most commonly temporal lobectomy) are at risk of developing 
psychosis for the first time (de novo). Interictal psychoses (i.e., schizophrenia-like 
psychosis of epilepsy) can develop in 3-12% of patients many months after anterior 
temporal lobectomy53,79 158 and seizure-related psychoses (usually post-ictal) can 
affect 1.3-13% of patients.53 79 8185 88158-160
Schizophrenia or schizophrenia-like psychoses appear to affect between 4.3 and 18%
RfL 87  I ‘79 • 1 A1of patients with epilepsy, ’ ’ the great majority of whom suffer from TLE.
Patients with TLE appear to have higher prevalence of schizophrenia than patients
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with generalised epilepsy (18% vs. 4% respectively). Interictal schizophrenic 
disorders occurred in 9% of epilepsy outpatients (N =l,611) compared with only 1% 
of age-matched migraine outpatients (N=2,167) at the same centre over an 18 year 
period.161 The prevalence of schizophrenia in the general population is ~1%.162 A 
Danish national epidemiologic study compared the incidence of schizophrenia in 
patients who had been admitted to hospital for epilepsy with that of the general 
population.151 A standardised incidence ratio of 1.48 for all epilepsy patients and 
2.35 for patients with psychomotor epilepsy was reported, although the epilepsy 
sample defined by the need for inpatient care may be considered unrepresentative.
Clinical features
People with epilepsy seem particularly liable to develop psychoses. These may take 
the form of a chronic interictal psychosis that closely resembles schizophrenia 
(known as schizophrenia-like psychosis of epilepsy-SLPE) or of an episodic 
psychotic state that is usually related to seizure activity.162 First presentation usually 
occurs 11 to 15 years after the onset of seizures.91
ICTAL PSYCHOSIS
Patients with absence status (generalised non-convulsive status) present with altered 
consciousness and some may experience delusions and hallucinations. Patients with 
complex partial (psychomotor, temporal lobe) status epilepticus may present with 
either a prolonged twilight or confusional state (continuous form), or a series of 
recurring seizures with partial responsiveness between seizures (cyclic form).91 The 
duration of symptoms varies from hours to days and EEG shows status epilepticus. 
Treatment is with AEDs.
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POSTICTAL PSYCHOSIS
STThis accounts for 25% of epileptic psychoses. It often follows an increase in 
seizure frequency or presents after prolonged tonic-clonic seizures, usually after a 
lucid interval of 1-6 days.53’91 In most patients, it presents as abnormal mood, with 
paranoid delusions and hallucinations. Consciousness may be normal or impaired 
and EEG sometimes shows increased epileptic and slow activity. Symptoms usually 
remit spontaneously within a few days, often without the need for neuroleptic 
treatment. In some cases, chronic psychosis may develop from recurrent or even a 
single episode of postictal psychosis.
PERIICTAL PSYCHOSIS
In periictal psychoses, psychotic symptoms develop gradually and in parallel to 
increases in seizure frequency.91 Consciousness is usually impaired and duration of 
symptoms is from days to weeks. The EEG shows increased epileptic and slow 
activity and treatment requires improvement of seizure control.
INTERICTAL PSYCHOSIS
Interictal psychoses occur between seizures and are not directly related to the ictus. 
They are less frequent than periictal psychoses and account for 10-30% of 
diagnoses.91 Despite similarities with schizophrenia, including the presence of first 
rank Schneiderian symptoms,53 SLPE can be differentiated by the preponderance of 
purely delusional states (typically with paranoid, mystical, and religious themes), 
preservation of affect and personality, and predominance of visual rather than 
auditory hallucinations.53 91 Psychoses in patients with generalised epilepsy may
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differ from psychoses in temporal lobe epilepsy; they are short-lasting and relatively 
mild, they tend to present as confusional states and usually remit before delusions or
01*1 79hallucinations are seen.
Clinical /  Risk factors
Following the work by Slater and Beard,163 who noted that 55 of their 69 patients 
with schizophrenia-like psychoses and epilepsy had a temporal lobe focus, several 
other studies demonstrated that psychoses in epilepsy were most often related to 
TLE,53 152 154,156,164' 170 whereas others failed to find such an association.171 It appears 
that about 76% of epilepsy patients with psychosis suffer from TLE.91 Other risk 
factors reported in the literature include: history of CPS (especially those involving 
mesial temporal or limbic structures); left temporal foci; severity of epilepsy (long 
duration, multiple seizure types, refractoriness, AED polytherapy); age of seizure 
onset before or around adolescence; forced normalisation (patients may become 
psychotic when their seizures come under control and the EEG becomes 
“normalised”); and temporal lobectomy.53,91
In some surgical series, a left temporal lobe focus was associated with preoperative 
SLPE in 85% of cases, while 85% of de novo psychoses followed right temporal 
lobectomy.162
Aetiology /  Biological factors
Psychoses in epilepsy can be related to a number of factors: (1) neuropathologic 
changes (e.g. neuronal damage in hippocampal and other structures, hamartomatous 
lesions, gangliogliomas); (2) neurophysiologic modifications (e.g. seizure-
no
suppressive inhibitory mechanisms that develop gradually in chronic epilepsy,
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altered dopaminergic activity); (3) biological factors (e.g. alcohol, menses, sleep 
deprivation), personality changes; psychosocial factors related to epilepsy (e.g. 
quarrels, agitation, fear of redundancy) and; (4) AEDs (e.g. due to forced 
normalisation, folate deficiency, drug toxicity or withdrawal, genetic 
predisposition).53 AEDs particularly associated with development of psychoses 
include vigabatrin, topiramate, and ethosuximide.53 Epilepsy and psychosis may arise 
out of cerebral dysfunction common to both, or psychosis may be a consequence of 
seizure activity (due to the effects of seizures on amygdala, hippocampal and septal 
areas).53 162 A recent study found a significant (16-18%) bilateral enlargement of the 
amygdala in patients with SLPE (N=26) compared with patients with TLE without
1 77psychopathology (N=24) and healthy volunteers (N=20). According to the authors, 
these findings support the notion that SLPE is a distinct nosologic entity differing 
from schizophrenia not only in clinical details but also in neurobiological aspects.
Recognition & Diagnosis
Diagnosis is based on the temporal relation of psychoses to the ictus, their duration 
and clinical characteristics, as well as on past psychiatric history and treatment in the 
case of interictal phenomena. Episodic psychoses (i.e., psychosis is related to 
increased seizure activity) tend to present as acute confusional states, while interictal 
psychoses can be more typical of schizophrenia.
Additional burden imposed on patients with epilepsy
Epilepsy patients suffering from episodic psychoses are often embarrassed and 
perplexed about what has happened to them while psychotic. They fear that further 
bouts will eventually lead to insanity. Patients with chronic psychoses, as well as
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their families, may require the full resources of community care.91 A study found that 
patients with refractory temporal lobe epilepsy and chronic psychosis who underwent 
temporal lobe resection (N=5) functioned better in activities of daily living, and that 
freedom from seizures improved their integration into psychiatric treatment
1 -7^
facilities. These results give a measure of the extra burden the condition of 
epilepsy poses on people with psychiatric comorbidity.
Treatments strategies
Treatment of psychoses in patients with epilepsy is similar to that of patients without 
epilepsy. There are special considerations, such as interactions with AEDs, the 
potential of all antipsychotic drugs (APDs) to lower seizure threshold and their side 
effect profile, and the polymorphism of the psychotic phenomena.91,149 Neuroleptics 
with a low potential for seizure precipitation, such as haloperidol, pimozide and 
sulpiride, can be used in the setting of episodic psychoses or when there is no 
alteration of seizure frequency. Psychoses during withdrawal of AEDs may require a 
combination of haloperidol with chlorprothixene.149 The first therapeutic step in 
alternative psychoses (i.e., the case of forced normalisation) is a moderate reduction 
of AEDs to release some excitation. If this is insufficient, risperidone or olanzapine 
can be useful. Interictal psychoses may require long-term treatment with APDs, such 
as risperidone or olanzapine. Blumer et al. viewed the interictal psychoses as 
interictal dysphoric disorders with psychotic features and recommended 
antidepressants (with the combination of a tricyclic antidepressant and a selective 
serotonin reuptake inhibitor), enhanced by a small amount of risperidone.174 A 
combination of risperidone with an antidepressant can be used for the treatment of 
psychoses developing from postoperative mood disorders in postsurgical patients.149
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The treatment of de novo postictal psychoses (arising with a relapse of seizures 
following epilepsy surgery) is similar to that of postictal psychoses. Clozapine may 
be used only in non-responders to all other APDs and needs to be introduced slowly, 
with EEG and haematological monitoring, as it increases seizure risk.149 Co­
administration of clozapine with carbamazepine is contraindicated because of risk of 
agranulocytosis, and valproate may be preferred on such occasions.
It is generally believed that psychoses do not improve with surgery and, therefore, 
patients with a history of florid psychosis are not considered candidates for 
surgery.162 173 Chronic schizophrenia, however, need not be a contraindication to
1 . 1 '7'!
epilepsy surgery and carefully selected patients may benefit from surgery. ’ It has 
also been suggested that a history of postictal psychosis should be considered a
1 fv)positive indication for surgery.
2.5 Conclusion
Several studies have assessed the type and prevalence of psychiatric comorbidity in 
people with epilepsy and compared them with healthy or other disease groups. Most 
are case-control or cross-sectional studies in highly selected subgroups of patients. 
They are characterised by considerable heterogeneity due to differences in 
methodology. These include the nosographic approach (method of disease 
classification), assessment method/case ascertainment, time frame of evaluation 
(duration of follow-up), study design, the size and characteristics of sample 
examined, selection of control groups, type of epilepsy, and the effect of treatment 
(Table 2). As a result, comparisons between them are difficult, as is the drawing of 
definite conclusions. Most of the available information shows that the prevalence of
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psychiatric disorders is higher than expected in people with epilepsy and certain 
conclusions can be drawn based on the current evidence.
Psychiatric comorbidity is present in a significant proportion of people with epilepsy, 
at least for some time during their lives. Six percent of people with epilepsy in the 
general population appear to suffer from a psychiatric disorder, while this percentage 
rises to 20-50% in more selected populations (e.g. general practice and hospital 
populations). In patients with temporal lobe epilepsy and/or refractory epilepsy the 
prevalence of psychiatric disorders is between 60 and 80%, which appears to be 
higher than in patients with idiopathic generalised epilepsy (~ 20-30%) and those 
with chronic somatic disorders (10-20%). Mood disorders in general affect between 
24 and 72% of people with epilepsy during a lifetime. Depression appears to be the 
most common psychiatric comorbidity in epilepsy affecting an average 30% (-10- 
50%) of patients with TLE during their lives. It occurs more commonly in patients 
with epilepsy than in patients with other neurological disorders,94 chronic medical 
conditions, or normal controls.96 Anxiety disorders in general appear to affect 10-
z o
25% of people with epilepsy in the community at one time. Reported prevalence in 
hospital populations varies between 7 and 27% and between 11 and 44% in patients 
with intractable epilepsy.69,121'175 Personality disorders were diagnosed in 1-2% in 
people with epilepsy in the community. Rates of personality disorders vary from 15- 
40% in patients with partial epilepsy and/or refractory epilepsy.54’79’81,85 Psychoses 
appear to afflict 2-7% of people with epilepsy in the community. Rates in patients 
with TLE and/or refractory epilepsy are around 10-20%, twice as high as in patients 
with idiopathic generalised epilepsy. Schizophrenia-like psychosis in epilepsy 
(SLPE) is the most common psychotic disorder affecting 10-18% of patients, mostly
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Nosographic approach 
DSM II**
DSM-III79
DSM-III-R54;59;69;75;80;81;133;161 
DSM IV86
ICD (1949)87 
ICD-857 152 
ICD-96668
ICD-1063'85_______________________________
Assessment method
Questionnaires
‘10.00
Epilepsy Questionnaire ’
Washington Psychosocial Seizure Inventory
(wpsir075
Q7Child Depression Inventory (CDI)
Revised Children’s Manifest Anxiety Scale 
(RCMAS)97
Self report scales
Minnesota Multiple Personality Inventory 
(MMPI)65 75
Beck depression inventory (BDI)74,81 
State trait anxiety inventory (STAI)74,81
Behaviour ratings7188 
Child Behaviour Checklist72,73
Structured / semistructured psychiatric
•  *  • 86;88 interview
Structured Clinical Interview for DSM-III-R 
(SCID)81
SCID-P (Patient version)54
SCID-II (Personality Disorders)133
Schedule of Affective Disorders and
Schizophrenia-Lifetime Version (SADS-L)75
Schedule of Affective Disorders and
Schizophrenia (SADS)74
Clinical Interview Schedule68,69
Mental Health Diagnostic Interview Schedule
(DIS)79;176;,7?
Patient records 66__________________________
Time frame of evaluation
Lifetime prevalence54,56,77,79,177 
Current prevalence69,79,87,89,122’176
Table 2. Methodological issues in studies of psychiatric comorbidity 
in epilepsy: differences in assessment methods used in studies.
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those with TLE. It appears that the risk of schizophrenia in patients with all types of 
epilepsy and in those with TLE is 1.5 and 2.35 times respectively higher than in the 
general population.
The types of psychiatric disorders reported for children are often different from those 
reported for adults, and there is a relative paucity of data. However, the prevalence of 
psychiatric disorders appears to follow the same trends of the broad diagnostic 
categories as adults.
The psychiatric comorbidity among people with epilepsy appears to be related to the 
chronicity and severity of epilepsy and shows increasing prevalence when moving 
from community-based and primary care cohorts to cohorts of patients with 
refractory epilepsy or seen at tertiary care centres. It also appears to be related to 
endogenous (e.g. genetic factors, the effect of seizures themselves and of the 
underlying cause of epilepsy) and environmental (or exogenous) factors. The latter 
include iatrogenic causes (e.g. the effect of medication or surgery), psychosocial 
factors, and presence of somatic comorbidity, such as head injury. Certain clinical 
factors are important in the assessment of patients with co-existing psychiatric 
disorders. These include seizure localisation and laterality, type of neuropathology, 
refractoriness, and duration of epilepsy. The diagnosis of psychiatric conditions in 
people with epilepsy can be more straightforward for interictal conditions but may be 
more difficult when these are associated with the ictus. Their management needs to 
take into account the effect of drug treatment on seizures, the potential for drug 
interactions, and any particular considerations for specific types. An important issue 
is the underdiagnosis and undertreatment of these disorders, which may occur in over
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50% of patients. Although it is very difficult to quantify the effect of comorbid 
conditions in epilepsy, it seems that they pose a significant burden on patients and 
their quality of life.
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Chapter 3
DIFFERENCES IN THE USE OF HEALTH SERVICES AMONG PEOPLE 
WITH AND WITHOUT EPILEPSY IN THE UNITED KINGDOM: SOCIO­
ECONOMIC AND DISEASE-SPECIFIC DETERMINANTS
3.1 Introduction
The impact of epilepsy on the individual can be affected by comorbidity14 and 
adverse socioeconomic outcome.9 People with epilepsy require medical care, which
1 751is organised across all levels and involves many different specialties. In a 
population-based survey in Canada, people with epilepsy had the highest level of 
hospital, emergency, medical and psychosocial services than healthy individuals, the
1 70general population, and the chronically ill. In an UK study, a relatively higher
demand for inpatient services was found for patients with epilepsy among all
1 80hospitalised patients in a health district. Among patients with epilepsy, newly or 
recently diagnosed cases, as well as patients with ongoing seizures, appear to make
10 1.1 O '}
higher use of primary and secondary care services. ’
The provision of health services for people with epilepsy in the UK has been 
assessed previously and recommendations made, in relation to the particular clinical 
needs and characteristics of patients, the standards of care and available 
resources.16183’184 Little, however, is known about the relative contribution of the 
comorbidity of epilepsy, and of socio-economic and demographic factors on the 
demand on health services in the UK by patients with epilepsy. Factors such as sex 
and socio-economic status appear to be related to the prevalence of epilepsy, with
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higher prevalence found in males and in people in the lower socio-economic 
groups.184’186 In addition, coexisting conditions, age and sex, and socioeconomic 
conditions are contributing factors to the cost of illness in epilepsy.181187 
Understanding the pattern of health services utilisation by people with epilepsy is 
important for public health and planning of health services. The socio-economic, 
demographic and disease-specific determinants of the use of health services by 
patients with epilepsy of all age groups is examined compared to people without 
epilepsy using data from the fourth national survey of morbidity in general practice 
(MSGP4).
3.2 Methods
The fourth national morbidity survey was a one-year prospective cohort study of 
502,482 patients registered with 60 general practices in England and Wales carried 
out between September 1991 and August 1992. The main objective of the survey was 
to examine the workload and pattern of disease in general practice in relation to the 
age, sex, and socio-economic status of patients. The study population comprised a 
1% sample of the general population. The practices that took part in the survey were 
larger, more likely to be computerised and had a greater interest in the collection of 
morbidity data than the average general practice. Despite this, the sample of patients 
was representative of the population of England and Wales for characteristics such as 
age, sex, and social class.
Trained field workers collected socio-economic data on 83% of the patients in the 
survey. The remaining 17% of patients either refused to be interviewed or left the 
practice or died before they could be interviewed. The information collected included
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details of employment status, occupation, housing tenure, household composition, 
ethnic group and marital status. For all patients in the survey, social class was 
derived from information on occupation and employment status (Box 2).
BOX 2 
Definitions of social class groups
I -  Professional & higher managerial
II -  Managerial
IIIN -  Skilled (non-manual)
HIM -  Skilled (manual)
IV - Partly Skilled
V -Unskilled
Where patients had retired from regular work, their main occupation before 
retirement was recorded and used to assign social class. For married or cohabiting 
women and for widows, social class was based on that of their partner or their former 
husband respectively. The Registrar-General’s classification of social class is used, 
which is the standard social classification system used in the United Kingdom.
3.2.i Recording and validation of data
Before the survey started, doctors and staff from each practice attended three two- 
day training sessions on the recording of morbidity data. Practices then collected data 
for two to four weeks before the start of the survey. These data were analysed and 
any errors or inconsistencies reported to the practices. Once the morbidity survey 
started, general practitioners and nurses recorded information on all face-to-face
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contacts with patients. Each reason for consulting and the place of contact was 
directly entered into patient records on the practice computer. Every consultation was 
assigned an ICD-9 (International Classification of Diseases Ninth Revision) code. 
When patients presented with more than one problem, doctors were asked to record a 
separate ICD-9 code for each problem. Hence, the number of diagnoses recorded was 
greater than the total number of contacts with general practitioners. However, the 
vast majority of contacts were for one problem only. Not all consultations resulted in 
a specific diagnosis. For example, some consultations may have been for preventive 
activities such as immunisation or for general advice. Where this occurred, relevant 
ICD-9 codes for preventive and health promotion activities were used. Data supplied 
by the practices were subject to regular checks to ensure validity.188
After the end of the survey, manual practice records were used to identify all patients 
seen either in the practice or elsewhere by the 60 practices on four separate days. Of 
the 28,000 patient contacts on these four days, 96% of contacts with doctors in the 
practice and 95% at home had been recorded in the data submitted by the practices. 
Finally, for a random sample of 999 patients, diagnostic data from paper records was 
compared with the electronic data submitted by the practices. This showed that 93% 
of diagnoses had been recorded correctly.
3.2.ii Health services workload and morbidity
General practitioners taking part in the survey were required to record confirmed 
diagnoses. For patients with epilepsy, this usually meant that a specialist had 
confirmed the diagnosis. Three measures of health services workload were calculated 
for patients with epilepsy (ICD-9 code 345) and for those without a diagnosis of
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epilepsy. The measures were the number of general practice consultations, the 
number of home visits and the number of secondary care referrals per person. A 
consultation was defined as a face-to-face contact with a general practitioner (GP), 
either at the doctor’s office, in the patient’s home or elsewhere (for example, in a 
community hospital). A home visit was defined as a face-to-face contact with a 
general practitioner in the patient’s home. A secondary care referral was defined as a 
decision to send a patient to see a hospital specialist, either in an outpatient clinic, as 
a hospital inpatient, or in an accident and emergency department.
3.2.iii Statistical methods
Risk ratios with 95% confidence intervals for the measures of health service 
workload were calculated using a generalised linear model with a Poisson error and a 
log link. The proportion of patients who consulted for disorders in each of the ICD-9 
chapters and the proportion of patients who consulted for selected disorders that are 
important causes of ill health was also calculated. Risk ratios with 95% confidence 
intervals for each of these proportions were calculated using the epitab function in 
the Stata software package (Stata Corporation, Texas, USA).
3.3 Results
Patients with a general practitioner diagnosis of epilepsy accounted for 0.33% of all 
patients in the morbidity survey (1,662 / 502,482). People with epilepsy had 
significantly higher general practice consultation rates than people without epilepsy 
(Table 3). In both sexes, consultation rates were increased more than two-fold. These 
increases were not related to age group or social class. After stratification, people 
with epilepsy among all age groups and social classes had significantly higher
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consultation rates than people without epilepsy. In both people with and without 
epilepsy, consultation rates were highest among older people and among people from 
social class V.
People with epilepsy also had significantly higher home-visiting rates than those 
without epilepsy (Table 4). Among males, home visiting rates were four-fold higher 
and among women, three-fold higher in people with epilepsy. Home-visiting rates 
increased with age in people with and without epilepsy. Among people without 
epilepsy, home-visiting rates also increased with decreasing social class. However, 
among people with epilepsy there was no consistent pattern between home-visiting 
rates and social class.
The mean annual number of referrals to secondary care was substantially higher 
among people with epilepsy than among those without (Table 5). In both males and 
females, there was a more than two-fold increase in referral rates to secondary care. 
After stratification for age, there was a much weaker association between age group 
and referral rates among people with epilepsy. This resulted in children with epilepsy 
having a more than five-fold relative increase in referrals to secondary care. After 
stratification for social class, there was still a more than two-fold increase in referral 
rates among all the social class groups in people with epilepsy than in those without 
epilepsy.
A significantly higher proportion of patients with epilepsy consulted for all the 
groups of diseases examined (Table 6), apart from infections. The greatest relative
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People with epile psy People without epilepsy
Number of 
people
Consultations 
per person
Number of 
people
Consultations 
per person
Rate ratio 95% Cl
Sex
Male 810 7.44 244790 2.93 2.54 2.48-2.61
Female 852 9.64 256030 4.46 2.16 2.12-2.21
Age group
0-4 52 8.13 37852 4.72 1.72 1.57-1.89
5-15 157 5.83 68042 2.34 2.49 2.34-2.67
16-24 270 7.17 67439 3.01 2.38 2.28-2.49
25-44 531 8.67 153829 3.29 2.64 2.56-2.71
45-64 376 9.41 101950 4.14 2.27 2.20-2.35
65-74 155 9.86 39431 5.14 1.92 1.83-2.02
75-84 98 10.28 24695 5.83 1.76 1.66-1.87
85+ 23 12.35 7582 5.55 2.23 1.99-2.50
Social class
I 77 8.31 30347 3.37 2.47 2.28-2.67
11 242 8.57 96291 3.85 2.23 2.13-2.33
IIIN 186 8.45 54486 4.28 1.97 1.88-2.07
him 386 9.03 118618 4.34 2.08 2.01-2.15
IV 286 8.82 61731 4.60 1.92 1.84-1.99
V 125 9.70 21387 4.89 1.98 1.87-2.10
Total 1662 8.57 500820 3.71 2.31 2.27-2.35
Table 3. Mean annual number of consultations per person
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People with epilepsy People without epilepsy Rate ratio 95% Cl
Sex
Male 0.84 0.21 4.09 3.79-4.41
Female 1.14 0.35 3.24 3.04-3.45
Age group
0-4 1.10 0.41 2.70 2.08-3.50
5-15 0.78 0.12 6.51 5.45-7.77
16-24 0.41 0.09 4.50 3.73-5.43
25-44 0.51 0.10 4.84 4.28-5.45
45-64 0.78 0.16 4.81 4.28-5.40
65-74 1.83 0.54 3.36 2.99-3.78
75-84 3.64 1.47 2.47 2.23-2.75
85+ 7.13 2.72 2.62 2.24-3.05
Social class
I 0.71 0.16 4.46 3.42-5.81
11 0.90 0.22 4.14 3.62-4.73
IIIN 0.66 0.28 2.30 1.93-2.75
HIM 0.99 0.29 3.44 3.11-3.81
IV 1.03 0.36 2.88 2.57-3.23
V 0.76 0.49 1.55 1.27-1.90
Total 1.00 0.28 3.54 3.38-3.72
Table 4. Mean annual number of home visits per person
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People with epilepsy People without epilepsy Rate ratio 95% Cl
Sex
Male 0.31 0.11 2.83 2.50-3.20
Female 0.39 0.14 2.70 2.43-3.01
Age group
0-4 0.56 0.09 5.87 4.08-8.46
5-15 0.39 0.07 5.70 4.44-7.33
16-24 0.31 0.09 3.37 2.72-4.18
25-44 0.31 0.12 2.60 2.23-3.03
45-64 0.30 0.15 2.03 1.69-2.45
65-74 0.41 0.19 2.22 1.74-2.84
75-84 0.53 0.25 2.11 1.61-2.77
85+ 0.48 0.25 1.88 1.04-3.09
Social class
I 0.30 0.13 2.32 1.54-3.49
II 0.36 0.14 2.53 2.05-3.12
IIIN 0.33 0.15 2.26 1.76-2.91
him 0.41 0.14 2.91 2.49-3.40
IV 0.39 0.15 2.64 2.19-3.19
V 0.35 0.15 2.32 1.72-3.13
Total 0.35 0.13 2.76 2.54-2.97
Table §. Mean annual number of referrals to secondary care per person
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ICD-9 Chapter People with epilepsy (%) People without epilepsy (%) Rate ratio 95% Cl
I Infections 15.0 14.0 1.07 0.95-1.20
II Neoplasms 4.6 2.4 1.91 1.53-2.38
III Endocrine 6.0 3.8 1.58 1.31-1.92
IV Haematological 1.9 1.0 1.93 1.36-2.72
V Mental health 17.7 7.3 2.43 2.19-2.70
VI Neurological* 21.8 17.3 1.26 1.15-1.38
VII Circulatory 14.2 9.3 1.53 1.36-1.72
VIII Respiratory 36.0 30.7 1.17 1.10-1.25
IX Digestive 13.7 8.7 1.57 1.39-1.77
X Genitourinary 15.8 11.3 1.40 1.25-1.57
XIII Musculoskeletal 19.0 15.2 1.25 1.13-1.38
XVII Injuries & poisoning 23.8 13.9 1.71 1.57-1.86
*Excludes epilepsy (ICD-9 345).
Table 6. Percentage of patients consulting for each ICD—9 disease groups
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increase (more than two-fold) in the proportion of patients consulting was for mental 
health disorders. Nearly two-fold increases were seen for neoplastic disorders and for 
haematological disorders. When specific disorders were examined (Table 7), a greater 
proportion of people with epilepsy consulted for each of the disorders examined, but 
because of the relatively small numbers in some groups, the increases were not always 
statistically significant. The largest relative increases in the proportion of patients 
consulting were seen for stroke and dementia. There was also a nearly five-fold 
increase in the proportion of patients who consulted for gastro-intestinal bleed.
3.4 Discussion
Patients with epilepsy as a whole made considerably greater use of health services 
than people without epilepsy, even after stratification for gender, age and social class. 
Moreover, a higher proportion of patients with epilepsy consulted for disorders in all 
disease groups examined, with the exception of infections. This was particularly the 
case for neoplasms, haematological disorders and mental health disorders. When 
some of the most common disorders seen in general practice were analysed 
separately, a higher proportion of patients with epilepsy consulted for dementia, 
stroke and gastrointestinal bleeding. A marginally higher proportion consulted for 
diabetes mellitus, ischaemic heart disease, heart failure, and arthritis. The association 
with gastrointestinal bleeding is particularly surprising, but should be interpreted with 
caution as it was based on a relatively small number of patients. Possible explanations 
could include a higher percentage of elderly people and a higher use of drugs with 
gastrointestinal toxicity by people in the epilepsy group.189 Information on the factors 
influencing the use of health services by epilepsy patients in the UK is lacking and
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Disorder People with 
epilepsy (%)
People without 
epilepsy (%)
Rate ratio 95% Cl
Diabetes mellitus 1.68 1.03 1.64 1.13-2.37
Ischaemic heart disease 2.23 1.59 1.40 1.02-1.93
Heart failure 1.62 0.83 1.97 1.35-2.86
Hypertension 4.27 3.90 1.09 0.87-1.37
Dementia 1.26 0.31 4.08 2.66-6.26
Stroke 2.83 0.36 7.77 5.84-10.34
Degenerative brain disorders 0.84 0.53 1.60 0.95-2.69
Peptic ulceration 0.66 0.47 1.40 0.78-2.53
GI bleeding 0.54 0.11 4.93 2.56-9.51
Arthritis 13.54 10.17 1.33 1.17-1.50
Table 7. Percentage of patients consulting for selected disorders
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there is generally very little information from other countries. The presented data is 
based on an unselected sample of about 500,000 people registered in general practices, 
providing considerable power to detect differences among the subsets of patients 
examined (people with and without a diagnosis of epilepsy). In this study, only people 
with a diagnosis of epilepsy receiving treatment for epilepsy from their general 
practitioner were studied. Hence, people with epilepsy who did not consult their 
general practitioner for an epilepsy-related problem would not have been identified as 
having the condition. For this reason, the prevalence of epilepsy of 0.33% in this study 
was lower than the 0.5% found in some other studies.184 Although a proportion of 
people with epilepsy may not be on treatment190,191 or may not consult a doctor,182
1 S')11 ftlthese patients are likely to be the ones with the least severe epilepsy. ’ This can 
introduce a bias, with more severe cases with greater morbidity being included, 
resulting in an increased use of health services. However, it is considered that patients 
being treated for epilepsy form the key group for the rational planning of services.
The generalisibility of these findings is potentially limited because the practices taking
part in the survey had volunteered. This resulted in fewer practices from the inner city
areas and hence lower rates of unemployment and ethnicity among the patients in the
study. The study sample was, nevertheless, reasonably similar to the population of
England and Wales for most socio-economic characteristics. The data was collected
prospectively and the post survey validation study showed that the diagnostic data was 
1 88recorded accurately. The use of ICD-9 disease categories is helpful for the statistical 
analysis, but it cannot serve as an indicator of an association with other diseases. This 
problem was partly overcome by examining the proportion of patients who consulted 
for conditions encountered commonly in general practice, where more specific
67
associations can be made. No assumptions can be made in the study about the type of 
association or about any association with a particular type of epilepsy, as the 
information required doing this was not collected. Other limitations were that it was 
not feasible to stratify the health service utilisation tables by comorbidity and that the 
comorbidity rates in people with and without epilepsy were not age-standardised.
This is the first large-scale study of its kind and hence there is very little previous 
research against which it can be compared. A few studies have reported on the 
prevalence of associated conditions in cohorts of patients with epilepsy, without 
making any comparisons with the general population or assessing their effect on the 
utilisation of health services.55,56 In case-control studies in particular, epilepsy has 
been associated with a number of other disorders, such as learning disability and 
cerebral palsy,50,51 migraine,21 psychiatric disorders (including depression, anxiety 
disorders, schizophrenia and behavioural disorders), ’ ’ non-epileptic seizures 
and cardiovascular conditions. The sample size in the current study was not 
sufficiently large to allow for separate analysis of these disorders and it was not 
feasible to look at the temporal association between comorbid conditions and epilepsy. 
For example, where epilepsy is associated with stroke, it cannot be certain whether the 
stroke was the cause of the epilepsy or whether epilepsy was present before a first 
stroke took place.
The standards of the medical care received by, and the characteristics of, patients 
treated for epilepsy in the UK have been previously assessed.16,183 No comparisons 
were made with the use of health services in the general population, although it was 
found that the majority of patients receiving treatment for epilepsy in the community
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have long-standing epilepsy, often intractable to medical treatment, and associated 
with considerable social handicap. The higher use of health services by people with 
epilepsy across the different stratifications found in this study corroborates and
17 0 ’ i s oextends findings from previous reports. ’ A rather surprising finding in this study 
is the relatively higher rate of GP consultations and home visits for people with 
epilepsy of higher socioeconomic classes. This suggests that the presence of epilepsy 
can lead to the loss of the “protective” effect of high social class on health status. An 
alternative explanation is that patients with epilepsy are receiving similar care 
irrespective of their social class, i.e., patients with epilepsy from lower social classes 
are not being discriminated against by the health service. This finding is in agreement 
with the results of another large UK study that found only a weak correlation between 
social deprivation and use of hospital in- and out-patient services by people with
1 fiSepilepsy. Another morbidity survey was used to identify the socioeconomic 
determinants of consultation rates in the general population and found evidence 
supporting previous research linking individual “deprivation” characteristics and 
morbidity.194 The authors, however, did not examine people with epilepsy separately. 
In a Finnish population study of the long-term prognosis of seizures with onset in 
childhood no differences were detected in socioeconomic status between patients and 
controls.195 The association between the relatively greater demand of GP services and 
social classes I and II could be attributed to individual patient characteristics, since 
these are much more powerful predictors of consulting patterns than the characteristics 
of the areas in which patients live, and the effects of individual socioeconomic factors 
themselves vary in different geographical areas.194 It might be that social class plays 
only a small role in the demand of health services among people with epilepsy. The 
differences in the use of health services in the various age groups cannot be compared
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with any previous studies. However, they do not appear to follow the age-specific 
incidence and prevalence rate curves196 and may be related to other factors.
3.5 Conclusions
Factors determining the demand on health services by people with epilepsy at all 
levels of care need to be studied and their effects taken into account in the design and 
organisation of health services. This study provides some insight into these factors and 
could serve as a guide for further and more detailed research.
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Chapter 4 
THE EPIDEMIOLOGY OF THE COMORBIDITY OF EPILEPSY IN THE 
GENERAL POPULATION
4.1 Introduction
The epidemiology of the comorbidity of epilepsies has not been well described. Data 
are limited on the cumulative incidence21 and prevalence55'58 120 150 of various 
comorbid conditions in adults with epilepsy in the community. One study compared 
rates of other conditions in controls and adults with childhood-onset epilepsy and 
reported increased psychiatric but not somatic comorbidity in the latter.57 Community- 
based and unselected population case-control studies have reported a higher risk of 
various somatic disorders in epilepsy.21,52’197'201 Psychiatric disorders also appear to 
occur more frequently in people with epilepsy, although most studies have been 
conducted in highly selected groups of patients, mainly with temporal lobe or 
refractory epilepsy. ’ Although case-control studies provide a measure of the 
association between epilepsy and other conditions, they do not provide the rates of 
these conditions in people with epilepsy and in the general population.
A cross-sectional population-based study was undertaken in order to describe the 
prevalence, and evaluate the prevalence ratios, of a number of somatic and psychiatric 
disorders in adults with epilepsy among a large cohort of people registered in general 
practices in the UK.
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4.2 Methods
4.2.i Data source
Data was extracted from the general practice research database (GPRD) for the period 
January 1, 1995 to December 31, 1998. The GPRD is a health database established in 
1987, which contains prospectively collected data from participating general practices 
in England and Wales. It holds anonymous computerised patient records, including 
demographic information, information on significant consultations, details of all 
issued prescriptions, results of investigations, hospital referrals and admissions. 
Participating general practices submit anonymised records at regular intervals, 
following agreed guidelines for recording clinical and prescribing data. Coding of 
diseases is based on Read and OXMIS systems. The comprehensiveness and accuracy 
of the data has been previously documented.202'204 The data for this study came from 
211 general practices with a combined list size of 1.3 million, representing 2.6% of the 
population in England and Wales. The GPRD Scientific and Ethical Advisory Group 
approved the study.
4.2.ii Study population
Patients were included in the analysis if they were alive and permanently registered at 
the practice for the last six months of each analysis year from 1995 to 1998. This was 
to ensure better validity of data. Children under the age of 16 years were excluded 
from the study, as they tend to suffer from different diseases from adults, and chronic 
diseases are rare in children. All Read Code and OXMIS diagnosis codes were 
converted to ICD-9 codes using a table developed by the NHS Centre for Coding and 
Classification and the UK Office for National Statistics. Case ascertainment was based
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on a clinical diagnosis of epilepsy recorded by the general practice, using codes for the 
various epileptic syndromes and seizure types (ICD-9, 345). All those who received 
a new diagnosis of epilepsy and/or consulted for epilepsy during the study period were 
identified from Read and OXMIS codes, and were used as the study group. The 
control group consisted of the remaining registered patients. The use of AEDs was not 
taken as a surrogate for the diagnosis of epilepsy, as not all people with epilepsy take 
AEDs, and AEDs can also be indicated for conditions other than epilepsy.
4.2.iii Measurement of study variables
A number of selected conditions were identified in both groups; these conditions may 
have preceded or followed the development of epilepsy. The selection of these 
conditions was based on their importance in adult clinical practice, either in terms of 
morbidity in the general population or in people with epilepsy (Boxes 3 & 4). This 
selection was also informed by the analysis of the MSGP4 (presented in Chapter 3). 
The diagnosis of epilepsy and all other conditions was based on entries by the general 
practitioner, informed - where available - by information from specialists, 
investigations and hospital admissions.
4.2.iv Outcome measures and statistical analysis
The period prevalence of epilepsy for 1995-1998 was calculated with a 95 percent 
confidence interval (estimated for a single proportion). Age- and sex-specific 
prevalence rates of the selected conditions, and of their diagnostic groups (ICD-9 
chapters), were produced for both groups in two age groups (16-64 and 64+ years) in a 
cross-sectional design. Age-standardised prevalence ratios were calculated, to allow 
for differences in the age distribution between the groups. Prevalence ratios were
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calculated per 10-year age band for the younger age group (16-24; 25-34; to 55-64) 
and per 5-year age band for the older age group (65-69; 70-74; to 80-84; 85+).
BOX 3. Conditions selected for analysis, with ICD-9 codings
MENTAL HEALTH
Neuroses 300
-Obsessive-Compulsive disorder 300.3
-Anxiety 300.0
-Hysteria 300.1
Depression 311
Organic psychoses 291-294
Schizophrenia 295
Alcohol Dependence 303
Dementia 290
SOMATIC
Fractures 800-829
Diabetes mellitus 250
Neoplasia (140-208, excluding 191-192)
Brain neoplasms 191
Meningiomas (malignant & benign) 192.1 +225.2
IHD 410-414
Heart Failure 428
Congenital heart disease 745-746
All CVAs 430-438
Haemorrhagic CVA 431
Ischaemic CVA 433-434
TIA 435
Migraine 346
Parkinson's disease 332
Pneumonias 480-486
Chronic bronchitis 491
Emphysema 492
Peptic ulcers 531-534
All GI bleed 578
Upper GI bleed 578.0
Lower GI bleed 578.1
Unspecified GI bleed 578.9
Eczema 691.8
Rheumatoid arthritis 714
Osteoarthritis 715
Cerebral degeneration (290+331)-(331.3-.4)
Alzheimer's disease 331.0
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BOX 4. Coding for ICD-9 chapters
ICD-9 CHAPTERS ICD-9 Coding
I. Infections and parasitic diseases 001-139
II. Neoplasms 140-239
III. Endocrine, nutritional and metabolic diseases and immunity 240-279
disorders
IV. Diseases of blood and blood-forming organs 280-289
V. Mental disorders 290-319
VI. Disease of the nervous system and sense organs t (320-389)-345
VII. Diseases of the circulatory system 390-459
VIII. Diseases of the respiratory system 460-519
IX. Diseases of the digestive system 520-579
X. Diseases of the genitourinary system 580-629
XI. Complications of pregnancy, childbirth and the puerperium 630-676
XII. Diseases of the skin and subcutaneous tissue 680-709
XIII. Diseases of the musculoskeletal system and connective tissue 710-739
XIV. Congenital anomalies 740-759
XV. Certain conditions originating in the perinatal period 760-779
XVI. Symptoms, signs, and ill-defined conditions 780-799
XVII. Injury and poisoning 800-999
t  Excluding epilepsy (345)
A pooled summary estimate for each age group was produced by the Mantel-Haenszel 
method. Prevalence ratios were calculated for all subjects (males and females 
combined) for each age group, as well as for all individuals across all ages.
4.3 Results
1,041,643 people aged 16 years and over were identified in the study (48.9% males), 
of whom 5,834 had epilepsy. The distribution is shown in table 8. The overall 
prevalence of epilepsy in the study group was 5.6 per 1,000 (95% Cl 5.5-5.7).
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16-64 years 64+ years
Epilepsy Non­
epilepsy
Epilepsy Non­
epilepsy
Male 2321 420312 533 86130
Female 2338 410851 642 118516
Table 8. Number of people identified in each subgroup.
4.3.i Prevalence of selected individual conditions and of conditions per ICD-9 chapter 
in epilepsy 
Individual conditions
The most common psychiatric conditions in epilepsy in adults were depression (18%), 
neuroses (15%) -especially anxiety (11%), and psychoses (9%). Neuroses were more 
pronounced in younger women (20%). Non-organic psychoses (Box 5) and dementia 
were particularly increased in the older age group (15% and 12% respectively). 
Schizophrenia affected less than 1% of patients. Overall, 41% of people with epilepsy 
received a diagnosis of a psychiatric disorder during the study period.
The most common somatic conditions in adults with epilepsy were fractures (10%), 
particularly in women over 64 years (17%), and asthma (9%), particularly in younger 
women (11%). Migraine was common in younger women (8%). In the older group the 
most common diagnoses in people with epilepsy were diabetes (9%), transient 
ischaemic attacks (18%), ischaemic heart disease (14%), heart failure (12%), neoplasia 
(7%), and osteoarthritis (12%). The most common neurological disorders in this age 
group were brain degenerative diseases (14%) and Parkinson’s disease (4%).
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BOX 5.
Organic Psychoses (291-294): Alcoholic psychoses, drug psychoses, transient 
organic psychotic conditions, chronic organic psychotic conditions
Other Psychoses (295-298): Schizophrenic psychoses, affective psychoses,
paranoid states, other non-organic psychoses
Dementia (290): senile dementia, pre-senile dementia, arteriosclerotic
dementia
Cerebral degeneration (290 + 331, excluding 331.3,331.4):
Senile and presenile organic conditions (Senile dementia, simple type; Presenile 
dementia; Senile dementia, depressed or paranoid type; Senile dementia with acute 
confusional state; Arteriosclerotic dementia; Other; Unspecified)
Other cerebral degenerations (Alzheimer's disease, Pick's disease, Senile degeneration 
of brain, Creutzfeldt-Jakob disease, Progressive multifocal encephalopathy, Cerebral 
degeneration in other diseases classified elsewhere, Other cerebral degeneration, 
Unspecified)
Excludes communicating hydrocephalus and obstructive hydrocephalus
Conditions grouped by ICD-9 chapter
Disorders of the respiratory system (61%) and skin (46%), injury & poisoning (45%), 
infections (41%), and psychiatric disorders (40%) appear more often in all adults with 
epilepsy. Diseases of the respiratory (61%), circulatory (59%), nervous (59%), and 
musculoskeletal (59%) systems are diagnosed more frequently in those over 64 years.
4.3.ii Prevalence ratios of selected conditions and conditions per ICD-9 chapter 
Individual conditions
Among psychiatric conditions in epilepsy, organic psychoses, alcohol dependence, 
schizophrenia, and non-organic psychoses have a 4-6 times higher prevalence in 
people with epilepsy than the general population without epilepsy (tables 9, 10 & 11). 
Hysteria is diagnosed four times more often in the younger age epilepsy group than in
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the non-epilepsy group, with men having a higher prevalence ratio than women, 
although the prevalence of hysteria is higher in women. Interestingly, with the 
exception of obsessive-convulsive disorder and hysteria in the older group (which 
have small numbers), all individual psychiatric disorders studied have significantly 
higher prevalence ratios in epilepsy in both age groups (tables 9, 10 & 11).
Brain tumours and meningiomas are diagnosed 55 and 31 times respectively more 
often in people with epilepsy. The prevalence ratio of brain tumours is more 
pronounced in the younger adult age epilepsy group than in the older group. The 
inverse picture is observed with meningiomas, where the risk is higher in the older 
epilepsy group (tables 9 & 10). The prevalence ratio of Alzheimer’s disease or stroke 
is higher in people with epilepsy, considerably so in the younger adult group (tables 9 
& 10). With the exception of osteoarthritis, rheumatoid arthritis, eczema and 
emphysema, all other studied conditions occur more frequently in adults with epilepsy. 
The prevalence of migraine is 60% higher in adults with epilepsy but only 40% higher 
in younger women with epilepsy, where prevalence of the condition is high (tables 9 
& 10). Prevalence ratios of individual comorbid disorders in all individuals, 
irrespective of age or gender are presented in table 11.
Conditions grouped by ICD-9 chapter
In the younger adult group, congenital anomalies are encountered nearly 3 times more 
frequently in epilepsy, especially in men (table 12). Mental health (chapter V) and 
blood disorders (chapter IV) occur twice as often in people with epilepsy and, again, 
the risk is higher in males. Males with epilepsy have a 50% increased prevalence ratio 
for neoplasia, but females do not. With the exception of conditions arising in the
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16-64 YEARS
MEN
Epilepsy Non-Epilepsy Rate Ratio
(N=2321) (N=420312) (95% C.I.)
N (%) N (%)
MENTAL HEALTH DISORDERS
Neuroses 281 (12.1%) 22020 (5.2%) 2.36 (2.11-2.63)
Obsessive-Compulsive disorder 5 (0.2%) 427(0.1%) 2.08 (0.86-5.02)
Anxiety 219(9.4%) 15829 (3.8%) 2.56(2.25-2.90)
Hysteria 6 (0.3%) 207 (0.05%) 5.36(2.38-12.06)
Depression 332 (14.3%) 23661 (5.6%) 2.59(2.35-2.86)
Schizophrenia 19(0.8%) 1004 (0.2%) 3.45 (2.19-5.42)
Organic psychoses 79 (3.4%) 2120 (0.5%) 6.67 (5.35-8.31)
Other psychoses 107 (4.6%) 4008(1.0%) 4.89 (4.05-5.89)
Alcohol Dependence 94 (4.0%) 2960 (0.7%) 5.94 (4.86-7.25)
Dementia 7 (0.3%) 57(0.01) 24.30(11.13-53.08)
SOMATIC DISORDERS
Fractures 235 (10.1%) 20317(4.8%) 2.01 (1.78-2.23)
Diabetes mellitus 65 (2.8%) 7654(1.8%) 1.66(1.31-2.10)
Neoplasia 27(1.2%) 3152 (0.7%) 1.68(1.16-2.44)
Brain neoplasms 15 (0.6%) 52 (0.01%) 54.69 (30.84-96.98)
Meningiomas 0 0 0
IHD 63 (2.7%) 8085 (1.9%) 1.56(1.23-1.98)
Heart Failure 14 (0.6%) 1122 (0.3%) 2.49(1.48-4.20)
Congenital heart disease 10(0.4%) 155 (0.04%) 11.63 (6.14-22.02)
CVA 70 (3.0%) 1187 (0.3%) 11.65 (9.24-14.69)
Haemorrhagic CVA 9 (0.4%) 69 (0.02%) 24.63 (12.31-49.26)
Ischaemic CVA 8 (0.3%) 210(0.05%) 7.54 (3.73-15.22)
TIA 35 (1.5%) 986 (0.2%) 7.09 (5.11-9.84)
Migraine 84 (3.6%) 6745 (1.6%) 2.22 (1.80-2.74)
Parkinson's disease 2(0.1%) 230(0.05) 1.71 (0.43-6.88)
Pneumonias 27(1.2%) 1555 (0.4%) 3.25 (2.22-4.74)
Asthma 173 (7.5%) 24129 (5.7%) 1.26(1.10-1.46)
Chronic bronchitis 5 (0.2%) 768 (0.2%) 1.29 (0.54-3.10)
Emphysema 4 (0.2%) 283 (0.1%) 2.82 (1.05-7.55)
Peptic ulcers 31 (1.3%) 3157(0.8%) 1.88 (1.32-2.67)
GI bleed 35 (1.5%) 1697(0.4%) 3.80 (2.73-5.30)
Upper GI bleed 24(1.0%) 1001 (0.2%) 4.34 (2.90-6.49)
WOMEN OVERALL
Epilepsy Non-Epilepsy Rate Ratio Rate ratio
N-2338 N=410851 (95% C.I.) (95% C.I.)
N (%) N (%)
471 (20.1%) 45355 (11%) 1.87(1.72-2.02) 2.03(1.90-2.17)
12 (0.5%) 675 (0.2%) 3.10(1.76-5.49) 2.71 (1.68-4.37)
333 (14.2%) 30902 (7.5%) 1.95 (1.77-2.16) 2.16(2.0-2.34)
13 (0.6%) 639 (0.2%) 3.72 (2.15-6.43) 4.13(2.62-6.50)
550 (23.5%) 54850 (13.3%) 1.79(1.67-1.93) 2.04(1.92-2.16)
14 (0.6%) 562 (0.1%) 4.59(2.70-7.78) 3.83 (2.72-5.40)
43 (1.8%) 1233 (0.3%) 6.26 (4.63-8.46) 6.48 (5.42-7.74)
116(5.0%) 6375 (1.6%) 3.26 (2.73-3.90) 3.89 (3.42-4.43)
32 (1.4%) 1173 (0.3%) 5.01 (3.53-7.1) 5.64 (4.74-6.72)
9 (0.4%) 72 (0.02%) 26.40(13.19-52.84) 25.22(15.02-42.33)
166 (7.1%) 11434 (2.8%) 2.61 (2.25-3.02) 2.20 (2.00-2.42)
58 (2.5%) 5601 (1.4%) 2.00(1.55-2.58) 1.80(1.52-2.15)
22 (0.9%) 4788(1.2%) 0.90 (0.60-1.38) 1.22 (0.92-1.61)
19(0.8%) 38(0.01%) 90.36(52.19-156.46) 70.70 (47.70-104.80)
1 (0.04%) 8 (0%) 23.62 (2.84-196.24) 13.57(1.75-105.20)
33 (1.4%) 3853 (0.9%) 1.76(1.26-2.46 1.63 (1.34-1.98)
7 (0.3% 628 (0.2%) 2.31 (1.01-4.85) 2.44(1.59-3.73)
7 (0.3%) 183 (0.04%) 6.62 (3.11-14.07) 8.89 (5.47-14.46)
72 (3.1%) 807 (0.2%) 17.75(14.04-22.43) 14.19(12.04-16.73)
5 (0.2%) 40 (0.01%) 24.28 (9.50-62.04) 24.43 (13.99-42.66)
12(0.5%) 127 (0.03%) 18.74(10.37-33.88) 11.87 (7.57-18.61)
38(1.6%) 867 (0.2%) 8.89 (6.47-12.22) 7.95 (6.33-9.98)
182 (7.8%) 22116(5.4%) 1.44(1.25-1.65) 1.63(1.45-1.83)
3 (0.1%) 167 (0.04%) 3.63 (1.16-1 1.35) 2.51 (1.041-6.06)
36(1.5%) 1417(0.3%) 4.71 (3.40-6.55) 3.94 (3.08-5.05)
265 (1 1.3%) 31481 (7.7%) 1.45 (1.29-1.62) 1.37(1.25-1.50)
14 (0.6%) 884 (0.2%) 3.18 (1.88-5.37) 2.30 (1.46-3.60)
3 (0.1%) 203 (0.05%) 3.00 (0.96-9.39) 2.92 (1.38-6.14)
25 (1%) 1759 (0.4%) 2.73 (1.84-4.03) 2.17(1.67-2.81)
27(1.2%) 1085 (0.3%) 4.56 (3.12-6.66) 4.09 (3.19-5.25)
22 (0.9%)
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64+ YEARS
MEN WOMEN OVERALL
Epilepsy Non-Epilepsy Rate Ratio Epilepsy Non-Epilepsy Rate Ratio Rate ratio
N=533 N=86130 (95% C.I.) N=642 N=118516 (95% C.I.) (95% C.I.)
N (%) N (%) N (%) N (%)
MENTAL HEALTH DISORDERS
Neuroses 51 (9.6%) 4104 (4.8%) 2.00(1.54-2.60) 70(10.9%) 11473 (9.7%) 1.14(0.92-1.43) 1.36(1.15-1.61)
Obsessive-Compulsive disorder 1 (0.2%) 38 (0.04%) 4.24 (0.58-30.79) 0 91 (0.1%) 0 1.36 (0.19-9.70)
Anxiety 40 (7.5%) 3237 (3.8%) 1.99(1.47-2.69) 58 (9.0%) 9291 (7.8%) 1.17(0.91-1.49) 1.37(1.13-1.65)
Hysteria 1 (0.2%) 29 (0.03%) 5.54 (0.76-40.49) 1 (0.2%) 102 (0.1%) 1.83 (0.26-13.12) 2.67 (0.66-10.77)
Depression 73 (13.7%) 4867 (5.7%) 2.39(1.93-2.96) 108(16.8%) 13277 (1 1.2%) 1.5 (1.26-1.78) 1.72(1.50-1.97)
Schizophrenia 8(1.5%) 85 (0.1%) 15.39(7.50-31.56) 1 (0.2%) 187(0.2%) 1.00 (0.14-7.21) 5.85 (3.02-11.32)
Organic psychoses 9(1.7%) 242 (0.3%) 5.95 (3.07-11.50) 10(1.6%) 503 (0.4%) 3.46(1.86-6.43) 4.23 (2.72-6.70)
Other psychoses 66(12.4%) 2062 (2.4%) 4.94 (3.94-6.21) 105 (16.4%) 4704 (4.0%) 3.75 (3.15-4.46) 4.10(3.57-4.70)
Alcohol Dependence 9(1.7%) 333 (0.4%) 4.47(2.32-8.60) 8(1.2%) 166 (0.1%) 9.22 (4.56-18.64) 6.13(3.80-9.90)
Dementia 52 (9.8%) 1135(1.3%) 6.92 (5.32-9.00) 87(13.6%) 2626 (2.2%) 5.38 (4.43-6.52) 5.83 (4.99- 6.81)
SOM ATIC DISORDERS
Fractures 54(10.1%) 2761 (3.2%) 3.10(2.40-4.01) I l l  (17.3%) 10398 (8.8%) 1.89(1.59-2.24) 2.10(1.82-2.43)
Diabetes mellitus 46 (8.6%) 6893 (8.0%) 1.08 (0.82-1.42) 64(10.0%) 7179 (6.1%) 1.66(1.31-2.10) 1.37(1.15-1.64)
Neoplasia 40 (7.5%) 7078 (8.2%) 0.89 (0.66-1.20) 39(6.1%) 6839 (5.8%) 1.03 (0.76-1.40) 0.97 (0.78-1.20)
Brain neoplasms 2 (0.4%) 16(0.02%) 20.87 (4.83-90.12) 0 0 0 11.55 (2.78-48.08)
Meningiomas 1 (0.2%) 3 (0.00) 57.88 (5.73-584.21) 1 (0.2%) 1 (0.00) 184.67(12.44-2740.43) 91.88(16.70-505.47)
IHD 87(16.3%) 12005 (13.9%) 1.16(0.96-1.41) 78 (12.1%) 11551 (9.7%) 1.23 (0.99-1.51) 1.21 (1.05-1.40)
Heart Failure 55 (10.3%) 6015 (7.0%) 1.41 (1.10-1.81) 81 (12.6%) 7885 (6.7%) 1.74(1.42-2.13) 1.60(1.37-1.88)
CVA 129 (24.2%) 3547 (4.1%) 5.69 (4.89-6.62) 134 (20.9%) 4441 (3.7%) 5.15 (4.43-5.97) 5.46 (4.91-6.07)
Haemorrhagic CVA 0 80 (0.1%) 0 3 (0.5%) 94 (0.1%) 5.72(1.82-17.98) 2.92 (0.93-9.13)
Ischaemic CVA 20 (3.8%) 484 (0.6%) 6.62 (4.27-10.27) 12 (1.9%) 424 (0.4%) 5.14(2.91-9.08) 6.09 (4.30-8.62)
TIA 89(16.7%) 3361 (3.9%) 4.15 (3.42-5.02) 125(19.5%) 4752 (4.0%) 4.52 (3.86-5.29) 4.38 (3.88-4.94)
Migraine 7(1.3%) 551 (0.6%) 2.10(1.00-4.42) 9(1.4%) 1784 (1.5%) 0.98 (0.51-1.88) 1.23 (0.76-2.00)
Parkinson's disease 25 (4.7%) 1184(1.4%) 3.28 (2.23-4.82) 22 (3.4%) 1215 (1.0%) 3.2 (2.12-4.84) 3.29 (2.48-4.36)
Pneumonias 31 (5.8%) 2139(2.5%) 2.25 (1.59-3.17) 50 (7.8%) 2596 (2.2%) 3.19(2.46-4.15) 2.78 (2.25-3.426)
Asthma 36 (6.8%) 5557 (6.5%) 1.05 (0.76-1.44) 39(6.1%) 7882 (6.7%) 0.94 (0.69-1.28) 0.99 (0.79-1.23)
Chronic bronchitis 16(3.0%) 1872 (2.2%) 1.36(0.84-2.20) 13 (2.0%) 1707(1.4%) 1.43 (0.83-2.45) 1.41 (0.98-2.03)
Emphysema 2 (0.4%) 651 (0.8%) 0.49 (0.12-1.96) 1 (0.2%) 332 (0.3%) 0.58(0.08-4.12) 0.54 (0.17-1.67)
Peptic ulcers 20 (3.8%) 1700 (2.0%) 1.89(1.23-2.92) 8(1.2%) 1417(1.2%) 1.04 (0.52-2.08) 1.55(1.08-2.25)
GI bleed 18 (3.4%) 1228(1.4%) 2.30(1.46-3.64) 24 (3.7%) 1402 (1.2%) 2.96 (2.0-4.39) 2.67(1.98-3.60)
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ALL INDIVIDUALS
Prevalence ratio
(95% C.I.)
MENTAL HEALTH DISORDERS
Neuroses 1.90 (1.79-2.02)
Obsessive-Compulsive disorder 2.57 (1.61-4.10)
Anxiety 1.99 (1.85-2.14)
Hysteria 3.92 (2.55-6.04)
Depression 1.98 (1.87-2.09)
Schizophrenia 4.13 (3.05-5.61)
Organic psychoses 6.05 (5.13-7.14)
Other psychoses 3.98 (3.62-4.38)
Alcohol Dependence 5.70 (4.84-6.71)
Dementia 6.34 ( 5.47-7.35)
SOMATIC DISORDERS
Fractures 2.17 (2.00-2.35)
Diabetes mellitus 1.57 (1.39-1.78)
Neoplasia 1.05 (0.89-1.25)
Brain neoplasms 55.05 (38.00-79.75)
Meningiomas 31.44 (9.16-107.91)
IHD 1.34(1.19-1.50)
Heart Failure 1.68(1.45-1.95)
Congenital cardiac abnormalities 7.34 (4.58-11.75)
CVA 6.96 (6.38-7.60)
Haemorrhagic CVA 10.62 (6.52-17.32)
Ischaemic CVA 7.49 (5.69-9.86)
TIA 4.94 (4.44-5.50)
Migraine 1.60(1.43-1.80)
Parkinson's disease 3.19(2.44-4.18)
Pneumonias 3.19(2.72-3.74)
Asthma 1.30(1.19-1.41)
Chronic bronchitis 1.67 (1.26-2.21)
Emphysema 1.25 (0.67-2.34)
Peptic ulcers 1.92(1.55-2.37)
GI bleed 3.37 (2.78-4.08)
Upper GI bleed 4.31 (3.41-5.46)
Lower GI bleed 2.16(1.43-3.25)
Unspecified GI bleed 2.85 (1.77-4.59)
Eczema 0.90 (0.47-1.74)
Rheumatoid arthritis 0.99 (0.67-1.47)
Osteoarthritis 1.02 (0.91-1.15)
Cerebral degeneration 6.80 (5.96-7.76)
Alzheimer's 8.05 (5.89-11.00)
Table 11. Prevalence ratios of comorbid disorders in all individuals, 
irrespective of age or gender
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perinatal period (chapter XV), diseases in all other chapters occur slightly more often 
in people with epilepsy.
In the older group, the prevalence ratio of mental disorders in people with epilepsy is 
twice that of the background non-epilepsy population (table 13). Similarly, the 
prevalence ratios of infections, blood and genitourinary disorders, injuries & poisoning 
are about 50% higher. The prevalence ratio of cardiovascular, nervous and digestive 
disorders, although common in older adults with epilepsy, is only 20-40% higher. 
Musculoskeletal conditions do not occur more often in people with epilepsy in this age 
group (table 13).
4.4 Discussion
4.4.i Principal findings
In this large population-based study, the frequency of selected conditions, as well as 
groups of conditions, is described in a primary care cohort of adults with and without 
epilepsy, stratified by age and sex. As expected, conditions common in the general 
population were also common in adults with epilepsy. However, the prevalence ratio 
of all specific disorders under study was increased in adults with epilepsy with the 
exception of eczema, rheumatoid arthritis and osteoarthritis. Psychiatric disorders 
occurred twice as often. The prevalence ratio of somatic disorders across categories 
was increased in people with epilepsy with the exception of musculoskeletal and 
connective tissue disorders in older adults. Congenital anomalies were increased in 
younger adults with epilepsy, but perinatally acquired conditions were not (probably 
related to poor survival in this group).
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16-64 YEARS
MEN WOMEN O V ER A LL
Epilepsy Non-Epilepsy Rate Ratio Epilepsy Non-Epilepsy Rate Ratio Rate ratio
N=2321 N=420312 (95% C.I.) N=2338 N =410851 (95% C.I.) (95% C.I.)
N (%) N (%) N (%) N (%)
ICD-9 CHAPTERS
I. Infections and parasitic diseases 783 (33.7%) 96840 (23.0%) 1.45 (1.37-1.53) 1157(49.5% ) 148663 (36.2%) 1.34(1.29-1.40) 1.39(1.34-1.44)
II. Neoplasms 128(5.5% ) 15541 (3.7%) 1.52(1.29-1.80) 173 (7.4%) 29477 (7.2%) 1.06 (0.91-1.22) 1.22 (1.09-1.36)
III. Endocrine, nutritional and metabolic diseases
and immunity disorders 197(8.5% ) 26493 (6.3%) 1.45(1.27-1.65) 341 (14.6%) 32283 (7.9%) 1.98(1.80-2.18) 1.75(1.62-1.89)
IV. Diseases o f blood and blood-forming organs 75 (3.2%) 4993 (1.2%) 2.75 (2.19-3.44) 250(10.7% ) 27283 (6.6%) 1.58(1.41-1.78) 1.78(1.60-1.97)
V. Mental disorders 840 (36.2%) 57612(13.7% ) 2.68 (2.54-2.83) 1009 (43.2%) 97878 (23.8%) 1.84(1.76-1.93) 2.15 (2.08-2.23)
VI. Disease o f  the nervous system
and sense organs 905 (39.0%) 110608 (26.3%) 1.50(1.43-1.58) 1125 (48.1%) 146322 (35.6%) 1.37(1.31-1.43) 1.43 (1.38-1.47)
VII. Diseases o f the circulatory system 416(17.9% ) 48281 (11.5%) 1.67(1.54-1.81) 437(18.7% ) 56934(13.9% ) 1.45 (1.34-1.57) 1.55 (1.47-1.65)
VIII. Diseases o f the respiratory system 1255 (54.1%) 186419 (44.4%) 1.21 (1.16-1.25) 1584 (67.8%) 242827 (59.1%) 1.14(1.11-1.17) 1.17(1.14-1.20)
IX. Diseases o f the digestive system 748 (32.2%) 79881 (19.0%) 1.73 (1.63-1.84) 926 (39.6%) 104843 (25.5%) 1.58(1.50-1.66) 1.65( 1.58-1.71)
X. Diseases o f  the genitourinary system 306(13.2% ) 40594 (9.7%) 1.39(1.25-1.54) 1286 (55.0%) 189918(46.2% ) 1.19(1.15-1.24) 1.24 (1.19-1.29)
XI. Complications o f  pregnancy, childbirth 
and the puerperium
661 (28.3%) 94718(23.1% ) 1.19(1.11-1.27)
XII. Diseases o f the skin and subcutaneous tissue 961 (41.4%) 120743 (28.7%) 1.43 (1.36-1.50) 1134 (48.5%) 156394 (38.1%) 1.26(1.12-1.32) 1.34 (1.30-1.38)
XIII. Diseases o f the musculoskeletal system
and connective tissue 985 (42.4%) 157827 (37.5%) 1.16(1.10-1.21) 1203 (51.5%) 182490(44.4% ) 1.20(1.15-1.24) 1.18(1.15-1.22)
XIV. Congenital anomalies 35(1.5% ) 1782 (0.4%) 3.48 (2.50-4.85) 34(1.5% ) 2432 (0.6%) 2.37(1.70-3.32) 2.84 (2.24-3.60)
XV. Certain conditions originating
in the perinatal period 1 (0.04%) 146 (0.03%) 1.22 (0.17-8.72) 10(0.4% ) 1831 (0.4%) 0.89 (0.48-1.66) 0.93 (0.51-1.68)
XVI. Symptoms, signs, and ill-defined conditions 1744 (75.1%) 181805 (43.3%) 1.75(1.71-1.79) 1961 (83.9%) 247043 (60.1%) 1.40(1.38-1.43) 1.55 (1.53-1.58)
XVII. Injury and poisoning 1095 (47.2%) 132692(31.6%) 1.47(1.41-1.53) 1022 (43.7%) 110863 (27.0%) 1.62(1.54-1.69) 1.53 (1.48-1.58)
Table 12. Rates of disease groups per gender and epilepsy status in people aged 16-64 years.
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64+ YEARS
MEN WOMEN O V ER A LL
Epilepsy Non-Epilepsy Rate Ratio Epilepsy Non-Epilepsy Rate Ratio Rate ratio
N=533 N=86130 (95% C.I.) N=642 N =118516 (95% C.I.) (95% C.I.)
N (%) N (%) N (%) N (%)
ICD-9 CHAPTERS
I. Infections and parasitic diseases 192 (36.0%) 20940 (24.3%) 1.47(1.31-1.65) 279 (43.5%) 34049(28.7% ) 1.50(1.38-1.64) 1.48(1.38-1.59)
II. Neoplasms 65(12.2% ) 9595 (11.1%) 1.08 (0.86-1.35) 78(12.1% ) 10772 (9.1%) 1.33 (1.08-1.64) 1.21 (1.04-1.41)
III. Endocrine, nutritional and metabolic diseases
and immunity disorders 113(21.2% ) 16513(19.2% ) 1.11 (0.94-1.31) 193 (30.1) 21579(18.2% ) 1.67(1.48-1.88) 1.41 (1.28-1.552)
IV. Diseases of blood and blood-forming organs 54(10.1% ) 4935 (5.7%) 1.71 (1.33-2.21) 82(12.8% ) 9623 (8.1%) 1.51 (1.23-1.84) 1.57 (1.34-1.84)
V. Mental disorders 218(40.9% ) 12974(15.1% ) 2.69 (2.42-2.98) 297 (46.3%) 27338(23.1% ) 1.96(1.81-2.14) 2.19 (2.05-2.33)
VI. Disease o f  the nervous system
and sense organs 324 (60.8%) 40164 (46.6%) 1.29(1.21-1.38) 373 (58.1%) 58219(49.1% ) 1.17(1.10-1.25) 1.22 (1.17-1.28)
VII. Diseases o f  the circulatory system 335 (62.9%) 39743 (46.1%) 1.35 (1.26-1.44) 393 (61.2%) 54863 (46.3%) 1.31 (1.23-1.39) 1.33 (1.27-1.39)
VIII. Diseases o f the respiratory system 335 (62.9%) 44285 (51.4%) 1.22(1.14-1.30) 391 (60.9%) 63663 (53.7%) 1.13(1.07-1.21) 1.17(1.12-1.22)
IX. Diseases o f the digestive system 285 (53.5%) 33204 (38.6%) 1.37(1.27-1.49) 346 (53.9%) 46993 (39.7%) 1.34(1.25-1.44) 1.36(1.29-1.43)
X. Diseases o f  the genitourinary system 203 (38.1) 21275 (24.7%) 1.52 (1.37-1.70) 305 (47.5%) 36745 (31.0%) 1.52(1.40-1.65) 1.51 (1.42-1.62)
XI. Complications o f pregnancy, childbirth
and the puerperium 138(21.5% ) 19382(16.4% ) 1.33 (1.15-1.55)
XII. Diseases o f the skin and subcutaneous tissue 264 (49.5%) 33249 (38.6%) 1.28(1.17-1.39) 341 (53.1%) 50071 (42.2%) 1.25(1.16-1.34) 1.26(1.19-1.33)
XIII. Diseases o f the musculoskeletal system
and connective tissue 302 (56.7%) 45985 (53.4%) 1.06(0.98-1.14) 390 (60.7%) 73074 (61.7%) 0.99(0.93-1.05) 1.01 (0.96-1.06)
XIV. Congenital anomalies 2 (0.4%) 378 (0.4%) 0.85 (0.21-3.41) 8(1.2% ) 564 (0.5%) 2.64(1.32-5.28) 1.85 (0.99-3.44)
XV. Certain conditions originating
in the perinatal period 0 0 0 1 (0.2%) 80 (0.1%) 2.27 (0.32-16.22) 1.51 (0.21-10.82)
XVI. Symptoms, signs, and ill-defined conditions 481 (90.2%) 58142 (67.5%) 1.33 (1.29-1.37) 580 (90.3%) 86137(72.7% ) 1.24(1.20-1.27) 1.27 (1.25-1.30)
XVII. Injury and poisoning 216(40.5% ) 21105 (24.5%) 1.64(1.48-1.82) 319(49.7% ) 38921 (32.8%) 1.49(1.37-1.61) 1.53 (1.44-1.63)
Table 13. Rates of disease groups per gender and epilepsy status in people aged 64 years and older.
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4.4. ii Strengths and weaknesses of the study
This study uses information from the GPRD, a large and well-validated general
practice derived database that has been used for epidemiological research for over 10
206years. The population of participating practices was large: 1.3 million in 1998 (over 
one million adults), and the age/sex distribution of this population was broadly similar 
to that of England & Wales in the same year. All practices passed quality tests on the 
data they supplied to the database. Selection criteria for the study population resulted 
in under-representation of more mobile -  and possibly healthier - population groups 
and exclusion of people who died. Because prevalence is the result of both the 
condition’s incidence and its mortality rate, factors influencing survival may lead to 
spurious associations between disorders. However, it is considered unlikely that the 
studied conditions affected survival differently in adults with and without epilepsy. An 
under-representation of healthy individuals in the study cohort may also result from 
young people without illness who are not registered with a GP. This would lead to 
overestimation of disease rates compared to the total population and, subsequently, to 
underestimation of PRs in epilepsy. Ninety eight percent of the UK population, 
however, is registered with a GP and the degree of any such underestimation of 
ratios would be small.
The calculated prevalence ratios are weighted averages of the age band-specific PR 
estimates. The stratum-specific PRs appear to be consistent across the 10-year age 
bands (although not always statistically significant due to smaller numbers). The 
consistency o f estimated ratios across different practices could not be assessed (so as 
to check for any regional or urban-rural variations), as the information on practice
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characteristics is not released for confidentiality purposes. However, the population is 
representative o f the population of England and Wales.
The main limitation of this study is that the diagnosis was not validated, for example, 
by examining whether patients had their diagnosis confirmed by a specialist, because 
of resource constraints. Misdiagnosis is an important problem in the management of 
epilepsy, with as many as 20% of cases inaccurately diagnosed.3,208 Another limitation 
is that the study only includes people coming into contact with the health service and 
would not include cases that had not come to a GP’s or specialist’s attention. A 
proportion of people with epilepsy may not consult a doctor, especially prevalent cases 
of epilepsy, the elderly, and people whose seizures are well controlled.182 This can 
introduce an admission-rate bias, with more severe cases with greater morbidity being 
included in the study. People with epilepsy are known to make higher use of health 
services than people without epilepsy (refer to Chapter 3) however, it is not known 
what proportion of the health services requirement is due to the severity of epilepsy, 
its treatment, aetiology or other factors. It was not feasible to look at the temporal 
association between epilepsy and comorbid disorders. For example, where epilepsy is 
associated with a brain tumour, it cannot be established whether the brain tumour was 
the cause of epilepsy or whether epilepsy was present before the development of the 
tumour.
4.4.iii Comparison with other studies
The period prevalence of epilepsy between 1995-1998 in the study was 5.6 per 1,000 
(95% Cl 5.5-5.7/1,000). This is lower than the 1998 age-standardised prevalence 
reported previously by the researcher’s group (7.4/1,000) using the same GPRD
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practices.209 This discrepancy arose because of differences in case selection. In the 
previous study the prevalence figure included people who had a diagnosis of epilepsy 
recorded several years prior to the study period.209 In the current analysis no prior 
information was available. Hence, only diagnoses recorded during the study period 
would have been included and the method used resulted in a lower prevalence of 
epilepsy.
This is the first large-scale study of the comorbidity of epilepsy in an unselected 
population. Its findings are consistent with those of previous community-based and 
unselected population case-control studies that suggest a higher risk of vascular 
disorders (strokes, myocardial infarction, peripheral vascular disease,
loo-Tnihypercholesterolaemia, left ventricular hypertrophy), migraine, hypertension, ’ 
dementia,200 brain tumours,210 fractures,197 and depression210 in epilepsy. The size of 
the risk (here expressed as a prevalence ratio) cannot be compared, however, as some 
of these studies were conducted in incident cases of epilepsy199'201210 and studied the 
prevalence of conditions before the development of epilepsy,199,200,210 or assessed the
91.1  0 7
incidence of co-occurring conditions. ’
The higher prevalence ratio of somatic disorders in this study contrasts with the results 
from a population-based cohort study in Finland, which reported increased psychiatric
cn
but not somatic comorbidity in comparison to controls. That study, however, was 
conducted in adults with childhood-onset epilepsy and a mean age of 35.6 years at the 
end of follow-up, who have different baseline characteristics from the younger adult 
epilepsy group in this study. In addition, the sample size of only 220 people with 
epilepsy may not have been large enough to detect any real differences. A population-
87
based prevalence study in 713 adults with epilepsy in Sweden reported a 5.9% 
prevalence o f psychiatric disorders and a 50% prevalence of somatic disorders and 
disabilities.55 This compares with a 40% period prevalence of psychiatric disorders in 
this study and a much higher prevalence of somatic disorders.
The MSGP4 showed that higher proportion of people with epilepsy consulted for 
neoplasms, haematological and mental health disorders, diabetes, ischaemic heart 
disease, heart failure, dementia, stroke and gastrointestinal bleeding than people 
without epilepsy in the community (refer to Chapter 3). Although these estimates were 
not age-standardised, and rate ratios compared proportions rather than prevalence 
rates, results were very similar to this study, adding further support to the GPRD 
findings. It is noteworthy that in both studies the risk of gastrointestinal bleeding was 
significantly raised (Risk Ratio [RR] 4.93 in the MSGP4 study and PR 3.37 in this 
study) (further discussion below under PEPTIC ULCERS AND
GASTROINTESTINAL BLEED).
4.4.iv Association of individual disorders with epilepsy
The conditions that appear to occur more frequently in people with epilepsy in this 
study and their possible association with epilepsy, according to the scheme proposed 
by Lipton and Silberstein19 and discussed earlier (Chapter 1), are discussed here in 
more detail. Eczema, rheumatoid arthritis and osteoarthritis are not discussed, as they 
do not occur more frequently in epilepsy. The psychiatric conditions (with the 
exception of alcohol dependence) are also omitted from further discussion, since they 
have been reviewed previously in the thesis (Chapter 2).
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FRACTURES
Two reasons may underlie the association of fractures and epilepsy: fractures may 
occur as a result of injury in people with epilepsy, or post-traumatic epilepsy may 
develop as a result of accidents causing head trauma.211 Injuries are common in 
epilepsy, with up to 30% of people with the condition reporting injuries.212 The 
incidence of extremity fractures in a group of adult patients with epilepsy attending an 
outpatient clinic in Sweden (expressed as the Standardised Morbidity Ratio) was 2.4 
times higher (95% Cl 1.5-3.6) in comparison to the general population. Nearly half 
of the fractures in the study were definitely or possibly seizure related. Seizures 
associated with falls (atonic and tonic-clonic seizures, in particular) increase the risk 
of injury, but any seizure that is associated with alteration of consciousness may result 
to injury. Epilepsy and its treatment, including the newer drugs, are risk factors for 
low bone density214 and may, therefore, predispose further to osteoporotic fractures. 
The elderly may be particularly at risk, as epilepsy was shown to be an independent
7 1 Srisk factor for osteoporotic hip fractures in women aged 70 years and over and 
women 65 years and older on AEDs have a two- to three-fold risk of fractures
71 f \ ’ 71 7compared to women of similar age without epilepsy. ’ Another study also showed
71^that men 45 years or older were at higher risk of fractures. In the currrent study, 
however, the PR of fractures was no different between the age groups [PR 2.20 (95% 
Cl 2.00-2.42) for the 16-64 years vs. PR 2.10 (95% Cl 1.82-2.43) for the 64+ years
1 Q7group] (tables 9 & 10). A large population-based study by Annegers et al. found no 
definite evidence to support the contention that the incidence of fractures is greatly 
increased by long-term AED use, as it would be expected in the case of AED-induced 
osteoporosis. Taken together, these data suggest that the role of AED-induced
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osteoporosis in the incidence of fractures in people with epilepsy in the community 
may be limited.
DIABETES
Diabetes does not appear to be directly associated with epilepsy and, so far, long-term 
use of AEDs is not known to predispose to the development of diabetes. Diabetes is a 
major risk factor for cerebro- and cardiovascular disorders, that are known risk factors 
for epilepsy, and thus indirectly predisposes to epilepsy.
ISCHAEMIC HEART DISEASE (IHD) & HEART FAILURE
These conditions reflect systemic vascular disease (including cerebrovascular) and 
share risk factors for epilepsy, such as hypertension, left ventricular hypertrophy,
r n .  i  Q Q * 9 A 1
myocardial infarction, and peripheral arterial disease. ’ ’ Cerebral arteriosclerosis
without a history of stroke is associated with higher incidence of late onset epilepsy
j\Q
and is often the only finding on imaging in elderly patients with new-onset seizures. 
Compared with subjects free of these conditions in the population, IHD increases the
n i Q
risk of stroke by 2 and heart failure by 4. IHD and heart failure are also associated 
with atrial fibrillation that further increases the risk of stroke in their presence by a
7 1factor of 2-3, especially in the elderly. ’ In the Rochester study, the incidence of 
IHD in people with epilepsy (expressed as a Standardised Morbidity Ratio) was 1.63 
(95% Cl, 1.20-2.15) times higher compared to people in the community.221 The risk
was 50% higher in people with idiopathic epilepsy and nearly 100% higher for those
771with remote symptomatic epilepsy. In the current study the prevalence of these 
conditions is higher in the younger adult age group (PR 1.63 vs. 1.21 in the 64+ group) 
(tables 9 & 10), most probably because of their lower prevalence in the general
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population o f the same age group, and because it appears that the attributable risk of 
stroke for these conditions decreases with age.219
STROKES/CEREBROVASCULAR DISEASE
Cerebrovascular disease is the most commonly identified antecedent of epilepsy, 
accounting for 11 % of cases, particularly in the elderly.222 The incidence of epilepsy 
as a late sequel of stroke has been estimated at 2.5% and 3.3% in two large population- 
based studies with adequate follow-up.223,224 Seizures occur more commonly with 
haemorrhagic stroke than with ischaemic stroke,224 with the prevalence of epilepsy in 
patients with primary intracerebral haemorrhage reported to be 6.5% in 2- to 5-year 
survivors. The risk of haemorrhagic stroke in patients with epilepsy in current study 
was much higher than the risk for ischaemic stroke, particularly in the younger age 
group (tables 9 & 10). The small numbers of patients with haemorrhagic stroke in the 
older age groups may be related to misclassification or reflect the poor survival of 
these patients in the study. Risk factors for the development of epilepsy following 
ischaemic stroke are early seizure occurrence (within 2 weeks of stroke), stroke 
recurrence and increased disability.223,224 In this study, the risk of ischaemic stroke was 
higher among women in the younger age group (18.74% vs. 7.54% in men), because 
of the significantly lower number of strokes in the non-epilepsy population in this 
group (127 women vs. 210 men). Strokes are the most common cause of seizures in 
the elderly accounting for up to 37% of new cases. ’
CONGENITAL HEART DISEASE (CHD)
CHD occurs in at least 10 per 10,000 live bom children.228 Over the past 20 to 30 
years, major advances have been made in the diagnosis and treatment of CHD in
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children. As a result many children with such disorders survive to adulthood. The CNS 
is one o f the most common sites of complications associated with CHD and, in 
addition, cardiac abnormalities can be associated with congenital cerebral
• 228  229dysgenesis. ’ Any kind of acquired CNS injury (such as hypoxic-ischaemic 
encephalopathy, vascular events and brain abscesses) or developmental anomaly can 
result to seizures. Cerebrovascular and/or hypoxic events can be the result o f cyanotic 
conditions with right-to-left shunt (transposition of the great arteries and tetralogy of 
Fallot’s account for 90% of such complications), acyanotic conditions with right-to- 
left shunt (i.e., patent foramen ovale) and paradoxical embolisation, and hypothermic
'J'JQ
cardiopulmonary by-pass operations in young infants. CHD also occurs in 
syndromes with multiple congenital abnormalities, further predisposing them to
9 9 0  991seizures, such as Down’s syndrome, Kallmann’s syndrome and tuberous
sclerosis. Coarctation of the aorta may be associated with intracranial aneurysms,
9 9 9which increase the risk for stroke if not repaired early. In this study, no patients with 
CHD were detected in the 64+ age group, most probably due to premature death.
INTRACRANIAL NEOPLASMS
Intracranial tumours are a common cause of epilepsy in adults. Seizures occur at 
presentation in 15-95% of patients with intracranial tumours, depending on the type of 
tumour, with low-grade gliomas and meningiomas presenting more commonly with 
seizures (65-95% and 40% respectively).234 The most frequent primary brain tumours
99c
in adults are gliomas and primary CNS lymphomas. Incidence of gliomas is around
99^
5-10 per 100,000 of the general population. Low-grade gliomas affect mainly young
9 9 c
adults (mean age, 35 years in astrocytomas and 45 years in oligodendrogliomas). 
Primary glioblastomas tend to occur in older patients (mean age, 55 years), whereas
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secondary glioblastomas tend to occur in younger adults (45 years of age or less).234 In 
this study, the highest PR of primary brain neoplasms is seen in the younger age group 
(PR 70.70 vs. 11.55 in the older age group, (tables 9 & 10), particularly in women (PR 
90.36 vs. 54.69 in men (table 9). In contrast, no brain neoplasms were detected in 
women of the older age group (table 10).
Meningiomas have a total annual incidence of around 8 per 100,000,234 with a peak 
incidence around 45 years of age and female preponderance.234,236 The majority are 
asymptomatic discovered incidentally at autopsy; their incidence in symptomatic 
patients is about 2 per 100,000.234 The higher PR of meningiomas is seen in the older 
age group in this study (PR 91.88 vs. 13.57 in the younger group, tables 9 & 10). This 
may be explained by the fact that their incidence appears to increase with age, that 
they are associated with a high post-operative seizure occurrence (even in patient with 
no pre-operative seizure disorder), ’ and that they have a high rate of recurrence 
after resection.234 In addition, the majority of meningiomas are slow growing, benign 
tumours associated with favourable outcome and, therefore, survival to an older age.234
NEOPLASIA (excluding brain tumours)
Metastatic disease to the brain occurs in 15-28% of all cancer patients239,240 and 
epilepsy can be the presenting symptom in these patients, observed in 15-25% of 
cases.236 However, people with epilepsy in this study do not appear to have higher 
rates of neoplasia other than brain tumours (tables 9 & 10). This is because cancer 
cases with secondary brain metastases that could give rise to seizures have been 
excluded. This finding may mean that tumours that do not metastasise to the brain do 
not increase the risk of seizures.
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MIGRAINE
Data from the Epilepsy Family Study of Columbia University showed that the 
incidence o f migraine in people with epilepsy is 2.4 times higher (95% Cl, 2.0-2.9) 
than in people without epilepsy.241 This study used information from structured 
telephone interviews and its results indicated that migraine and epilepsy were strongly 
correlated, irrespective of seizure type, age of onset, aetiology, or family history of 
epilepsy. It is possible that the comorbidity of migraine and epilepsy is based on an 
underlying state of neuronal hyperexcitability that increases the risk of both 
disorders242 but does not appear to be due to a shared genetic susceptibility.24 In this 
study, men with epilepsy were diagnosed twice as often with migraine compared to the 
non-epilepsy population in both age groups, but in women the prevalence was 
increased only in the younger age group (PR 1.44 vs. 0.98 in the older group) (tables 9 
& 10). The discrepancy in the risk of migraine between the genders is difficult to 
explain. In the Epilepsy Family Study, the risk of migraine among people with 
epilepsy was 1.4 times higher in women compared to men.243 It may be that migraine 
is underdiagnosed in men without epilepsy or in women with epilepsy by general 
practitioners in UK. The prevalence of migraine in adults with epilepsy in the above 
study was 24%, a much higher percentage than the 4.8% prevalence in this study. As 
noted by Andermann and Andermann 244, findings in this area are difficult to interpret 
because of variations in definitions of migraine and epilepsy, method of patient 
identification, and sample size. One important aspect is that migraine is commonly
48underdiagnosed in people with and without epilepsy: According to a US study, 29% 
of men and 40% of women with migraine in the general population reported a medical 
diagnosis, and in the Epilepsy Family Study only 44% of people with epilepsy 
reported physician-diagnosed migraine.245 Why is the comorbidity of migraine and
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epilepsy not adequately recognised? Epilepsy may be considered as a more serious 
disorder than migraine. As a result, the migrainous symptoms of patients with epilepsy 
may be overlooked or attributed to the seizures. In addition, the diagnosis of atypical 
migraine symptoms can be difficult in the presence of epilepsy,244,246 and some 
patients with both conditions may not report their headaches because these are 
effectively treated with an AED (e.g., sodium valproate).247
ASTHMA, CHRONIC BRONCHITIS, EMPHYSEMA
These conditions appear to occur more frequently in people with epilepsy between 16- 
64 years compared to those without epilepsy, but not in people with epilepsy over 64 
years (tables 9 & 10). For asthma the excess prevalence is rather small (37% higher or 
PR 1.37), however the PR for chronic bronchitis and emphysema in people with 
epilepsy is 2.3 and 2.92 times higher, respectively.
Asthma is a complex syndrome with many clinical phenotypes in both adults and 
children. For many patients, the disease has its roots in infancy, and both genetic 
factors (atopy) and environmental factors (viruses, allergens, and occupational 
exposures) contribute to its inception and evolution. A case-control study suggested 
a higher incidence of allergy (including asthma) in children with epilepsy than in 
controls.249 Respiratory syncytial virus (RSV) -an extremely common cause of 
childhood respiratory infections- has been implicated with the development of asthma 
in children.250 It has also been associated with the development of encephalopathy 
presenting with seizures in a minority (1.8%) of children with bronchiolitis.251 The 
relevance o f these findings in an adult population is, however, unknown. A number of 
studies have suggested that epilepsy and asthma may be related conditions. There has,
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however, been little epidemiologic data published to support this association. A recent 
retrospective study found no association between idiopathic epilepsy and asthma.252 
The association between the two conditions may be indirect through shared risk 
factors: smoking is a risk factor for persistence of asthma into adulthood,253 as well as 
for vascular disease and cancer.254 The latter two conditions can cause epilepsy 
through strokes and metastases.
An association between pseudoseizures and asthma has been reported recently. 
According to the authors, both asthma and anxiety hyperventilation may be important 
risk factors for the development of pseudoseizures, and somatisation, anxiety 
hyperventilation and dissociative elaboration may have accounted for the observed 
association. If people with epilepsy (with or without pseudoseizures) suffer a higher 
incidence of “psychogenic” asthma is not currently known.
The association of chronic bronchitis and emphysema with epilepsy can perhaps be 
explained through smoking. The commonest cause for these conditions is cigarette 
smoking, which is also a known risk factor for cerebrovascular disease and 
cancer254 that can cause epilepsy.
PNEUMONIAS
Pneumonia can occur nearly 3-4 times more often in people with epilepsy in this study 
(tables 9 & 10). Does this reflect -at least in part- the higher prevalence of chronic 
bronchitis and emphysema in people with epilepsy in this cohort? These conditions, 
along with diabetes, renal failure, heart failure, alcoholism and neoplastic disease 
(among others) that occurred more frequently in people with epilepsy in this cohort
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(tables 9 & 10), are associated with the severity of CAP and are risk factors for
257mortality. It is not known, however, if these conditions are risk factors for CAP in 
adults.258
Community acquired pneumonia (CAP) is usually due to Streptococcus pneumoniae 
and Haemophilus influenzae, with less common causes including atypical pathogens 
{Mycoplasma pneumoniae, Legionella and Chlamydia pneumoniae), viruses and
“J C Q
aspiration. Mycoplasma infection is associated with the development of 
meningoencephalitis that can be complicated with seizures, however this is
A / ’ i
observed more commonly in children. Aspiration pneumonia may complicate 
seizures (particularly GTCS), although this does not appear to be a common 
occurrence.262
9 fCXPneumonia is a common terminal event in people with epilepsy, especially those 
with severe epilepsy, such as institutionalised patients264 and patients with mental 
retardation.265 In the NGPSE the total number of deaths from pneumonia in the cohort 
of people with definite and probable epilepsy (N=792) was 39 among 199 deaths over 
a period of 11-14 years. The majority of these deaths occurred in people over 50 
years and in the first 7 years of follow up. This may be due to the high incidence of 
strokes in this age group that can be complicated by aspiration. Aspiration pneumonia 
is the commonest cause of death in patients with dysphagia due to neurologic 
disorders.267 Among patients with stroke, pneumonia is seven times as likely to 
develop in those in whom aspiration can be confirmed than in those who do not 
aspirate.268 This association may partly explain the higher risk of pneumonia in people 
with epilepsy.
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DEMENTIAS
A considerably higher prevalence ratio for Alzheimer’s disease (AD) appears to exist 
in the younger adult epilepsy group than the older group (PR 40 vs. 7 respectively) 
(tables 9 & 10). Findings were similar for all dementias (PR ~25 vs. ~6) and cerebral 
degeneration (PR 27 vs. 6) (tables 9 & 10). Both a diagnosis of AD and a diagnosis of 
other dementias have been associated with at least a six-fold increased risk of 
unprovoked seizures, after controlling for age and sex, and in the absence of other 
prior neurologic insult.269 The discrepancy between the age groups in this study may 
be related to the severity of the underlying condition associated with epilepsy and, 
therefore, reflect more aggressive early-onset disease. One study in patients with 
uncomplicated, definite AD on autopsy found that patients with new-onset, 
unprovoked seizures had a younger age of dementia onset than did the AD patients 
without seizures and that, at seizure onset, they had advanced dementia, averaging 6.8
770years into their AD. The development of new-onset seizures in advanced AD was
771also described in another study and appears to accelerate the progression of
• 777dementia. Although the latter finding was described in institutionalised patients with 
a clinical diagnosis of probable AD, it raises the question that seizures “facilitate” the 
diagnosis of dementia in some patients, possibly because it forces them to require 
medical attention and because the manifestations of dementia become more prominent 
and easy to diagnose.
Epilepsy itself may be a risk factor for the development of AD. In a re-analysis of 
eight case-control studies on AD, more cases than controls reported epilepsy before 
the onset of AD (PR 1.6, 95% Cl 0.7-3.5), especially for epilepsy with an onset within
273 •10 years of onset of dementia. This may be due to shared risk factors such as
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cerebrovascular disease. Indeed, permanent cognitive impairment resulting from 
cerebrovascular disease is the second most common form of dementia in most parts of 
the world274 and cerebrovascular disease is also the most commonly identified 
antecedent o f epilepsy accounting for 11% of cases,222 as described above. In addition, 
epilepsy (particularly TLE) has been associated with focal or generalised cerebral and 
cerebellar volume loss. ‘ It has been proposed that this damage is primarily the 
result of a prior neurological insult and not of epilepsy.278 The increased risk of 
cerebral atrophy in epilepsy does not appear to be related to seizure recurrence and is 
associated with age and multiple AED exposure. ’
PARKINSON’S DISEASE
Parkinson’s disease (PD) occurs about 3 times more commonly in people with 
epilepsy (tables 9,10 &11). The association between the two disorders is intriguing 
because they involve different parts of the CNS.
Pathologically, PD is characterised by progressive cell loss in the substantia nigra and 
other subcortical nuclei in association with the presence of Lewy bodies and Lewy 
neurites.285 The cerebral cortex (particularly the cingulate gyrus and entorhinal cortex) 
and the hippocampus can be also affected in PD, although this appears to contribute to 
the cognitive dysfunction in this group of patients and it is not known if it increases 
the risk of seizures. A large study of patients with parkinsonism (N=368) found that 
epilepsy was significantly less frequent in this group, especially in Parkinson's
287disease.
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Seizures and AED treatment do not appear to be risk factors for the development of
286PD. Wennberg et al. analysed intracranial potentials recorded from DBS electrodes 
in association with scalp EEG spikes and sleep discharges in six patients with 
intractable epilepsy treated with thalamic deep brain stimulation (DBS) and one 
patient with PD treated with DBS of the subthalamic nucleus.288 They showed that the 
intracranial waveforms represented volume conduction from discharges generated in 
the neocortex and not locally generated activity from cortical-subcortical neural 
propagation.
The diagnosis of PD is made clinically, however other disorders with prominent 
symptoms and signs of parkinsonism, such as drug-induced and arteriosclerotic 
parkinsonism, may be confused with Parkinson’s disease until the diagnosis is 
confirmed at autopsy. This may particularly be the case in a primary care setting, 
such as the one used for this study. If parkinsonism is substituted for PD, 
cerebrovascular disease and dementia arise as shared risk factors that may explain the 
association between epilepsy and PD.
Parkinsonian symptoms such as rigidity and postural instability develop in roughly 
30% of patients with AD. A similar percentage of patients with PD eventually have
^OQ
dementia due to AD or other causes. The risk of AD in the current study is 
considerably high in both age groups and particularly the younger group (PR 40 vs. 7) 
(tables 9, 10 & 11 and comments on dementia above).
Dementia with parkinsonism as an early feature frequently progresses more rapidly 
than uncomplicated AD.274 In many cases of dementia with parkinsonism, Lewy
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bodies can be found in areas of the brain where they do not typically occur in 
idiopathic PD, such as the cerebral cortex. These bodies can occur either without the 
prominent changes typical of AD (diffuse Lewy-body disease) or with them (the 
Lewy-body variant of AD).274 These pathological findings suggest more extensive 
neurodegeneration (particularly in the cortex) than either condition alone that may 
increase the risk of seizures in these patients.
Parkinsonian features are also common in vascular dementia, the second most 
common cause of dementia in most parts of the world.274 Vascular parkinsonism 
accounts for around 12% of all cases,290 and although it is probably a distinct clinical
• 2Q| • •entity to PD it is not always easy to differentiate from PD. Patients with 
parkinsonism associated with vascular disease have a history of stroke and risk factors 
for stroke.292
In conclusion, cerebrovascular disease is a common cause both of epilepsy (see 
comments above) and parkinsonism, and its presence would predispose patients to 
both disorders. Similarly, AD and dementia appear to be shared risk factors both for 
epilepsy and parkinsonism.
PEPTIC ULCERS AND GASTROINTESTINAL BLEED
The PR of gastrointestinal (GI) bleeding is significantly raised in this study (PR 3.37), 
as well as the risk of peptic ulcers (RR 1.92). The PR of bleeding is higher in the 
younger adult group (PR 4.09 vs. 2.67 in the older group) and is mainly attributed to 
upper GI bleeding (PR 4.31 vs. 2.16 for lower GI bleeding). A possible explanation is 
higher use of aspirin, non-steroidal anti-inflammatory drugs, or excess alcohol
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consumption by people with epilepsy, factors that contribute significantly to upper GI 
bleed.293 Aspirin is an important part of treatment in conditions such as IHD, occlusive 
CVA, and TIA, which occurred more frequently in people with epilepsy in this study 
(tables 9,10,11). Alcohol dependence is also more common in this group (tables 
9,10,11). AEDs are not known to increase the risk of GI bleeding, as it is for example 
the case with selective serotonin uptake inhibitors (SSRIs).294
ALCOHOL DEPENDENCE
The relationship between alcohol and seizures is complex and multifaceted. Excessive 
alcohol use (exceeding 51 grams of ethanol per day) was shown to be an independent, 
dose related risk factor for unprovoked seizures.295 Alcohol itself may induce
9Q (\ 9Q7seizures or exacerbate pre-existing epilepsy. In addition, people who chronically
abuse alcohol have an increased frequency of structural abnormalities in the brain that
may contribute to seizures, including cerebral vascular lesions and lesions due to head
injury.298'300 Alcohol use may result in low AED levels in patients with epilepsy and
lead to seizure exacerbation, due to poor compliance, reduced absorption, and hepatic 
101enzyme induction.
Patients are described as alcohol dependent when they meet the criteria for substance 
dependence.302 Epidemiological data suggest the prevalence of epilepsy in alcohol- 
dependent patients of western industrialised countries may be at least triple that in the 
general population, whereas the prevalence of alcoholism is only slightly higher in 
patients with epilepsy than in the general population.303 In this study, however, the 
prevalence o f alcohol dependence was nearly 6 times higher in the epilepsy than in the 
non-epilepsy group (tables 9,10,11). The much higher risk may be due to different
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rates o f case identification in people with and without epilepsy. According to a 
hospital-based study, fewer than half of patients that screened positive for alcohol 
dependence and abuse were identified by their physicians and detection rates differed 
according to speciality.304 In addition, patients with alcohol problems are more likely 
to be identified by their physicians if they have medical complications304 and women 
are less likely to be identified than men.305 Therefore, an admission-rate bias may have 
accounted -a t least in part- for the results in this study.
The highest prevalence of alcohol dependence was observed in younger males (16-64 
years) with epilepsy in comparison to the other age and sex groups (4% vs. 1.4% of 
younger females vs. 1.7% of older males and 1.2% of older females) (tables 9,10,11). 
These findings are in accord with epidemiological studies which found that the 
prevalence o f alcohol abuse and dependence is higher in males than females306,307 and 
that heavy drinking is inversely associated with age.308
4.4.v Implications for practice
These results demonstrate higher comorbidity in adults with epilepsy than in those 
without. Their generalisibility is potentially limited because of the case selection that 
possibly favoured more severe cases and cases of symptomatic epilepsy being 
included in the cohort; people with epilepsy in remission and no comorbidity may not
150 • 1 R V 100consult a doctor. ’ ’ The results are, however, valid for adults with epilepsy who
come to medical attention. In this setting, increased awareness is needed for the 
diagnosis and treatment of diseases co-occurring with epilepsy, as this may have 
profound consequences for the quality of life and mortality of patients, as well as for 
the burden on health services. Co-occurrence of conditions in a person can complicate
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diagnosis or have adverse prognostic implications. For example, patients with epilepsy
/ \ Q  Q
often have medically undiagnosed -and untreated- migraine, depression, or 
anxiety.53 -The presence of epilepsy in people with AD may reflect more aggressive 
early-onset disease,310 and this may be the case for other neurodegenerative disorders 
(comments in the preceding discussion under DEMENTIA).
Conditions such as neoplasms -in particular brain tumours-, cerebrovascular and 
ischaemic heart disease, and pneumonias are associated with increased mortality in 
people with epilepsy. The risk of these conditions was found to be higher in the 
epilepsy cohort in this study, which might explain the high mortality associated with
1 9remote symptomatic epilepsy. It is not known what proportion of the health services 
requirements is due to the comorbidity of epilepsy, its treatment, or other factors. The 
MSGP4 study has shown that people with epilepsy make higher use of health services 
and consult more frequently for a number of disorders than people without epilepsy 
(Chapter 3), suggesting that comorbidity contributes significantly to the burden on 
health services for people with epilepsy. Epilepsy is known to be more common in 
people from lower socio-economic groups311 and this may also contribute to the higher 
prevalence of comorbidity in people with epilepsy.
4.5 Conclusions
The findings suggest that the risk of many common psychiatric and somatic disorders 
is increased in adults with epilepsy who consult a primary care physician. This means 
that the presence of epilepsy should increase, not reduce, the suspicion that other 
disorders may be present. Conditions commonly seen in primary care are also 
common in people with epilepsy; however, doctors should also have a high degree of
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suspicion for other disorders. The findings also emphasise the importance of taking a 
holistic view of the health of people with epilepsy when they consult doctors. This 
requires treating the epilepsy itself but also any other present conditions, as well as 
ensuring that patients are given adequate advice on the general aspects of their health.
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Part II
MORTALITY IN EPILEPSY
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Chapter 5 
REVIEW OF MORTALITY IN EPILEPSY
5.1 Introduction
Despite an overall good prognosis for seizure control ’ epilepsy is a potentially 
life-threatening condition and carries an excess mortality. This is consistently shown, 
both in population-based studies and in studies of more selected populations, such as 
institutionalised patients and clinic attendees.12314 People with epilepsy have a 
mortality rate (the number of deaths that occur in a defined population divided by the 
person-years at risk in that population) 2-3 times higher than that of the general
19population. This is better expressed as the Standardised Mortality Ratio (SMR), 
which is the ratio of the observed number of deaths in an epilepsy population to that 
expected based on the age- and sex-specific mortality rates in a reference population in
1 r
a given time. The causes of death in people with epilepsy can be classified into 3 
groups: deaths that are unrelated to epilepsy; those that occur as a result of the cause of 
epilepsy; and those in which the epilepsy itself is the cause of death (Box 6).314
The proportion of deaths due to a particular cause in a cohort of patients in a given 
period can be described by the Proportional Mortality Rate (PMR), which compares 
the relative contribution of various causes to the overall mortality in this 
population.12,316 PMR is not a direct measure of the ratio of rates of death between 
populations and does not express the risk of members of a population contracting or 
dying from a disease. Comparisons of PMR between groups or populations can be 
meaningful only if  the cause-specific mortality rates are known so that differences
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BOX 6. Causes of death in epilepsy
Unrelated deaths
Neoplasms outside the central nervous system
Ischaemic heart disease
Pneumonia
Others
Related to underlying disease
Brain tumours
Cerebrovascular disease
Cerebral infection-abscesses and encephalitis
Inherited disorders, e.g. Batten’s disease
Epilepsy related deaths 
Suicides
Treatment related deaths 
Idiosyncratic drug reactions 
Medication adverse effects 
Seizure related deaths 
Status epilepticus 
Trauma, bums, drowning 
Asphyxiation, aspiration 
Aspiration pneumonia after a seizure 
Sudden unexpected death in epilepsy
Adapted from Nashef et al. 1995317
between populations relate to variations either in the number of deaths of interest
i ^
(numerators) or the total number of deaths (denominators). For example, an observed 
excess of a particular cause of death in an epilepsy group may represent a true 
increased risk, but may also merely represent a deficit of deaths due to other causes.
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The underlying disease, of which epilepsy is a symptom, is the main cause of death in 
newly diagnosed cases, and is associated with increased mortality whether epilepsy is
1 1 0
present or not. Epilepsy itself, and probably to a very much lesser extent its
• T 1Qtreatment, is a major cause of death in chronic epilepsy. It has been suggested that 
the long term use of antiepileptic drugs (AEDs) increases the incidence of malignant 
neoplasia and osteoporosis, thereby potentially affecting long term mortality rates in 
people with epilepsy.
5.2 Measures and Methods
Methodological difficulties permeate studies of the mortality of epilepsy. Definitions 
of epilepsy and classification of seizures may differ between studies, as well as the 
accuracy of epilepsy diagnoses and the classification of causes of death. The 
International League Against Epilepsy (ILAE) has published guidelines for
T 1 5epidemiological research, which deal with the issue of definition and classification, 
and are based on the ILAE classification of epileptic seizures and syndromes.5,6 For 
example, until recently, the term cryptogenic was interchangeable with idiopathic. In 
the new classification the term “idiopathic” is reserved for seizures occurring in 
epilepsy with a presumed genetic origin, and “cryptogenic” characterises seizures 
occurring in otherwise normal people with no clear cause. Other problems included 
the exact definitions of sudden unexpected death in epilepsy (SUDEP) and other 
seizure-related deaths, as well as the inclusion in the epilepsy group of patients with 
acute symptomatic seizures, a category known to be associated with increased 
mortality.319
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The accuracy of information on the cause of death depends on the methods employed. 
Death certificates can be an unreliable source114,321,322 and, although autopsy and 
supplementary clinical data improve accuracy, they are subject to bias and error.319 In 
the ongoing UK National General Practice Study of Epilepsy,323 epilepsy was 
mentioned in 10 of 181 patients with definite epilepsy (own data). Furthermore, SMR 
cannot be calculated in studies utilising registers of death certificates because the 
number of person-years at risk in the study population is usually not known. 
Diagnostic inaccuracy in life may be as high as 15-20%, owing to confusion with 
syncope and psychogenic attacks or as a result of overinterpretation of EEGs.108 324 
Case ascertainment is subject to bias: retrospective studies based on hospital records 
may significantly underestimate the number of cases in the community,324 especially 
the elderly, the very young and individuals whose seizures were not witnessed;113 and 
population-based studies may include people without epilepsy.325
Despite the small number of mortality studies in epilepsy, different study types and 
reference populations have been used, rendering comparison between studies and 
application to the general population problematic. Studies from selected
i n ^ '1 0 8  D 7populations, such as hospital-based case series ’ ’ ' epilepsy residential
centre106,111,115 and epilepsy centre case series110 offer the advantage of more reliable 
diagnoses and accurate classification of cause of death. Their disadvantages are that 
most include small numbers of patients and, most importantly, suffer from selection 
bias, as they tend to represent more severe and chronic cases. This is likely to 
exaggerate mortality and epilepsy related deaths, and results cannot be applied to the 
general epilepsy population. Cross sectional and prevalent population studies fail to 
ascertain new cases of epilepsy and therefore miss the high initial mortality of
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epilepsy, and can misrepresent particular causes of death such as brain tumours.113 
Insurance cohorts ’ represent highly selected prevalent cases and utilise the lower 
mortality rates of non-rated policy holders as the standard.318 The heterogeneity 
between studies was evident in a recent attempt at a meta-analysis of comparative 
studies investigating mortality in epilepsy patients.326 The authors performed a 
detailed quantitative review of relevant follow-up studies conducted in the last 100 
years, in order to investigate the extent and causes of the differences found in studies 
of mortality in epilepsy. Nineteen studies matched their criteria, assessing community, 
general medical and institutional populations. A summary estimate, however, could 
not be calculated because of considerable variation in mortality risk ratios of the 
studies. This variation was explained mainly by differences in the “source population” 
(which characterises the setting from which patients were recruited) and secondarily 
by case selection.
The ideal approach is of large scale, general population based prospective incidence 
studies with comprehensive case ascertainment, accurate diagnosis, sound aetiological 
assignment, long follow-up and efficient tracing of patients.324 The National General 
Practice Study of Epilepsy (NGPSE) studies in the UK,113,116 the study conducted in 
Rochester, Minnesota114 and the study in Vasterbotten County in Northern Sweden332 
appear to fulfil these criteria to a great extent.
5.3 Overall Mortality
Premature mortality in patients with epilepsy is reported to be significantly higher than 
in the general population. SMRs for community-based studies range between 1.3 
and 3.1 (1.6 and 2.6 for studies using incident cases) (Box 7).
I l l
A community-based study of mortality in children aged 1-14 years using a state-wide 
paediatric mortality surveillance system in Victoria, Australia found an all-cause SMR 
of 13.2 (95% Cl: 8.5-20.7).333 A long term study in which a cohort of 245 Finnish 
children with epilepsy were followed up for more than 30 years reported an increased 
risk of death and decreased probability of survival in those who had not entered 
remission.195 A community-based cohort study in Nova Scotia, Canada which 
followed 692 children who developed epilepsy between 1977 and 1985 reported 
SMRs >5 in the first 15-20 years after diagnosis.334 The majority of deaths in people 
whose seizures start in childhood occur in adulthood. ’
Studies of selected populations tend to have higher SMRs. In a large cohort study of 
all patients over 15 years old in whom a diagnosis of epilepsy was recorded at 
discharge from any hospital in Stockholm during 1980-1989, an SMR of 3.6 (95% Cl
1 HR3.5-3.7) was estimated. This cohort comprised a total of 53,520 person-years and
4.001 deaths. In a retrospective study of the survival status of out-patients seen in a 
Dutch epilepsy centre over a 40 year period (38,665 person-years, 404 deaths), the 
SMR was 3.2 (95% Cl 2.9-3.5).110 In a cohort of adult outpatients with epilepsy at a 
tertiary referral centre in the UK (1849 patient-years) the SMR was 5.1 (95% Cl 3.3- 
7.6).337 SMRs for institutionalised populations (i.e., patients living in epilepsy 
residential centres) range between 1.9 and 3.0.111,115,326
5.3.1 Risk factors/Determinants of mortality
The higher risk of premature death does not apply equally to all people with epilepsy 
and serves only as a summary measure, masking important differences in mortality 
among the population with epilepsy. Studies of mortality in epilepsy calculate
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mortality rates according to aetiology, duration and type of epilepsy, age, and sex. In 
its published guidelines for epidemiological studies the ILAE proposed that the 
epilepsies and epileptic seizures be categorised into aetiological groups: idiopathic, 
cryptogenic, acute symptomatic, remote symptomatic, and progressive 
symptomatic.315 No studies to date have strictly adhered to the new classification 
scheme. Prior to this new scheme, the three major aetiological groupings usually 
included the idiopathic (or cryptogenic, or primary), remote symptomatic (or 
postnatally acquired secondary epilepsy), and (congenital) neuro-deficit group.
Idiopathic (and/or cryptogenic! epilepsy has the lowest long-term mortality with 
SMRs ranging from 1.5 to 1.8 in population studies109,114,327 suggesting that mortality 
rates in this group are above those of the general population by only 50-80%. Other 
studies, however, failed to show a significant increase in mortality in this 
group.116,332,339 Studies in children follow the same population trends in mortality in 
idiopathic and cryptogenic cases329,333 as well as in cases without severe neurological 
deficit.334
Although the overall chances of achieving remission are similar in patients with 
remote symptomatic epilepsy and idiopathic epilepsy, the same is not true of their 
relative risk o f premature death.313 Long-term mortality is greatly increased in remote 
symptomatic epilepsy with reported SMRs of 2.2 (95% Cl 1.8-2.7) in the Rochester 
study,114 2.3 (95% Cl 1.4-3.5) in an Icelandic study,339 3.7 (95% Cl 2.9-4.6) in the 
NGPSE,116 and 3.3 (95% Cl 2.4-4.5) in the Vasterbotten County study.332 Considering 
people with symptomatic epilepsy, the risk of death appears to be over ten times
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BOX 7. Community-based studies of overall mortality of epilepsy
Study Setting Method Aee at entrv Person-vears SMR (95% CIV
Alstrom 1950 327 Sweden clinical series 23yrs N/A 2.4 (2.0-2.8)
Voute 1967 1,8 Europe insurance policy holders Adults N/A 3.1
Zielinski 1974 221 Warsaw 3-yr prevalence cohort All -20,000 1.8
Hauser et al. 1980 114 Rochester, MN, USA 29-yr retrospective incidence cohort All 8,233 2.3(1.9-2.6)
Olafsson et al. 19983W Iceland 30-yr retrospective incidence cohort N/A 6,308 1.6(1.2-2.2)
Loiseauetal. 1999340 Gironde, France 1 -yr prospective incidence cohort t All 804 9.3 (7.9-10.9)
Lindsten et al. 2000”2 Sweden 11 -yr prospective incidence cohort >17yrs 850 2.5 (1.2-3.2)
Lhatoo et al. 2001116 United Kingdom 14-yr prospective incidence cohort All 11,400 2.1 (1.8-2.4) %
Camfield et al.2002”4 Nova Scotia, Canada >15-yr retrospective incidence cohort 28d-16yrs N/A 8.8(4.1-13.4)
* Cl denotes confidence interval, 
f  Early mortality was assessed.
J The NGPSE study113,116 included patients with symptomatic and unprovoked seizures.
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higher for those with congenital neurological deficit or CNS tumours, and 2-3 times 
higher in patients with cerebrovascular disease or alcohol abuse.116 The reported SMR 
in a prevalent paediatric population with epilepsy in Australia was 49.7 (95% Cl 31.7-
77.9) for remote symptomatic epilepsy.333 In a population-based study, children with 
disorders sufficient to cause functional neurological deficit were 22 times more likely to 
die prematurely than those without.334 The authors concluded that children with remote 
symptomatic epilepsy and no neurological deficit are unlikely to die as a result of
334seizures.
The neuro-deficit group, consisting of patients with gross neurological deficit and/or 
learning difficulties presumed to have been present or acquired at birth, has the highest 
long-term mortality with reported SMRs in the range of 11.0 (95% Cl 6.9-16.4)114 and 
25 (95% Cl 5.1-73.1).116 The excess mortality is attributed to the small number of 
deaths expected in the young age group and the high death rate among children with
TIO
neurological deficit, irrespective of the presence of epilepsy.
Seizure type also plays a role: Patients with absence seizures do not appear to be at 
higher risk of death 114, while those with generalised tonic-clonic seizures carry SMRs 
of 3.5-3.9 for the first 5-10 years from diagnosis114 332 and those with myoclonic seizures 
of 4 .1.114 The SMR for complex partial seizures was not significantly increased in the 
Rochester study114 but was reported as 2.1 (95% Cl 1.2-3.6) in the Vasterbotten County 
study.332
Mortality risk increases with severity of epilepsy, usually assessed by seizure frequency. 
In one study, patients with “severe” epilepsy or frequent seizures had significantly
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higher SMRs compared with patients with “slight” epilepsy or free from seizures.328 
Patients whose seizures responded to AED treatment exhibited lower mortality than 
people with poorly controlled seizures (SMR 2.13 vs. 3.77 respectively). In the 
Rochester study114 patients entering remission had a SMR of 2 for the first five years of 
seizure freedom but the SMR was not significantly elevated thereafter. These results 
were corroborated in two recent studies assessing long-term mortality in cohorts of 
patients who underwent epilepsy surgery.325,341 SMRs in patients with persistent 
seizures were 4.69 (95% Cl 2.33-7.75)325 and 7.4,341 with a reported rate of death of 
1.37 per 100 person-years. In contrast, mortality in patients who became seizure-free 
post-operatively did not differ from that of the general population.325,341.
Age-specific SMRs show increased death rates at all ages among people with epilepsy, 
although this increase is more pronounced in people under 50 years of age and declines 
sharply after age 60.108,110,114;116;321,328,339. SMRs have been reported for age groups up to 
50 years of between 6 to 8, in comparison to SMRs of <2 for patients older than 70 
years.114 314 328 This may be explained by the high mortality in patients with neurological 
deficit at birth and in young patients with remote symptomatic epilepsy due to head 
trauma and brain tumours, as well as the highly increased risk for sudden death in 
younger adults with epilepsy114 318 An important factor contributing to the high SMRs in 
the young is also the very low mortality observed in children and the younger age 
groups in the general population.
Mortality rates in epilepsy vary over time, being higher in the first years after diagnosis. 
SMRs reported for all cases for the first year were 3.8 in the Rochester study,114 6.6 in 
the NGPSE study,116 and 7.3 in the Vasterbotten County study.332 SMRs for the first
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four years ranged between 2.0 and 3 .1.114,314,339 Mortality rates declined to near normal 
in years 4-9 in the NGPSE study,116 in years 2-9 in the Vasterbotten County study,332 
and after the first ten years in the Icelandic339 and Rochester studies.114 Rates increased 
again in years 25-29 of follow-up in the Rochester study,114 in years 9-14 in the NGPSE 
(but not in the idiopathic epilepsy group)116 and in years 9-11 in the Vasterbotten 
County study.332 Trends in the Rochester study114 persisted for the three aetiological 
groups (idiopathic, remote symptomatic, neurodeficit group) when analysed separately, 
with much higher initial SMRs for the neurodeficit group. Results similar to this last 
group were reported by a study of mortality in attendees of a Dutch epilepsy centre 
cohort.110
Higher SMRs have been reported in males than females in some studies109,110,114,191,328 
but not in others.111 116 325 332 337
5.4 Cause-specific mortality
Cause-specific mortality refers to deaths occurring in the population or a cohort due to a 
particular cause.
5.4.i Epilepsy related deaths
Deaths attributed to epilepsy itself include suicide, treatment related deaths, SUDEP, 
and seizure related deaths, such as deaths occurring in status epilepticus and accidents 
caused by seizures such as drowning and bums (table 14). The proportion of deaths due 
to epilepsy is described by PMR which tends to be higher in selected population studies, 
ranging between 18 and 4jo/oi05-i07,n o ,111,115,328 m  com m unity studies where it is
between 1 and 13% .114,116,321,333 However, two community studies of children in
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Finland195 and Victoria, Australia333 found the epilepsy PMR to be 45% and 22% 
respectively. A review of the literature from 1910 to 1974, which consisted mainly of 
studies in institutionalised patients, reported an average epilepsy PMR of 42.7%.342 The 
wide range of the epilepsy PMR may be explained by differences in patient 
characteristics and population selection, diagnostic criteria, duration of follow-up, and 
classification of causes of death.
Deaths in status epilepticus (SE) follow the population trends of epilepsy related 
deaths and comprise up to 12.5% of all deaths. Status appears to be an important cause 
of death, especially for patients in epilepsy hospitals and centres.106 107 111 The case- 
fatality rate in SE may be as high as 20%, but can be much higher in patients with acute 
symptomatic seizures, myoclonic seizures, and elderly patients (especially those >65 
years).343,344 In a study of incident cases of generalised convulsive status epilepticus, the 
case fatality rate was highest in patients with a diagnosis of anoxia, CNS infection, or 
stroke.344 The long-term mortality of SE was assessed in patients who survived at least 
30 days after a first episode of SE in Rochester, Minnesota.343 The overall SMR was 2.8 
(95% Cl 2.1-3.5), but the SMR was significantly elevated in all subgroups with 
symptomatic SE: acute [3.8 (95% Cl 2.5-5.4)], remote [3.0 (95% Cl 1.8-5.0)], and 
progressive [3.1 (95% Cl 1.6-5.0)]. SE was considered progressive symptomatic in the 
presence of non-static central nervous system (CNS) conditions, such as CNS tumours 
and degenerative neurologic disorders.343 There was no increase in mortality in patients 
without an underlying cause of SE (i.e., idiopathic/cryptogenic), suggesting -according 
to the authors- that SE by itself does not alter long-term mortality.343 This finding is 
further supported by other studies, which report that patients who develop status
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following discontinuation of AEDs or as part of unprovoked epilepsy, and children with 
epilepsy have low mortality rates.345'348
Accident related deaths comprise between 1.2 and 6.5% of all deaths in community- 
based stuides114,116,321 and between 7.3 and 42% in selected population studies, with 
SMRs ranging from 2.4 .5 6.105' 109 ,11;115’326;328 People with epilepsy may sustain a fatal 
accident either during a seizure or as a consequence of a seizure. These could be due to 
traffic, bums, trauma, aspiration or drowning. The uniformly elevated SMRs and PMR 
suggest that all people with epilepsy are at higher risk of dying due to accidents than the 
general population. People with symptomatic epilepsy may be particularly at risk as is 
suggested in a population-based incidence cohort study in Iceland. The authors reported 
that the SMR for deaths due to accidents, poisonings and violence was 7.27 (95% Cl 
1.96-18.62) for male patients with remote symptomatic epilepsy and 1.76 (95% Cl 0.47- 
4.51) for those with idiopathic/cryptogenic seizures.109 In countries where bathing is 
favoured over showering, a higher rate of death from drowning might be expected 
although this has never been properly investigated.
SUDEP is defined as a sudden, unexpected, witnessed or unwitnessed, non-traumatic 
and non-drowning death in patients with epilepsy, with or without evidence for a seizure 
and excluding documented status epilepticus, in which post-mortem examination does 
not reveal a toxicologic or anatomic cause for death.349 Specific criteria may be applied 
to classify SUDEP into definite, probable and possible. Patients who do not meet these 
criteria can be classified as non-SUDEP deaths, and there is also a category of 
insufficient data?50 In the UK it is estimated that 500 deaths per annum are SUDEP.351 
Reported risk factors for SUDEP include frequent generalised tonic-clonic seizures; age 
20-40 years; acquired epilepsy (primarily from traumatic brain injury or
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encephalitis/meningitis); intractable epilepsy; frequent changes of AEDs; and early- 
onset epilepsy, with seizure severity being the strongest factor. ’ ' AED 
polytherapy may be an additional independent factor in adults354 but not in children.357 
Most sudden epilepsy deaths are unwitnessed and occur during sleep.358 When 
witnessed, most deaths occur in association with a seizure and respiratory compromise 
is a prominent feature. In some cases, the patient begins recovering from the seizure 
but then has a secondary cardiac arrest, possibly related to hypoventilation.359 Proposed 
mechanisms for SUDEP include central and obstructive apnoea and cardiac arrhythmia, 
although the exact mechanism remains unknown. SUDEP has been reported to be 
responsible for 2-18% of all deaths in epilepsy.212,342,360 Interestingly, SUDEP 
accounted for 6 of 11 deaths in a selective group of patients with recurrent seizures 
following epilepsy surgery. Its incidence rates range from 0.35-1.2 per 1,000 person- 
years in population-based studies317,353,356,360*364 to 5 per 1,000 in referral 
populations115,337,352,354,365’367 and to 1 per 100 in surgical series.325,368 In a well-designed 
study, the SMR for SUDEP was 23.7 (95% Cl 7.7-55.0) compared with sudden death in 
the general population.356 The risk in children remains uncertain, although a rate of 
1:1,500 has been estimated.320 Children of school age with severe epilepsy and learning 
difficulties appear to be at high risk of SUDEP, with an incidence of sudden death 1:295 
cases per year.317 The overall age and sex standardised mortality ratio in this young 
cohort was 15.9 (95% Cl 10.6-23).
It has been reported that people with epilepsy are at higher risk of committing suicide 
than the general population103,105*111 but other investigators have been unable to 
demonstrate such an increase.112*115 In these studies the suicide PMR range between 0 
and 20% and the SMRs between 1 and 5.8. Incidence cohorts114,116 are known to have
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lower mortality rates than prevalence cohorts because they include small numbers of 
cases with symptomatic or severe epilepsy, which are over-represented in prevalence 
cohorts and which are associated with higher mortality. In addition, people who attend 
hospitals have higher morbidity and mortality than community cohorts. In the large 
prevalence study o f 9,061 adult patients who were once hospitalised for epilepsy in 
Sweden the SMR for suicide was 3.5 (95% Cl 2.6-4.6).108 The rate of suicide may be 
extremely high among depressed patients with epilepsy. Major depression in epilepsy 
has been associated with significantly decreased self-reported quality of life, increased 
disability and missed work, increased medical utilisation and medical costs. ’ Mental 
illness, drug addiction, early onset of epilepsy (particularly onset during adolescence), 
and personality disorder have been associated with increased risk, with some evidence 
that risk of suicide may decline with duration of epilepsy.102,103 People with epilepsy 
were reported to have a fivefold-increased risk of suicide attempts compared with the 
general population. Anticonvulsants, particularly barbiturates, were used in most cases 
of self-poisoning.104 A literature review based on studies published up to 1983 
concluded that patients with severe epilepsy had a suicide rate 5 times higher, and 
patients with TLE 25 times higher, than the general population.103 A later meta-analysis 
by the same group concluded that the overall SMR for death due to suicide in epilepsy 
was 5.1 (95% Cl 3.9-6.6). This was based on studies mostly published in the 1970s and 
1980s, and mainly including patients with TLE, institutionalised patients, patients from 
surgical series, and out-patients.117 In this analysis, the highest suicide rates were 
observed in patients with surgically treated TLE whose risk was increased by a factor of 
80 [SMR 87.5 (95% Cl 35-180)].117 This was, however, estimated on the basis of earlier 
surgical series published in 196887 and 1969118 that do not reflect current standards of 
treatment and/or patient selection criteria. Rates from these early studies may be higher
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than we would expect today with modem management and less use of barbiturates. The 
recently published follow-up results of the UK NGPSE study with a total of 11,400 
patient-years did not show any excess of suicides.116 Another recent study reported five 
suicides in a 12-year period in a total of 10,739 patients with epilepsy seen at a single 
US centre from 1987 to 1999.119 This number is comparable with the average number of 
suicides in the general US population of about one per 10,000 people per year. All 
suicide cases had a history of early onset (mean age 9.5 years), long-standing CPS 
(mean duration 29 years) and very high seizure frequency (often daily). Suicide 
occurred in all patients after a short interval (3 months to 3 years) of having obtained 
full seizure control for the first time after temporal lobectomy (3 patients), vagal nerve 
stimulation, or medication. These patients had been diagnosed with interictal dysphoric 
disorder (IDD), a syndrome described previously by the authors.78 IDD comprises 
intermittent affective and somatoform symptoms, presenting with intense depressive 
moods with suicidal intensity in some, and with psychotic features and dysphoric
• oosymptoms (i.e., irritability, fear, anxiety) in others. According to the authors, suicide 
in epilepsy results from specific neuropsychiatric disorders (including IDD and post­
ictal depression) associated with epilepsy rather than as the result of unfortunate
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psychosocial difficulties imposed by the chronicity and severity of epilepsy. ’ 
Management of specific psychiatric disorders and, hence, prevention of suicide in 
epilepsy can be attained by appropriate use of antidepressant (tricyclic antidepressants 
and selective serotonin receptor inhibitors) and psychotropic medication.119 People with 
epilepsy and previous psychiatric history, including a history of suicide moods or 
attempts, should be referred to a neuropsychiatrist with experience in epilepsy.
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5.4.ii Deaths unrelated to epilepsy
Most deaths are not attributed to epilepsy and can be related or unrelated to the 
underlying cause of epilepsy (Table 14). Deaths in the remote symptomatic group most 
commonly occur as a result of the underlying cause of epilepsy or from a complication 
of it.114’116’195’329*333’334 Causes include neoplasia, cerebrovascular disease (CVD), 
ischaemic heart disease (IHD), and pneumonia. The first three causes do not contribute 
to mortality in children populations.329 333
Malignant neoplasia accounts for 16-29% of deaths in community and hospital-based 
studies and carries increased mortality with SMRs ranging from 1.7- 
4.8.108,109,114,116,321,326,340 SMRs are significantly higher in patients with remote 
symptomatic seizures than in patients with seizures of unknown origin.109 Epilepsy 
centre studies probably underrepresent neoplasia, as these patients tend to be admitted 
to other facilities.115
Brain tumours are an important cause of epilepsy as well as cause of death, and may 
contribute from Va to 1/3 of all deaths due to neoplasia in epilepsy.108,114,116 It is 
estimated that the incidence of primary brain tumours among patients with epilepsy is 
22 times higher than in the general population. Reported SMRs range from 3.4- 
5.4111 ;326;332 th o u g h  in one study hospitalised patients with epilepsy appeared to be at 
much higher risk with a reported SMR of 29.9.108 The question of brain tumour 
association with anticonvulsant exposure and/or duration of seizures was raised in a
T7H 177number of reports. ’ It appears that the excess numbers of brain tumours occurred 
within 5-10 years of the seizure disorder diagnosis and decreased significantly over 
time, which suggests that the brain tumours account for the seizures and are not due to
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AED exposure.111,369,378,379 The SMR for neoplasia remains 1.4-2.5 even when CNS 
tumours are excluded.108,110111,114,116 No specific tumour type or site showed significant 
excess of deaths in large studies108,111,114 with the exception of studies showing excess 
deaths due to lung,110,116 pancreatic and hepatobiliary cancer (although the latter could 
be artefact due to small numbers).115 There may be a small risk of developing cancer 
following exposure to AEDs and a relationship between lung cancer and barbiturates 
and between non-Hodgkin’s lymphoma and phenytoin has been shown in two large
•  379380  •studies. ’ The incidence of non-CNS cancers in a population-based cohort of 
patients diagnosed with seizure disorder in Rochester, Minnesota was not found to be 
elevated in comparison to the general population.369 In the same study, there was no 
association between cancer incidence and duration of seizures or use of AEDs.
People with learning difficulties and epilepsy are subject to mortality rates that are 5- 
16 times higher than in the general population. ’ The risk of death appears to be 
highest in those with generalised seizures (SMR 8.1, 95% Cl 5.7-11.5), lowest in people 
with partial seizures without secondary generalisation (SMR 3.7, 95% Cl 1.0-13.6), and
701 '
intermediate in people with secondarily generalised seizures. In comparison, people 
with learning difficulties and no epilepsy have an SMR of 1.6 (95% Cl 1.3-2.0).381 
These results indicate that, in this group of patients, mortality is either increased as a 
result o f the seizures or reflects the severity of the underlying condition. The risk of 
death among children with epilepsy and learning difficulties or cerebral palsy was 
reported as 1 per 100 person-years in one study.109
Cerebrovascular disease (CVD) PMR is 14-16% in population-based series109;114;116;321 
and in a large hospital-based series,108 and 5-6% in referral populations.106;111;115;326;328
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SMRs range between 1.8 and 5.3 reflecting a mortality spectrum from epilepsy centre 
cohorts to general population cohorts, with hospital cohorts in the 
middle.108,111,114,116,326,332 CVD is the major cause of epilepsy among the elderly382 and 
in a large Swedish hospital-based study it accounted for 44% of deaths in people with 
epilepsy over 75 years in whom the SMR was almost 4.108 Patients with remote 
symptomatic epilepsy are at particular risk114,116 suggesting that the underlying 
pathology is responsible for deaths in this group. This is supported by the finding that 
people with idiopathic epilepsy in the Rochester Study had a SMR for CVD of 1.4 (95% 
Cl 0.6-2.6).114
PMR for ischaemic heart disease (IHD) are similar to those for 
CVD.106,107,110,111,114,116,321,328 IHD events include angina pectoris, myocardial infarction 
and sudden cardiac death. The latter is defined as death in individuals who had no 
previous clinical diagnosis of IHD and who died within 24 hours of onset of symptoms 
suggestive of acute coronary insufficiency. The vast majority of IHD deaths in
10Repilepsy occur in patients over 45 years. Mortality rates for IHD are not significantly 
increased overall for people with epilepsy, with SMRs reported in most studies between
1.1 and I.6.109' 111 114 116 221 In contrast, an SMR for heart disease of 2.5 (95% Cl 2.3-2.7) 
was reported in a cohort of hospitalised persons over 15 years old diagnosed with 
epilepsy.108 Raised SMRs for heart disease in epilepsy have also been reported for
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patients under 65 years old, for patients with remote symptomatic epilepsy ’ and 
patients with neurodeficit.114,221 In the Rochester study221 there was an increase in the 
incidence of myocardial infarction both in patients with idiopathic and remote 
symptomatic epilepsy, as well as of sudden cardiac death in patients with remote 
symptomatic epilepsy. There was no relationship between the use of AEDs and
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incidence rates for IHD or sudden cardiac death.221 In the Vasterbotten County study of 
a cohort with newly diagnosed unprovoked seizures, myocardial infarction was not 
associated with a significantly increased SMR in epilepsy [1.5 (95% Cl 0.73-3.2)].332
Pneumonia is a common cause of death in epilepsy especially in institutionalised 
patients, and often reflects a terminal event in patients with poorly controlled seizures, 
poor general condition and debilitation.106 108,111,115’116 321 PMR for pneumonia range 
from 25% in studies of inpatients in epilepsy institutions and hospitals106 111,115,116,321 to 
5% in studies of patients in the community,112,114,321 as well as in series based on 
hospital admissions and epilepsy centre attendance.108,110 SMRs range between 3.5 and 
10.3.108,110,111,114,116 The majority of deaths due to pneumonia occur in elderly 
patients108,115,116,321 which may denote increased susceptibility to pneumonia in this 
epilepsy population.108,113 Pneumonia, however, is an important cause of death in 
children with epilepsy, especially those with remote symptomatic seizures, infantile 
spasms and severe psychomotor retardation. Pneumonia accounted for 30% of deaths 
in a study o f children with epilepsy in the community, as well as in another study of a 
population with onset of seizures in childhood.195 SMR due to pneumonia in young age 
groups appears to be higher than in the elderly108,110 reflecting the low incidence of this 
cause of death in the corresponding age group in the general non-epilepsy population 
and the severity of the underlying condition or its complications in children and young 
adults with epilepsy. In a large hospital-based study, the overall SMR for pneumonia 
was 4.2 (95% Cl 3.6-4.8) with 40% of deaths due to pneumonia occurring in patients 
>75 years, in whom the SMR was 2.4 (95% Cl 1.9-2.9). Although the relevant SMR 
was not reported, it appears that the high SMR for pneumonia was due to fewer cases 
but higher SMR for pneumonia in the younger age groups.
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5.5 The size of the problem
In the UK, at any one time, there are at least 300,000 people treated for epilepsy.351 The 
recently published National Sentinel clinical audit of deaths in people with 
epilepsy in the UK commissioned by the National Institute for Clinical Excellence 
(NICE) looked at the post-mortem investigations and medical care received by patients 
who died and had epilepsy mentioned in the death certificate.351 The audit found 2,412 
deaths with epilepsy on the death certificate among all individuals who died in the UK 
between September 1999 and August 2000, although it could not establish the true 
number of deaths in people with epilepsy from national data. Epilepsy was considered 
to be the probable cause in 812 of these deaths (-34%) from examination of the death 
certificate and clinical notes from primary and secondary care as well as post-mortem 
findings. The audit identified a series of shortcomings in the patients’ care that “may 
have contributed to a substantial number of potentially avoidable deaths”. Findings 
included poor record keeping throughout primary and secondary care, deficient 
management (such as inadequate access to specialist care, inadequate drug management 
in 20% of adults and 45% of children, lack of appropriate investigations, and 
inconsistent follow-up), poor information to patients and their families, and 
inadequacies in the investigations of deaths. There were particular problems in the 
management of epilepsy in patients with associated problems such as learning 
difficulties. It is notable that only 3% of the patients who died (none of them children) 
were known to be seizure-free at the time of their last visit to a physician, but 7% of 
patients were not on antiepileptic treatment at the time of death. The audit estimated that 
deaths in 39% of adults and in 59% of children were “potentially or probably 
avoidable”.
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Specific measures for the prevention of SUDEP have been proposed elsewhere based on 
the findings o f this audit.384 Patients at risk should be identified, and they and their 
families educated about this possibility. Early and aggressive treatment should be 
directed to patients with continuing seizures (especially generalised convulsions) and 
should include measures to promote compliance and identification of seizure 
precipitants. Patients with seizures not responding promptly to treatment should be 
referred early to a neurologist for the classification of seizure type and epilepsy 
syndrome, appropriate diagnostic work-up, and development of a patient-specific 
treatment plan. Patients whose seizures are refractory to treatment for more than 2 
years despite best efforts should be referred to a comprehensive epilepsy centre for re- 
evaluation and consideration of surgery, or other treatments such as vagal nerve 
stimulation and clinical trials of AEDs under development. Finally, pathologists should 
be educated and alert about SUDEP, and they need to look for evidence for or against 
such a diagnosis.
5.6 Conclusion
Patients with epilepsy are subject to higher standardised mortality rates than people in 
the general population, with overall SMRs between 2 and 3. Although numbers may 
vary due to differences in methodology and the population studied, findings have been 
fairly consistent across studies. Mortality is significantly higher in people with 
symptomatic epilepsy, especially those with an accompanying neurological deficit, in 
which case it tends to follow the mortality of the underlying cause of epilepsy. SMRs 
are higher in the first 5-10 years after diagnosis of epilepsy and in younger people due 
to the low expected mortality in this age group. People with idiopathic epilepsy and 
people who enter long-term remission seem also to be affected, but to a much lesser
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extent. Major contributors to death in patients with epilepsy are brain tumours, 
cerebrovascular disorders, and pneumonia in elderly or institutionalised patients. 
SUDEP is the most important cause of epilepsy-related deaths, particularly in the 
young, and in people with frequent seizures and/or suboptimal AED treatment. Despite 
the adverse prognosis for particular groups of patients, it is important to realise that a 
proportion of seizure-related deaths, as well as SUDEP, can be prevented by optimising 
treatment and care for these patients. In addition, patients and their families need to be 
aware of the risk of death associated with epilepsy. In the event of death, appropriate 
post-mortem investigations should be carried out in order to classify the cause of death. 
The circumstances of death and the received medical care should be looked at to 
identify any management inadequacies.
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Chapter 6
LIFE EXPECTANCY IN PEOPLE WITH NEWLY DIAGNOSED EPILEPSY
6.1 Introduction
Epilepsy is a potentially life-threatening condition and carries a risk of premature 
mortality. This has been consistently shown both in population-based studies and in 
studies of more selected populations, such as institutionalised or hospitalised 
patients.12,314 Standardised mortality ratios (SMR) for epilepsy range between 2 and 3 in 
community studies.12
The higher SMRs in people with epilepsy might suggest a diminished life expectancy in
this group. The mean life span o f a subgroup of patients in a Polish study was 12.5 years
after the onset of seizures, an average 20 years shorter than that of the general 
^  1
population. This subgroup excluded patients whose epilepsy was due to brain 
tumours or cerebrovascular diseases. In a study of Finnish children with epilepsy 94% 
were alive 10 years after the onset of seizures, 88% 20 years after onset, and 75% 40 
years after onset.195 Ninety six percent of these children reached the age of 10 years, 
89% the age of 20 years, and 80% the age of 40 years. In the same study, 87% of 
children with idiopathic seizures reached 40 years of age, compared with 93% of those 
with cryptogenic seizures, and 73% of those with remote symptomatic seizures. These 
studies suggest a shortening of life expectancy in people with epilepsy, the extent of
I O C
which is not precisely known. Carrol and Barnes suggest this shortening to be in the 
order of one to two years if the epilepsy is well controlled and up to five years for very 
severe refractory epilepsy. However, these figures are not based on precise data and
385reflect the authors’ practice.
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An estimation of life expectancy in a cohort of people with epilepsy and a comparison 
to that of the general population is attempted here. Data from the UK National General 
Practice Study o f Epilepsy (NGPSE), a prospective, population-based study of epilepsy
323were used. Two previous studies using data from the NGPSE reported increased 
SMRs for all-cause mortality following a diagnosis of epilepsy up to a maximum of 14 
years of follow-up.113,116 In these analyses, SMRs were highest during the first years 
after diagnosis and declined with time.116 The absolute reduction in life expectancy in 
this cohort is reported here, which was estimated using a parametric survival model 
based on the Weibull distribution.
6.2 Patients and Methods
6.2.i Life-Exnectancv in the general population
Life expectancy at a given age in a specific population is derived from a life table for 
that population and is defined as the average number of years a person of that age will 
live when subject to the mortality rates contained in the life table. It is determined by 
the mortality rates at each age within the specified population over the entire age range 
of the life table. The most recent life table (English Life Tables No. 15) was used, based
TR7on mortality in England and Wales centred on the census year 1991. Separate life 
tables are published for men and women, and for each year from birth, and provide 
information on:
• the number of survivors (lx) to age x of 100,000 live births (of the same sex who 
subsequently experience mortality similar to that of the population of that sex in 
England and Wales during 1990-1992),
• the mortality rate (qx) between age x  and (x+1), (defined as the number dying 
between age x and (x+1) in the same population, divided by /*), and
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• the average expectation of life (ex) (the average number of years that those aged 
x  will live thereafter)387 
The mortality rates at each age in these Life Tables are modified as described below to 
estimate life expectancies for people with epilepsy.
6.2.ii NGPSE and mortality
In the NGPSE cohort116,323 patients between 1 and 90 years old with newly diagnosed 
epilepsy were recruited from 275 general practices. Seven hundred and ninety two 
patients were followed from index seizure either to death or to the end of the follow-up 
period. The index seizure was the seizure leading to diagnosis of epilepsy. Five hundred 
sixty four patients were diagnosed with definite epilepsy -defined as the occurrence of 
one or more afebrile seizures- and 228 with possible epilepsy. In the first analysis, 
considering patients with definite epilepsy,113 the SMR was highest during the first year 
after diagnosis [SMR 6.6 (95% Cl 4.8 to 8.7)], approximately halved during the 
subsequent 3 years [SMR 3.1 (95 % Cl 1.8 to 5.1)], and then halved again between 4 
and 6 years [(SMR 1.6 (95% Cl 0.6 to 3.5)]. The SMR declined to 1.3 (95% Cl 0.5 to
2.9) 6 to 8 years after diagnosis, which, though suggesting higher mortality than the 
general population, is not statistically significant. The second analysis116 with follow-up 
extended to 14 years, produced a similar pattern, with a significantly increased SMR of 
1.8 (95% Cl 1.1 to 2.7) even 9 to l4  years after diagnosis. SMRs differed according to 
the aetiological grouping of epilepsy (Box 8): 1.3 (95% Cl 0.9 to 1.9) for the 
idiopathic/cryptogenic group (N=346), 3.7 (95% Cl 2.9 to 4.6) for the remote 
symptomatic (N=119), 3.0 (95%CI 2.0 to 4.3) for the acute symptomatic (N=83), and 
25 (95%CI 5.1 to 73.1) for the congenital deficit group (N=16).116 The highest SMRs 
were observed in the 0-49 and 50-59 years group with definite epilepsy [5.4 (95%CI 3.2
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to 8.4) and 8.4 (95%CI 5.3 to 12.7) respectively]. It is expected that the increased SMRs 
will produce a reduction in life expectancy compared with the general population.
BOX 8.
Definitions of aetiological epilepsy groups in the NGPSE,323and number of people 
and number deaths per group in the current study.
Idionathic/Cryptogenic: patients with idiopathic seizures or seizures of no known 
predisposing cause [344 people; 45 deaths]
Acute symptomatic: patients with seizures starting within 3 months of an acute insult 
(eg, alcohol-related seizures and metabolic disorders) [83 people; 37 deaths]
Remote symptomatic: patients with seizures associated with central nervous system 
lesions acquired postnatally (eg, previous brain trauma and cerebrovascular accident) 
[83 people; 57 deaths]
Congenital deficit: patients with seizures associated with congenital or perinatally 
acquired neurological abnormality (eg, cerebral palsy and neurological deficits present 
at birth) [16 people; 3 deaths]
For the purpose of this analysis, subjects were divided into 2 groups, 
idiopathic/cryptogenic and symptomatic. The latter group comprised patients previously 
in the acute symptomatic, remote symptomatic and congenital deficit groups with the 
exceptions of patients with epilepsy due to brain tumours who were excluded from the 
analysis.
6.2.iii NGPSE and life expectancy
Complete information on survival status in the NGPSE is available up to 31 December 
2001, which extends observations reported previously by four years116 and updates 
previous analyses both for numbers of deaths, and for interval of follow-up from index
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seizure. For those with definite epilepsy there have been 177 deaths (31%), with median 
(quartiles) follow-up o f 15.4 (10.9, 16.4) years, and a total of 7,147 person years. The 
present analysis excluded 38 patients (35 deaths) for whom the likely aetiology at 
diagnosis o f epilepsy was a brain tumour (Box 8). For each patient, the interval from 
date of index seizure to death or 31 December 2001, whichever is earlier, was calculated 
in weeks. These data together with various covariates were fitted to the Weibull survival 
model, using the program BMDP 2L (see Box 9). Covariates used were gender, age at 
diagnosis (and its square), and idiopathic/cryptogenic onset (yes/no), together with the 
product of the last factor and age at diagnosis (that is, the interaction between them). As 
expected, the value of the shape parameter (Box 9), was less than one, indicating 
decline in risk o f premature death with interval from diagnosis.
Annual mortality rates were predicted for each year following diagnosis of epilepsy for 
different combinations of the covariates gender, age at diagnosis, and 
idiopathic/cryptogenic onset. Diagnosis was assumed to occur six months after a 
birthday, and the death rate at that age was estimated by averaging the corresponding 
rate from the English Life Tables and that predicted by the Weibull model at a quarter 
year after diagnosis. Subsequently, the predicted death rates from the Weibull model (at 
mid-year points) replaced those in the English Life Tables, for as long as they exceeded 
them; estimates of life expectancy from the time of diagnosis, and subsequent years 
thereafter, were then calculated from the revised life table. Life expectancy calculations 
were performed using a Microsoft Excel database.
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BOX 9
Weibull hazard function
This is one o f several flexible functions that are used to model survival data; it has two 
parameters, A and y, and the hazard function (risk of death), h(t), is defined by:
h(t) = A.y.r', (1)
where t is the interval from start of follow-up. The two parameters determine the shape 
(y) and scale (X) o f the hazard function, which increases when y> 1, and decreases when 
y< 1. When yis  equal to one h(t) is equal to the constant, X, so the risk of death does not 
change with the interval from start of follow-up, and the survival curve is 
exponential. The two parameters, y and X, are determined by fitting the Weibull 
model to survival data using statistical software such as the program BMDP 2L.389 With 
the NGPSE data, the risk of death decreases with time from diagnosis, so we expect y  to 
be less than one.
Although the risk of dying depends upon the interval from diagnosis, it also varies with 
other factors (covariates) such as age and gender, and these must be taken into account 
when fitting the Weibull model. This is achieved by using a more general form of the 
model represented in equation (1), specifically:
h(t) = exp( B x.xx + B 2 .X2 ).X.yAT\ (2)
where "exp" denotes the exponential function, B\ and Bi are regression coefficients 
estimated when fitting equation (2) to data, and x\ and X2 denote the corresponding 
covariates (for example, age and gender). Equation (2) is similar in form to the Cox 
proportional hazards regression model, the only difference being that the underlying 
hazard function is estimated parametrically by the Weibull model, whereas in the Cox 
model it is estimated directly (that is, without a functional form, or semi-parametrically) 
from the data. Once the parameters, y  and X, B\ and B i, have been determined by fitting 
equation (2) to data, the risk of death at time, t, after diagnosis, can be determined and 
plotted for any appropriate values of the covariates.
The output from program BMDP 2L does not tabulate directly the values of the 
parameters in model (2) above, instead it uses a different parametrization of the Weibull 
model.388 Specifically, the program lists values of a constant (//), a scale parameter (cr), 
and regression coefficients (ax), where A is equal to exp(-plo), /  equals 1/cr, and Bx is 
equal to - a ja .  Further, since the follow-up intervals are recorded in weeks in the 
NGPSE, and mortality rates per year are required, the time-scale in equation (2) has to 
be re-scaled; this is achieved by multiplying X (the scale parameter) by 52.18Y (average 
number of weeks per year raised to the power, y).
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Using the Weibull survival model as described above life expectancy was estimated for 
men and women. Life expectancy was then compared to that in people of the same age 
and sex in the general population according to the English Life Tables. The estimated 
reduction in life expectancy is expressed as years of life lost.
6.3 Results
In this analysis o f 526 patients, age at diagnosis ranged from less than one to over 
ninety years, with deciles at 6, 11, 16, 20, 27, 38, 50, 63, and 73 years. Age at death 
(142 patients) ranged from 3 to 97 years, with 20 (14%) under 50 years, 31 (22%) 
between 50 and 69 years, and 91 (64%) aged over 69 years; 54 (38%) were eighty years 
and over. The number of deaths in each aetiological group is given in Box 6. Estimated 
years o f life lost and percentage of normal life expectancy lost by age at diagnosis, and 
years after diagnosis are shown in Tables 14 and 15 for men and women.
The reduction in life expectancy is minimal for people with idiopathic/cryptogenic 
epilepsy, who have about the same life expectancy as the general population. In this 
group, the reduction of life expectancy tends to be less than 2 years at age 50 or over 
and is less than one year before age 30. Women with symptomatic epilepsy lose 11 
years of life and men 12 years. The negative impact on life expectancy in people with 
symptomatic epilepsy is greater in the young and declines progressively with advancing 
age at diagnosis (Tables 14 & 15). People with symptomatic epilepsy continue to 
experience a decreased life expectancy even after 20 years from diagnosis (3 years lost 
in men and women diagnosed at age 20) (Table 15).
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Men with symptomatic epilepsy appear to suffer a slightly greater reduction in life 
expectancy than women when the diagnosis of epilepsy is made in the first 10 years of 
life and in the first 5 years from diagnosis. When, however, the number of years lost is 
expressed as a percentage o f the life expectancy then the differences become less 
obvious (Table 15). There is a trend towards diminishing number of years of life lost the 
longer someone survives and towards a progressively increased percentage of normal 
life expectancy lost with advancing age at diagnosis.
6.4 Discussion
People with newly diagnosed epilepsy appear to have a reduced life expectancy 
compared with the general population. The number of years of life lost is considerably 
higher for people with symptomatic epilepsy than for those with idiopathic or 
cryptogenic epilepsy at any age and, with longer survival, approaches zero.
To the best of my knowledge, there is no other publication reporting life expectancy 
estimates in people diagnosed with epilepsy so these results cannot be directly 
compared with other work. Some comparison, however, can be made with a 
retrospective study321 of 218 people with prevalent epilepsy who died between 1967 and 
1969 in Warsaw, the only study where information on life expectancy was reported. In 
this cohort, the observed average survival was 38 years shorter than expected in people 
with onset o f epilepsy in the first decade o f life and this loss diminished progressively to 
15.5 years with onset of epilepsy after the age of 40. The average shortening of survival 
was 25 years when the cause of epilepsy was unknown. Although not directly 
comparable, the reported shortenings of survival appear to be far in excess of the 
estimates from our study. This may be explained by the Polish study being a prevalent
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cohort with 55% of patients having secondary epilepsy and 58% having permanent 
neurological deficit.321
Men with symptomatic epilepsy appear to suffer a slightly greater life expectancy loss, 
possibly due to higher mortality associated with head injuries. When the number of 
years of life lost is expressed as a percentage of life expectancy in the general 
population the differences between the sexes tend to disappear.
The gradual reduction of years of life lost over time from diagnosis as estimated in this 
study is consequent upon the statistical model used and is based on the declining risk of 
death over time from diagnosis in the NGPSE. This, however, may not be entirely the 
case in other populations for the whole length of follow-up114,332 even in the NGPSE 
during the last five years of follow-up (years 4-9: SMR 1.5; years 9-14: SMR 1.8).116
The Weibull model confers both advantages and disadvantages. It is easy to fit to 
survival data using standard statistical software, and the incorporation of important 
covariates, such as age, is also simple. The Weibull model, though, imposes either a 
decreasing, constant, or increasing risk of death (according to whether the shape 
parameter is less than, equal to, or greater than one) over the entire follow-up period 
from diagnosis. It has already been demonstrated that within the NGPSE cohort the risk 
of death declines with interval from diagnosis. This assumption, however, can only be
'ion
valid for comparatively short periods since annual mortality rates increase with age.
A more realistic survival model that allows a bathtub (or U-shaped) hazard requires a 
more complicated hazard function and a period of follow-up that is longer than that
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available for the NGPSE. Choice of covariates and the way in which they influence 
overall mortality rates is partly limited by the amount of data available; 
just 142 deaths are considered, a number that is small, and can provide only limited 
guidance about influential factors and their form; age and gender were included, since 
they are known to affect annual mortality rates, as well as idiopathic or cryptogenic 
onset since these may well influence the mortality rates. An interaction between age at 
diagnosis and idiopathic or cryptogenic onset is also included since this was of 
statistical importance. The use o f a Weibull model does not allow for the incorporation 
of a time-dependent covariate, such as seizure recurrence. Therefore, it was not feasible 
to determine the extent to which seizures contribute to shortening of life expectancy. In 
the previous analysis of the NGPSE cohort116 it was found that seizure recurrence and 
antiepileptic drug treatment did not influence mortality rate.
The exclusion of patients with brain tumours aims to provide a better estimate of life 
expectancy in cases of acquired epilepsy. This is based on the premise that the tumour 
and not the occurrence o f seizures determines mortality in people with epilepsy with an 
underlying brain tumour. Information on survival following diagnosis of a brain tumour 
is available elsewhere.390 The majority of deaths in the NGPSE were due to neoplasia, 
ischaemic heart disease, cerebrovascular disease and pneumonias.116 These conditions 
are associated with increased mortality irrespective of the development of epilepsy or
M . 38U390-392not.
In modelling the effect of epilepsy on mortality rates certain crucial assumptions were 
made. First it is assumed that the mortality rate increases suddenly at the age of 
diagnosis and not before. This assumption may not be valid,
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Men
Age at diagnosis Years after diagnosis
(years) 0 1 2 3 4 5 10 15 20
1 0.6 0.6 0.5 0.5 0.4 0.4 0.2 0.0 0.0
5 0.6 0.6 0.5 0.4 0.4 0.3 0.1 0.0 0.0
10 0.6 0.6 0.5 0.4 0.4 0.3 0.2 0.1 0.0
20 0.8 0.8 0.7 0.7 0.6 0.5 0.3 0.1 0.0
30 1.2 1.1 1.0 0.8 0.7 0.6 0.2 0.0 0.0
40 1.3 1.2 1.0 0.8 0.7 0.5 0.1 0.0 0.0
50 1.4 1.2 0.9 0.7 0.5 0.4 0.0 0.0 0.0
60 1.3 1.1 0.8 0.5 0.3 0.2 0.0 0.0 0.0
70 1.6 1.4 1.0 0.6 0.4 0.2 0.0 0.0 0.0
Women
Age at diagnosis Years al[iter diagnosis
(years) 0 1 2 3 4 5 10 15 20
1 0.6 0.6 0.6 0.6 0.5 0.5 0.3 0.2 0.1
5 0.7 0.7 0.6 0.6 0.6 0.5 0.3 0.2 0.1
10 0.8 0.7 0.7 0.6 0.6 0.5 0.3 0.2 0.1
20 0.9 0.9 0.8 0.7 0.7 0.6 0.3 0.1 0.0
30 1.1 1.0 0.9 0.8 0.7 0.6 0.2 0.0 0.0
40 1.3 1.2 1.0 0.8 0.7 0.6 0.1 0.0 0.0
50 1.5 1.3 1.1 0.9 0.7 0.5 0.0 0.0 0.0
60 1.7 1.5 1.2 0.9 0.7 0.5 0.0 0.0 0.0
70 2.3 2.0 1.5 1.1 0.8 0.5 0.0 0.0 0.0
Years of life lost
(Based on gender and age specific annual mortality rates from English Life Tables No 15, and from a Weibull survival model from age of diagnosis 
of epilepsy with gender, age at diagnosis and its square, idiopathic / cryptogenic onset, and its interaction with age at diagnosis, as covariates)
Table 14: Estimated years of lost life expectancy following diagnosis of idiopathic/ cryptogenic epilepsy
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Men
Age at Years after diagnosis
diagnosis
(years) 0 1 2 3 4 5 10 15 20
1 13(75) 13(75) 12(75) 12(77) 12(77) 11 (/6) 9(74) 7 (12) 6(70)
5 13(75) 12 (75) 12(75) 11(77) 11(77) 10(76) 8(74) 7(12) 5(70)
10 12(75) 12 (75) 11 (75) 10(77) 10(77) 10(76) 8(74) 6(12) 4 (9)
20 11 (20) 10(20) 10 (19) 9(75) 9(75) 8(77) 6(74) 4(11) 3 (5)
30 10(22) 10(22) 9(21) 8(20) 8(79) 7(75) 5(74) 3(70) 1 (6)
40 9 (26) 9(25) 8 (24) 1(23) 7(27) 6(20) 4(74) 2 (5) 0 (2)
50 8 {30) 8 (30) 7(25) 6(25) 5(24) 5(22) 2(72) 1 (4) 0 (0)
60 1(37) 6 (36) 5(33) 5(30) 4(27) 3(24) 1(77) 0 (7) 0 (0)
70 5(47) 5(46) 4 (42) 4(35) 3(34) 3(30) K / / ) 0 (0) 0 (0)
Women
Age at Years after diagnosis
diagnosis
(years) 0 1 2 3 4 5 10 15 20
1 11 (14) 11(7 4) 11 (14) 10(7 4) 10(73) 10(73) 8(72) 6(70) 5(9)
5 11(75) 11 (14) 10 (14) 10(7 4) 9(73) 9(73) 7(77) 6(70) 4(5)
10 10(75) 10 (75) 10 (14) 9(14) 9(73) 8(73) 7(77) 5(70) 4(5)
20 10 (16) 9(16) 9(75) 8(75) 8(74) 8(74) 6(77) 4 (9) 3(7)
30 9(18) 9(75) 8(77) 8(76) 1(16) 7(75) 5(72) 3 (5) 2(5)
40 9(22) 8(27) 8(20) 7(19) 1(18) 6(77) 4(72) 2 (7) 1(3)
50 8(27) 8 (26) 1(24) 6(23) 6(21) 5(20) 3(72) 1 (6) 0(7)
60 7 (34) 7(33) 6 (30) 6(25) 5(26) 4(24) 2(73) 0 (3) 0(0)
70 6(44) 6(43) 5(39) 4 (36) 4(33) 3(29) l ( ^ ) 0 (0) 0(0)
Years of life lost {percentage o f normal life expectancy lost)
(Based on gender and age specific annual mortality rates from English Life Tables No 15, and from a Weibull survival model from age of 
diagnosis of epilepsy with gender, age at diagnosis and its square, idiopathic / cryptogenic onset, and its interaction with age at diagnosis, as 
covariates)
Table 15: Estimated years of lost life expectancy following diagnosis of symptomatic epilepsy
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particularly in individuals with stroke, cerebral palsy or mental retardation (MR), 
although the occurrence of epilepsy in people in the latter two conditions increases 
mortality further (SMR for MR only 1.6 vs. 5.0 for MR and epilepsy vs. 5.8 for MR 
and epilepsy and cerebral palsy).381 It is likely that any pathological or physiological 
process that ultimately manifests as seizures starts before the diagnosis of epilepsy is 
established, however there is no means of determining exactly when this happens. In 
addition it is assumed that the death rate at age of diagnosis is an average of that from 
the English Life Tables (first six months), and that predicted by the Weibull model at 3 
months from diagnosis (second six months). Thereafter, it is assumed that mortality 
rates will follow those from the Weibull model until they are exceeded by the annual 
rates in the standard population. Theoretically the “Weibull rates” themselves should 
perhaps increase as they converge to meet the standard population rates. Finally, in 
fitting a single model for mortality across the entire age range, we require broad age 
distributions for both age at diagnosis, and age at death. In this analysis of 526 
patients, age at diagnosis ranged from less than one to over ninety years and age at 
death ranged from 3 to 97 years. While the idiopathic/cryptogenic group can be 
considered relatively homogeneous in terms of mortality, the symptomatic group is 
heterogeneous and includes people who may differ appreciably in terms of the 
aetiology and mortality of epilepsy.
The tables give predictions o f years of life lost according to broad aetiologic groups of 
epilepsy, as well as age at, and interval from, diagnosis. They aim to provide a rough 
estimate of the average decrease in life expectancy in people with epilepsy (in UK). 
Their predictive value for an individual patient who falls in one of the two aetiologic 
groups cannot be established yet, particularly in the case of the symptomatic epilepsy
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group, given its heterogeneity. In addition, these predictions refer to a population with 
newly-diagnosed epilepsy and may overestimate survival in the case of a prevalent 
cohort or of specific subgroups of patients, such as those with refractory epilepsy, and 
those referred for epilepsy surgery.325 Nevertheless, these estimates may prove useful 
in clinical practice and the counselling of patients and their relatives, given the paucity 
of information in this area. These data may be useful in the medico-legal arena, where 
life expectancy is crucial in the calculation of damages resulting from acquired brain 
insults that may be complicated by epilepsy.
SMRs are increased in all types of epilepsy (with the possible exception of typical 
absence seizures).114 This model shows that in people with newly diagnosed epilepsy 
higher SMRs translate into a decrease in life expectancy, which is more pronounced in 
those with symptomatic epilepsy. Clearly, more work is needed in this area to produce 
more accurate estimates of life expectancy for the particular epilepsy types or 
syndromes, aetiology, presence of comorbid conditions, and refractoriness to 
treatment.
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GENERAL CONCLUSION
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GENERAL CONCLUSION
Epilepsy is a multifaceted and multifactorial condition with particular management 
considerations for different groups of patients and a significant impact on the lives of 
affected people and the society. Apart from the effect of seizures and their treatment 
on the individual, the impact of epilepsy on the individual can be further burdened by 
coexisting disorders and an increased risk of death.
A number of different definitions exist for “comorbidity” but for the purposes of this 
thesis the term refers to the disorders that co-occur more frequently in people with a 
given condition than would be expected in the general population without the 
condition, irrespective of causal association. I have studied the comorbidity of 
epilepsy at a general practice level in the UK using data from the GPRD, reviewed the 
relevant literature on psychiatric comorbidity, and discussed the association of 
epilepsy with a number of somatic disorders that occur more frequently in epilepsy. 
The psychiatric comorbidity includes organic and non-organic psychoses (including 
schizophrenia), alcohol dependence, neuroses and depression. Some interictal 
psychiatric disorders, such as schizophrenia-like psychosis of epilepsy and interictal 
dysphoric disorder appear to occur exclusively in epilepsy. These, together with the 
periictal psychiatric manifestations, such as forms of anxiety, depression and 
psychosis, appear phenomenologically different from those in people without epilepsy, 
although this is not yet recognised in the current disease classification systems. The 
somatic comorbidity commonly includes brain tumours and meningiomas, 
neurodegenerative disorders (including Parkinson’s disease, Alzheimer’s disease and 
other dementias), cerebrovascular accidents (including TIAs), congenital heart disease,
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gastrointestinal bleeding (especially from the upper GI tract), and pneumonias. Other 
disorders less strongly associated with epilepsy include neoplasias (only in men), 
peptic ulcers, diabetes mellitus, asthma, chronic bronchitis, emphysema (in younger 
adults), migraine, heart failure, and ischaemic heart disease. This list is not exclusive 
and other disorders (not studied here) may also occur more frequently in epilepsy. 
Eczema, rheumatoid arthritis, and osteoarthritis do not appear to be more frequent in 
epilepsy. The risk of somatic disorders across the diagnostic groups (ICD-9 categories) 
was increased in people with epilepsy with the exception of musculoskeletal and 
connective tissue disorders in older adults. Congenital anomalies were increased in 
younger adults with epilepsy, but perinatally acquired conditions were not (probably 
related to poor survival in this group).
The specific conditions studied here could cause epilepsy directly (eg stroke or 
tumour) or indirectly (eg congenital heart disease -v ia hypoxia/ischaemia or stroke), 
result from epilepsy (eg fracture following a seizure, depression or anxiety) or be 
associated with epilepsy via shared genetic (eg depression or migraine) or 
environmental factors (eg migraine, via head injury, gastrointestinal bleeding, via use 
of aspirin). In some cases epilepsy may indicate the severity of the underlying 
condition (eg degenerative conditions such as Alzheimer’s disease). In general terms, 
comorbidity could be characterised as causal or resultant, depending on its cause and 
effect relationship with epilepsy.
Analysis of data from the MSGB4 showed that people with epilepsy make a higher 
utilisation of health services compared with people without the condition in the 
community. They require more visits to the general practitioner, more home visits by
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the general practitioner, and more referrals to secondary care. I have shown that these 
people visit their GP more often for a number of comorbid disorders. It is, therefore, 
possible that the presence of comorbidity increases health care needs in this 
population, although this could not be shown directly by the data. The study of 
comorbidity can provide information for public health and the planning of health 
services. In the UK, services for epilepsy in both primary and secondary care are often 
fragmented and do not adequately meet the needs of people with epilepsy. This has 
been recognised and there is now greater awareness of the need to improve health 
services for this group.393
Mortality in epilepsy can reflect the mortality of the underlying conditions causing 
epilepsy or be associated with the effect of seizures. A review of the literature 
presented here showed that epilepsy carries an excess mortality, which is 2 to 3 times 
higher than in the general population and is expressed as the SMR. This mortality does 
not affect all patients equally, but is more pronounced in people with symptomatic 
epilepsy or epilepsy due to neurological deficit at birth than in people with idiopathic 
or cryptogenic epilepsy. Cause-specific SMRs in epilepsy show increased mortality 
from neoplasia (including brain tumours), cerebrovascular and ischaemic heart 
disease, pneumonias, and learning difficulties, which are comorbid in epilepsy. 
Therefore, it is safe to conclude that the presence of comorbidity increases mortality in 
epilepsy. Emphasis should be given to preventable causes of death in epilepsy, such as 
SUDEP, drowning and suicide.
Data on mortality from the NGPSE cohort was used to estimate life expectancy in 
people with newly diagnosed epilepsy by employing a survival model. I have found
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that the increased mortality risk translates into reduced life expectancy in people with 
epilepsy. This is only minimal in people with idiopathic/cryptogenic epilepsy and 
considerable in people with symptomatic epilepsy, suggesting again the adverse role 
of comorbidity in the risk of death.
People with epilepsy in the community who visit their GP suffer more frequently from 
a number o f psychiatric and somatic disorders, which can be associated with increased 
mortality and, subsequently, reduced life expectancy. These people also have 
increased health care needs, which may -to  an extent- be due to presence of disorders 
comorbid with epilepsy.
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